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Chapter 1  
Introduction 
 
All truths are easy to 
understand once they 
are discovered; the 
point is to discover 
them 
Galileo Galilei 
 
 
1.1 Biotin-Binding Proteins 
1.1.1 Biotin 
Originally called vitamin H [1], biotin is an essential water-soluble vitamin 
with a molecular weight of 244 g mol-1. It is a bicyclic molecule composed of 
a ureido (tetrahydroimidizalone) ring fused to a tetrahydrothiophene ring, 
which supports a valeric acid side chain.  
Biotin is an optically active molecule with three chiral centres, as shown in 
figure 1.1 [2]. 
 
 
 
Fig 1.1 (+)-biotin, known as vitamin H, with three chiral centres  
 
The tissues with the highest amounts of biotin are the liver, kidney and 
pancreas.  
 -2- 
Daily biotin requirements are relatively small and biotin is present in many 
foods. However, high levels of avidin, a glycoprotein which forms a very 
stable non-covalent complex with biotin (Kd =10
-15 M), were identified in 
chicken egg-whites [3]. For this reason, the excessive consumption of raw egg-
white prevents the body from absorbing vitamin H and leads to a rare 
nutritional problem, known as “egg-white injury” [4]. 
Biotin binds covalently to the !-amino group of a lysine residue in 
carboxylases, forming a biocytin complex. This covalent linkage is broken by 
biotinidase, an enzyme responsible for biotin recycling from the carboxylase. 
Thus, removed from the biocytin complex, biotin is again available for other 
enzymes [5]. 
The four carboxylases [6] which bind biotin as coenzyme and which are 
involved in metabolic reactions are: acetyl-CoA carboxylase, which produces 
malonyl-CoA through two catalytic activities (biotin carboxylase and 
carboxyltransferase) for the biosynthesis of fatty acids; pyruvate carboxylase, 
involved in the formation of oxaloacetate from pyruvate as precursor for 
gluconeogenesis; propionyl-CoA carboxylase, which provides 
methylmalonyl-CoA which is involved in the metabolism of amino acids and 
fatty acids, and 3-methylcrotonyl-CoA carboxylase, which catalyses the 
carboxylation of 3-methylcrotonyl-CoA which is implicated in the 
degradation of leucine.  
Beyond the biochemical role in carboxylation reactions, biotin regulates gene 
expression at the transcriptional or post-transcriptional level, interfering with 
fetal development and cell biology [7].  
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1.1.2 Chicken Avidin  
Chicken avidin is a homotetrameric protein consisting of four antiparallel "-
barrels with a molecular weight of approximately 63 kDa [8]. Estrogenic 
hormones stimulate avidin synthesis in the chick oviduct [9]. The protein is 
secreted in its natural host and the signal peptide is cleaved following 
secretion [10]. 
Each monomer consists of eight antiparallel "-strands, bears 128 amino acids 
and binds non-covalently to a single biotin molecule with very high affinity 
(Kd = 1.3 • 10
-15 M at pH 5). The protein is positively charged (pI = 10.5) with 
eight arginine and nine lysine residues in each monomer. The glycosylation 
content, composed of four to five mannose and three N-acetylglucosamine 
residues, accounts for about 10% of the molecular mass [11]. 
Avidin is water soluble and stable over wide pH and temperature ranges and 
in the presence of chaotropic reagents [11a, 12]. Stability is increased when 
biotin is bound. The high thermostability seems to be correlated with the 
presence of intramonomeric disulphide bridges, formed between C4 – C83 
cystein residues [13]. 
The presence of biotin reduces the flexibility of the loop L3,4 which is 
involved in van der Waals interactions with biotin, and makes avidin less 
susceptible to proteolytic cleavage [13b].  
The high pI of avidin and the presence of carbohydrate residues constitute a 
drawback in certain biotechnological applications, such as in drug delivery 
and imaging. For example, the positive charges on avidin and its 
glycosylation content can induce non-specific binding to DNA and cell 
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surfaces. These properties also lead to rapid clearance of avidin from the 
blood, with protein accumulation in the kidneys [11b, 14].   
Despite the centennial discovery of avidin, an exhaustive description of its 
biological functions still remains a challenge. The wide avidin distribution in 
the female reproductive tract and in the egg-white of many species is a 
suggestion of its important role in ovum survival and embryonic growth [15].  
However, avidin functions are not simply confined to reproductive sphere, 
since some non-oviductal chicken tissues, infected by bacteria or fungi, 
induce avidin production as defense mechanism against infection. Avidin is 
hence an antibiotic protein that inhibits microbial growth through biotin 
depletion [16]. 
Under stress conditions, avidin is produced even in chicken myoblasts and 
chondrocytes to prevent cell proliferation through extracellular biotin-binding 
and fatty acid biosynthesis inhibition [17]. 
 
1.1.3 Bacterial Streptavidin  
Streptavidin is an alternative biotin-binding protein with four antiparallel "-
barrels, isolated from the bacterium Streptomyces avidinii.  
Also streptavidin, isolated during an antibiotic investigation, inhibits bacterial 
proliferation by acting as biotin scavenger. 
The biotin-binding site is located at one end of each "-barrel and each 
monomer contributes to the binding on the neighboring subunit [18]. Thus, the 
streptavidin homotetramer acts as a dimer of dimer, with slightly lower 
affinity for biotin (Kd = 4 • 10
-14 M) compared to avidin [13a]. 
 -5- 
Although avidin is structurally and functionally comparable to streptavidin, 
there are differences in isoelectric point, glycosylation, primary structure and 
pharmacokinetics. Streptavidin is a non-glycosilated protein with a mildly 
acidic isoelectric point (pI = 6-7) [14, 19]. For this reason, streptavidin is 
preferred over avidin in biotechnological applications due to less non-specific 
binding to cell surfaces and DNA [20].  
Despite being devoid of cysteines and, consequently, disulphide bridges, 
streptavidin exhibits a thermal and structural stability similar to that of avidin, 
especially in the presence of biotin. The monomeric interactions become even 
tighter upon biotin binding. For this reason, holo-streptavidin maintains its 
tetrameric structure even in the presence of SDS, urea or heat treatment [20]. 
After expression in Streptomyces avidinii, streptavidin is a polypeptide of 159 
residues termed “mature streptavidin”, which is characterized by poor 
solubility and high propensity for aggregation [20]. During secretion, a peptide 
sequence consisting of 24 amino acids is proteolytically cleaved. Upon longer 
culture incubation, further proteolytic cleavages occur in both the N and C 
termini regions. The resulting most stable form of protein, consisting of 
residues 13-139, is called “core streptavidin” and is characterized by high 
solubility, low tendency to aggregate and enhanced binding affinity for biotin 
[20-21]. 
Regarding pharmacokinetics, streptavidin has an appreciably longer plasma 
half-life in blood compared to avidin, with a final accumulation in the 
kidneys [22]. 
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1.1.4 Structure of Avidin and Streptavidin  
Sequence alignment of avidin and streptavidin reveals that most of the 
conserved residues are directly involved in biotin binding [8a, 23]. The 
homology in the alignment of the two sequences is characterized by 30% of 
identity and 41% of similarity [8a] (Fig. 1.2). 
Particularly interesting is the homology around tryptophans 21-79-120 of 
streptavidin and the corresponding tryptophan residues 10-70-110 of avidin, 
implicated in the biotin-binding [24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 Sequence alignment of primary structures of avidin (residues 1-128) and 
streptavidin (residues 12-138). Positions of the eight "-strands are indicated by black 
arrows. The six highly homologous sequences are highlighted by rectangular boxes. Residues 
directly involved in biotin-binding are shaded in blue.  Conserved and similar residues are 
marked by stars and dots, respectively (modified from a figure by Livnah et al.) [8a] 
 
Streptavidin and avidin have an almost identical secondary structure, 
characterized by eight antiparallel "-strands, which fold to give an 
antiparallel "-barrel tertiary structure (Fig 1.3).  
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Fig. 1.3 Antiparallel !-barrel tertiary structures of a) avidin and b) streptavidin  
 
However, their structures differ mainly in the size and conformation of the six 
extended hairpin loops that connect the strands. In avidin the L3,4 loop is 
three residues longer than the corresponding loop in streptavidin [23b, 25]. Upon 
binding biotin, the loop closes, thus wrapping the ligand almost completely 
both in avidin and in streptavidin. 
Quaternary assemblies, containing four closely related biotin-binding sites, 
characterize both proteins. The biotin-binding site is located at one end of 
each "-barrel and is formed by the inner amino acids of the barrel and a Trp 
residue from the neighbouring subunit. The tryptophan from the adjacent 
monomer, corresponding to Trp-120 in streptavidin and Trp-110 in avidin, is 
involved in inter-monomeric contacts and stabilizes the tetrameric protein in 
the bound state [26]. 
 
1.1.5 Strept(avidin)-Biotin Interaction 
A deep biotin-binding pocket, which is partially occupied by five water 
molecules in the absence of biotin, is located at the centre of each subunit in 
both tetrameric proteins. Upon biotin binding, water is displaced [8a] and 
b. a. 
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biotin is tightly anchored via various residues in the pocket with the valeryl 
side-chain carboxylate exposed to the solvent. 
Hydrophilic residues are involved in hydrogen bonds with biotin, while 
aromatic amino acids creates a hydrophobic compartment to accommodate 
the hydrophobic biotin scaffold [27]. 
The avidin residues Trp-70, Phe-72, Phe-79, Trp-97, and Trp-110 from the 
neighboring monomer, are involved in hydrophobic interactions with biotin. 
The corresponding hydrophobic residues in streptavidin are provided by Trp-
79, Trp-92, Trp-108, and Trp-120 from the adjacent monomer [28]. 
Trp-110 of avidin and the analogous Trp-120 of streptavidin act as a 
hydrophobic lid for the binding pocket [29]. 
The ureido oxygen of the biotin bicycle forms hydrogen bonds with the 
streptavidin polar residues Asn-23, Ser-27 and Tyr-43 similarly to Asn-12, 
Ser-16 and Tyr-33 in avidin [30]. The ureido nitrogens, involved in hydrogen 
bonds with Thr-35 and Asn-118 in avidin, interact with Ser-45 and Asp-128 
in streptavidin. The valeric carboxylate of biotin forms only two hydrogen 
bonds with streptavidin (Asn-49 and Ser-88) as against five in avidin (Thr-38, 
Ala-39, Thr-40, Ser-73 and Ser-75). Furthermore, as discussed the loop L3-4 
in streptavidin is three residues shorter compared to the analogous loop in 
avidin (Fig. 1.4). For these reasons, streptavidin has a slightly lower affinity 
for biotin with respect to avidin [31]. 
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Fig. 1.4 Hydrogen-bonding interactions between biotin and L3,4 loop region of a) avidin 
and b) streptavidin. One residue on the streptavidin L3,4 loop is involved in hydrogen-
bonding interaction with the biotin carboxylate, whereas three hydrogen-bonds mediate 
interaction between avidin L3,4 loop and one of the carboxylate oxygens of biotin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. b. 
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Table 1.1 Summary of biotin-strept(avidin) interactions 
 
INTERACTION AVIDIN STREPTAVIDIN 
H-bond Asn-12 Asn-23 
H-bond Ser-16 Ser-27 
H-bond Tyr-33 Tyr-43 
H-bonda Thr-35 Ser-45 
H-bonda Asn-118 Asp-128 
H-bondb Thr-77 Thr-90 
H-bondc Ala-39 Asn-49 
H-bondc Ser-75 Ser-88 
H-bondc Thr-38 ! 
H-bondc Thr-40 
! 
H-bondc Ser-73 ! 
Hydrophobic Trp-70 Trp-79 
Hydrophobic Phe-79 Trp-92 
Hydrophobic Trp-97 Trp-108 
Hydrophobicd Trp-110 Trp-120 
Hydrophobic Phe-72 ! 
 
a Hydrogen-bonding interaction between a nitrogen atom of the biotin ureido moiety and L3,4 
loop of both proteins. 
 
b Hydrogen-bond involving the sulphur atom of the biotin tetrahydrothiophene moiety. 
c Hydrogen-bond between the biotin valeryl chain and L3,4 loop of both proteins. 
d Amino acid residues from the adjacent monomer. 
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1.1.6 Heterologous Expression Systems for Streptavidin and Avidin 
Chicken avidin and its bacterial analogue streptavidin constitute important 
tools in many biotechnological applications, which take advantage of the 
extremely high affinity for biotin. For this reason, large-scale production is 
required to keep up with demand [32]. 
However, avidin and streptavidin production in their native host suffers from 
several restrictions.  
Streptavidin expression in Streptomyces avidinii takes a relatively long time 
to culture (up to 10 days). Furthermore, the final product is a mixture of 
heterogeneous molecules, which require a further proteolytic cleavage [10b, 21]. 
Avidin constitutes only 0.05% of egg-white total protein [10b] and large batch-
to-batch variations have been observed [33]. 
Therefore, a lot of effort has been invested to identify successful heterologous 
systems for avidin and streptavidin expression. 
High-yield production of avidin in a soluble form has been achieved in 
eukaryotic structures, such as baculovirus-infected insect cells [34], Pichia 
pastoris [35], transgenic maize [36], tobacco and apple plant [37]. However, high-
costs of insect cultures and time-consuming plant construction acted as a 
deterrent to the application of these expression systems. Therefore, recent 
studies focused on bacterial production of active avidin as a deglycosylated 
protein, lacking of post-translational addition of carbohydrate residues. This 
novel avidin, more exploitable in biotechnological applications, was 
expressed in the periplasmic space of E. coli, by replacing the native signal 
peptide with a secretion signal peptide from Bordetella avium OmpA [10b]. 
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On the contrary, recombinant streptavidin was principally produced in different 
prokaryotic systems such as Bacillus subtilis [38] and Escherichia coli [26]. 
The cloned gene of streptavidin was efficiently expressed in the cytoplasm of 
E. coli by using T7 RNA polymerase/T7 promoter expression system. The 
protein was clustered in inclusion body and, afterwards, refolded after 
solubilization via dialysis against guanidinium chloride (6 M, pH 1.5) [26]. 
Although inclusion bodies can offer certain advantages, such as protein 
protection from proteolysis and partial purification by centrifugation, a soluble 
and active protein is often preferred. Consequently, recent studies have focused 
on finding engineered systems to increase streptavidin solubility in the 
expression strain.  
T7-tagged streptavidin, with N-terminal residues replaced by a T7-tagged 
peptide, was efficiently expressed in the cytoplasm of E. coli as functional 
protein [30, 39]. 
Moreover, a periplasmic production of streptavidin in a soluble form was 
performed in E. coli by using a signal peptide from bacterial OmpA [40]. 
 
1.1.7 Biotin-(Strept)Avidin Technology 
Owing to its unique and extraordinary characteristics, the biotin-(strept)avidin 
system has been exploited as important tool in a plethora of medical and 
biotechnological applications [41]. 
High stability of biotin-(strept)avidin complex ensured tight connection 
between biotinylated binders, which are selectively bound to specific targets, 
and (strept)avidin probes. The combined use of different binders and assorted 
probes increases the versatility of the system (Fig. 1.5) [42]. 
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Fig. 1.5 The essential components of avidin-biotin technology. Upon binding that involves 
a biologically active target molecule and a biotinylated binder, avidin probe recognizes 
specifically this biotinylated complex (modified from Ref. 43) [42] 
 
This established solidity has encouraged their use in many biological fields, 
including affinity chromatography [43], immunoassays [44], affinity 
cytochemistry and nanotechnology [45]. 
However, some disadvantages in (strept)avidin-biotin technology may hinder 
their application. The irreversible binding between (strept)avidin and biotin 
and the tetrameric avidin tendency to form oligomers can be a drawback [33, 
46].  
Then, the basic nature of avidin and the presence of carbohydrate moieties 
may limit the applicability of the system due to rapid clearance of avidin from 
the blood stream, and to unspecific and unwanted interactions with sugar-
binding proteins (e.g. lectins) as well as DNA [47]. 
For these reasons streptavidin, a non-glycosilated and uncharged analogue of 
avidin, has been selected as alternative in many applications. Nevertheless, 
streptavidin, more expensive than avidin, also presents its downsides, such as 
the presence of an Arg-Tyr-Asp sequence [48], responsible for unspecific 
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interactions with cell surface receptors [49], and high immunogenicity, which 
limits the application in drug targeting [50].  
Therefore, over the years a wide variety of chemically and genetically 
engineered avidin and streptavidin isoforms have been produced in order to 
improve their application in biotechnology [14] [51].  
An exciting exploitation of (strept)avidin-biotin technology is the affinity-
based targeting of imaging agents and drugs. Avidin has been used as a tool 
to transfer a cerebral vasodilator, known as VIPa (Vasoactive Intestinal 
Peptide analogue), through the blood-brain barrier. A covalent conjugate of 
avidin and TfRMAb (Transferrin Receptor Monoclonal Antibody) acts as 
brain drug transport vector, which localizes the complex to the blood-brain 
barrier (BBB). Upon binding of biotinylated VIPa to avidin, the whole 
complex is internalized through receptor-mediated endocytosis. Brain-
localized disulphide reductases rapidly release VIPa from the complex, 
activating the drug (Fig. 1.6) [52].  
 
 
Fig. 1.6 Avidin and covalently bound TfRMAb as a brain drug transport vector. Upon 
interaction between transferrin and its specific antibody, the TfRMAb-avidin complex is 
localized to the blood-brain barrier. Subsequently, avidin binds to the biotinylated peptide 
drug and the whole assembly is internalized into the brain (modified from a figure by Bickel 
et al.) [52-53] 
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A further application in vivo of avidin and streptavidin as drug carriers is 
cancer pre-targeting therapy [54]. Upon administration, a biotinylated antibody 
binds to a specific antigen expressed in tumor cells, forming a stable 
complex. Subsequently, the antigen-antibody complex is recognized by 
(strept)avidin, which binds to the biotin moiety. A biotinylated radionuclide 
binds to the (strept)avidin-antibody-antigen assembly with consequent cancer 
detection and diagnosis, treatment monitoring and some direct therapeutic 
applications (Fig. 1.7) [54c].  
 
 
Fig. 1.7 Immuno-imaging and radiotherapy. The (strept)avidin-biotin technology is 
exploited for drug delivery in cancer cells (modified from a figure by Schetters) [54a] 
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1.2 Artificial Metalloenzymes 
1.2.1 Chirality 
“ I call any geometrical figure, or group of points, chiral, and say it has 
chirality, if its image in a plane mirror, ideally realized, cannot be brought to 
coincide with itself.” [55]. This celebrated statement was attributed to 
mathematician and physicist Lord Kelvin, who coined the term chirality in 
1873. Non-superimposability of the mirror image is a necessary and sufficient 
condition for chirality.  
Nature is chiral. A fascinating example is provided by (+)- and (-)-limonene; 
these two enantiomers interact differently with the olfactory glands and are 
responsible for the characteristic orange and lemon smells, respectively [56].   
 
 
 
 
 
 
 
Fig. 1.8 (R) and (S) enantiomers of limonene. The naturally occurring (R) and (S) 
enantiomers of limonene smell of orange and lemon, respectively, since differently 
recognized by the chiral nasal receptors [56] (figure modified from wheatoncollege website) 
 
Many biological molecules, including amino acids, sugars, nucleic acids, 
vitamins, hormones and alkaloids, exist as one single enantiomer.  
Enantiomers interact differently with chiral systems and, for example, two 
enantiopure components of an asymmetric substrate will interact differently 
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with a chiral enzyme. This biological phenomenon is called chiral 
recognition.  
Chiral discrimination is of great importance especially in the medical field, 
since one enantiomer is often pharmaceutically active whereas the other can 
be inactive or even toxic.  
The historical example of thalidomide emphasizes the importance of chirality 
in the pharmaceutical field. In the early 1960s, thousands of pregnant women 
took this antiemetic drug as racemic mixture to alleviate morning sickness. 
Unfortunately, thousands of children were born with severe malformations as 
a consequence. Only one enantiomer of thalidomide displayed antiemetic 
activity; the other enantiomer was teratogenic and harmed the developing 
fetus, causing deformities [57].  
 
Fig. 1.9 An example of problems caused by drug administration as racemate. Only the 
(S)-enantiomer of thalidomide caused birth deformities (distomer), while the (R)-enantiomer 
displayed therapeutic activity (eutomer) [57] 
 
 
In the aftermath of the thalidomide tragedy, the USA Food and Drug 
Administration (FDA) introduced guidelines for the development of new 
stereoisomeric drugs. The statement required full pharmacological and 
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toxicological characterization of each enantiomer and encouraged the 
commercialization of enantiomerically pure drugs [58]. 
 
1.2.2 Enantioselective Catalysis 
First coined by Jöns Jakob Berzelius in 1835, the term catalysis refers to the 
acceleration of a chemical reaction induced by a substance, known as a 
catalyst, that participates in the reaction without undergoing any permanent 
chemical change. 
Catalysts provide an alternative mechanism for the reaction, by stabilizing the 
transition state formed between the reactants and providing a more favorable 
spatial orientation for product formation [59]. 
 
Fig. 1.10 Stabilization of the transition state  (TS) in the presence of a catalyst 
 
Catalysts change the kinetics of a chemical process, while the overall 
thermodynamics are maintained: only a thermodynamically favorable 
reaction can be speeded up by a catalyst.  
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From a physical viewpoint, catalysts can be divided into two categories [60]: 
• Homogeneous catalysts: exist in the same phase as reactants and 
products, these highly efficient catalysts act in mild reaction 
conditions. 
• Heterogeneous catalysts: exist in a different phase than reactants and 
products. They guarantee easy separation from products.   
From a chemical perspective, homogeneous catalysts can be further classified 
into three different types: 
• Organocatalysts: small organic molecules which can act as 
catalysts. 
• Organometallic catalysts: metal complexes with metal-carbon bonds 
or with ligands such as phosphines, hydrides and amines [61]. 
• Biocatalysts: biological macromolecules such as enzymes and 
ribozymes. 
Organometallic complexes with chiral ligands around the metal catalyze 
enantioselective reactions [62]. 
The trio Knowles-Noyori-Sharpless pioneered the field of asymmetric 
catalysis and, for this reason, they were awarded the 2001 Nobel Prize in 
chemistry. 
Barry K. Sharpless developed chiral catalysts for asymmetric oxidations such 
as, for example, chiral epoxidation. An allylic alcohol was catalytically 
oxidized to the chiral epoxide (R)-glycidol using titanium tetra(isopropoxide) 
and optically active diethyl tartrate  ((+)-DET) catalysts [63]. 
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Fig. 1.11 Asymmetric oxidation of allylic alcohols to chiral epoxides [63b] 
 
William Knowles produced the first high enantioselective transition metal 
catalyst for asymmetric hydrogenation of dehydro amino acids [64]. Rhodium 
complexes containing chiral phosphine ligands were able to catalyze the 
enantioselective addition of H2 to a prochiral olefinic substrate, generating a 
chiral product [65]. This process was exploited to produce the anti-Parkinson 
drug, L-dopa, using the chelating diphosphine ligand (R,R)-DIPAMP [66]. 
 
 
Fig. 1.12 Enantioselective synthesis of anti-Parkinson L-DOPA [66b] 
 
Ryoji Noyori devised highly enantioselective asymmetric hydrogenation 
reactions [67]. This catalytic reaction, performed with (S)-BINAP-
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ruthenium (II) complex, was exploited for the enantioselective production of 
the anti-inflammatory drug naproxen [68]. 
 
 
Fig. 1.13 Enantioselective production of the anti-inflammatory Naproxen [68b] 
 
In the past decades, new asymmetric catalysts have been developed through 
the successful combination of metal centre and ligands, which modulate the 
steric and electronic properties of the catalyst. 
 
1.2.3 Homogeneous vs. Enzymatic Catalysis 
In a biomimetic spirit, ligand design was often based on principles from 
enzymatic reactions, but there are significant differences between 
homogeneous and enzymatic catalysis [69]. Enzymes influence the 
enantioselectivity of a reaction through the conformation of active site. Their 
catalytic site can be accessible through a restricted channel, which also 
controls the selectivity of the reaction.  
The first-coordination sphere of the metal in organometallic catalysts 
influences the enatioselectivity of a reaction as well as providing electronic 
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and steric control. Solvent, salts and counter ions, constituting the second-
coordination sphere also have a steric and electronic influence. 
The high specificity of an enzyme often limits the scope of applications, even 
if the recent directed evolution approach has evolved promiscuous enzymatic 
activity [70].   
Homogeneous catalysts display a large substrate scope and both enantiomers 
of a chiral product can be produced. 
Organometallic catalysts are more suitable for non-polar substances (e.g., H2, 
CO and olefins), whereas biocatalysts are effective with polar substrates (e.g., 
carbohydrates and biopolymers). Concerning solvent compatibility, enzymes 
react in aqueous media, while homogeneous catalysts react predominantly in 
organic solvent. 
These features, outlined in the table 1.1, highlight the relative 
complementarity between homogeneous and enzymatic catalysis [71]. 
 
Table 1.2 Representative features of enzymatic and homogeneous catalysis [71] 
 Enzymatic 
Catalysis 
Homogeneous 
Catalysis 
Turnover 
Number 
Large Small 
Optimization Genetic Chemical 
Substrate Scope Small Large 
Enantiomers Single Enantiomer 
Access to Both 
Enantiomers 
Reaction 
Medium 
Mostly Aqueous Mostly Organic 
 
 
1.2.4 Artificial Metalloenzymes 
Life depends upon metals. These elements play an important role in the 
activity of biological macromolecules, acting as electron transfer agents [72]. 
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Metals usually perform their functions in the active sites of enzymes, acting 
as cofactors. Nitrogen, oxygen or sulfur atoms from polypeptide chains or 
protein prosthetic groups are involved in metal ion coordination.  
Proteins containing a metal ion cofactor (metalloenzymes) function as carrier 
proteins, signal transduction proteins and enzymes. Metal ions can be 
attached to the protein active site as part of a prosthetic group, e.g. Fe (II) in 
hemoglobin, or built into the structure of the enzyme molecule, e.g. Zn (II) in 
alcohol dehydrogenase [73]. 
In enzymes the metal (usually a transition metal) is embedded in a highly 
organized protein framework, which provides exceptional control through the 
second coordination sphere. 
In the light of the relative complementarity between homogeneous and 
enzymatic catalysts, much effort has been aimed towards the design of 
enantioselective artificial metalloenzymes. These hybrid systems combine the 
principal features of these two catalytic kingdoms. 
Artificial metalloenzymes result from the incorporation of an achiral active 
catalytic moiety into a chiral pocket of the host protein, which provides a 
well-defined second coordination sphere and controls enantioselectivity .  
 
1.2.4.1 Anchoring of Catalyst into the Protein 
Over the years different strategies, such as covalent and supramolecular 
approaches, have been applied to anchor the catalytic metal complex into the 
protein in order to obtain an artificial metalloenzyme [74]. 
For covalent anchoring, the protein is covalently coupled to an 
organometallic moiety in order to achieve a hybrid catalyst. As pioneer of this 
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method, Kaiser demonstrated that “chemical mutations” of specific amino 
acid residues, close to the active site, lead to a “semisynthetic” enzyme, with 
different catalytic activity compared to the original protein [75]. His main work 
focused on the conversion of a hydrolytic enzyme (papain) into a 
semisynthetic oxido-reductase by a covalent linkage of various flavins to the 
Cys25 of papain [76]. 
 
 
 
Fig. 1.14 Covalent modification of Cys25 in the active site of papain by a flavin 
derivative [75] 
 
The resulting flavopapain performed efficient oxidation of N-alkyl-1,4-
dihydronicotinamides [76]. 
 
 
 
Fig. 1.15 N-alkyl-1,4-dihydronicotinamides oxidation performed by flavopapain [76]  
 
Since this work, many other proteins have been covalently modified by 
incorporating transition metal complexes to yield promising hybrid catalysts. 
Hilvert developed a methodology to convert the serine-protease subtilisin into 
an artificial peroxidase through chemical modification of the active site 
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Ser221 into seleno-cysteine. The resulting seleno-subtilisin catalyzes the 
stereoselective reduction of racemic hydroperoxides [77]. 
 
 
Fig. 1.16 Asymmetric seleno-subtilisin catalyzed reduction of racemic 
hydroperoxides [77b] 
 
Supramolecular anchoring is a non-covalent approach based on the high 
affinity between a protein (host) and a small molecule (guest).  
Chemical modifications of the guest, such as, for example, introduction of a 
spacer or modification of the ligand scaffold, ensure the selective attachment 
of the catalyst into the protein. Protein mutagenesis can be used to optimize 
artificial metalloenzyme performance through genetic modification [71, 78]. 
 
 
 
 
 
 
Fig. 1.17 Supramolecular anchoring of an active catalyst within a host protein. Host 
protein displays high affinity for the anchor represented by green triangle. Chemo-genetic 
modifications can improve the performance of the artificial metalloenzyme, without 
influencing the host-guest binding affinity [71] 
 
Serum albumins are plasma transport proteins with high affinity towards 
different hydrophobic guests. The hydrophobic and chiral pocket provides an 
asymmetric environment for the transition state. These proteins have been 
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exploited for the supramolecular incorporation of metal-containing cofactors, 
for the catalysis of enantioselective reactions.  
An asymmetric hydrogenation catalyst introduced by Wilson and Whitesides, 
in 1978, constituted a turning point in the artificial metalloenzymes field. 
Avidin was converted into an enantioselective hybrid enzyme by embedding 
an achiral biotinylated rhodium-diphosphine moiety within the biotin-binding 
pocket [79].  
As Whitesides confirmed, protein chirality can significantly control the 
enantioselectivity of reactions, and the Rh(I)-diphosphine complex was not 
inactivated by protein interactions or aqueous solutions. 
 
 
 
 
Fig. 1.18 Asymmetric hydrogenation of N-acetamidoacrylate into N-acetamidoalanine, 
catalyzed by Whitesides’s system. The biotinylated rhodium-diphosphine complex 
embedded into the avidin scaffold is the first example of artificial metalloenzymes based on 
avidin-biotin technology [80] 
 
At the interface between organometallic catalysis and enzymatic chemistry, 
artificial metalloenzymes represent a complementary approach to asymmetric 
transformations. Substrate scope and operating conditions are mainly 
influenced by the catalytic metal-ligand components, while enantioselection 
depends upon the biomolecular scaffold. Chemo-genetic optimization of this 
semisynthetic catalytic system can increase the performance of artificial 
metalloenzymes.
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Chapter 2 
Optimization of Streptavidin 
Production 
!
The man of action has 
to believe, the inquirer 
has to doubt – the 
scientific investigator 
is both 
Charles Sanders Peirce 
!
2.1 Introduction 
2.1.1 Directed Evolution and Rational Protein Re-Design 
Protein engineering is a young discipline developed as a means to obtain 
valuable proteins. By modifying a protein sequence, protein engineering 
provides modified macromolecules with increased activity or a more 
comprehensible structure-activity relationship.  
Protein engineering methodology entails two general approaches: rational re-
design and directed evolution.  
Rational re-design is performed by site-directed mutagenesis, a 
straightforward and inexpensive technique that allows site-specific mutation 
into the gene encoding for the protein of interest [1]. 
Since a single point mutation may significantly disrupt protein folding, 
rational re-design requires large knowledge about protein structure and 
! -32- 
sequence-activity relationship. According to rational protein re-design, only 
“logical” amino acid residues, as for example residues close to the active site 
or within the binding pocket, are usually modified, in accordance with three 
dimensional crystal structures [2]. 
The increasing number of protein structures, solved by NMR spectroscopy or 
X-ray diffraction, has improved access to public data promoting rational re-
design strategy. Furthermore, molecular modeling provides a method to 
predict the effects of selected mutations on the selectivity, activity or stability 
of a protein [3].  
In contrast, directed evolution, also called molecular evolution or evolutive 
biotechnology, involves random mutagenesis of the gene of interest to 
generate mutant libraries [2]. This approach requires several rounds of 
“screening and selection” of mutants with improved features, including an 
appropriate high throughput screening system for identifying the evolved 
variants.  
Different methods can introduce random mutations into genes. Error-prone 
polymerase chain reaction (epPCR), based on the error rates of DNA 
polymerases, represents a milestone in this field. This strategy induces amino 
acid substitutions in the encoded protein through errors in DNA amplification 
as a consequence of imperfect reaction conditions (e.g. by varying nucleotide 
ratios or by adding Mn2+ to increase the error-rate or Mg2+ to stabilize non-
complementary base-pairs) [4]. 
Another important methodology exploited in directed evolution to introduce 
point mutations into genes is known as saturation mutagenesis [5]. This 
approach entails the insertion of codons encoding all possible 20 amino acids 
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at an established position of the protein, generating a library of 20 protein 
variants [6]. 
An alternative strategy to introduce random mutations within the gene 
generating new proteins with novel activities is DNA shuffling. This strategy, 
also called “sexual PCR” because it is akin to the generation of genetic 
diversity during meiosis, involves gene fragmentation by DNAse I and 
subsequent reassembly by PCR [7].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 Rational Protein Re-Design and Directed Evolution. Rational re-design strategy 
requires a protein structure to tailor new mutants. After expression in the host organism (e. g. 
E. coli), variants are purified and analyzed for suitable properties. Directed evolution is 
performed by random mutagenesis, which generates mutant gene libraries. Protein libraries 
are expressed in the host organism and screened. Selection is based on different parameters, 
such as substrate scope and protein stability [2] 
 
A successful combination of rational re-design and directed evolution offers 
the exciting possibility to generate mutant gene libraries with desired 
structural and functional properties [2] . 
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2.1.2 Enantioselectivity of Enzymes Controlled by Directed Evolution 
Asymmetric catalysis is of great importance in the chemical and 
biotechnological fields, since different agents often exert their specific effect 
only as enantiopure compounds. Besides organocatalysts, catalytic antibodies 
and organometallic complexes, enzymes can also perform catalytic 
transformations with high enantioselectivity [6].  
In 1994, Stemmer was the pioneer of in vitro DNA shuffling as a method to 
perform enzyme evolution [8]. Native !-galactosidase from E. coli is weakly 
specific for !-D-fucosyl substrates and displayed an enhanced !-fucosidase 
activity after seven rounds of DNA shuffling and colony screening on 
chromogenic fucose compounds [9].  
In 1998, Kagamiyama modified the substrate specificity of aspartate 
aminotransferase (AspAT) by directed evolution. Five rounds of DNA 
shuffling increased the activity of AspAT for the non-native substrates valine 
and 2-oxovaline [10]. 
In 2000, Arnold inverted the enantioselectivity of hydantoinase by directed 
evolution. A combination of random mutagenesis, saturation mutagenesis, 
and screening led to conversion of the D-selective hydantoinase into an L-
selective enzyme, with high-production of L-met [11]. 
Directed evolution, as a means to control enzymatic activity, also increased 
the enantioselectivity (E) of a lipase from P. aeruginosa in favor of the (S)-
configured acid (S-B) [6, 12].  
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Fig. 2.2 The hydrolytic kinetic resolution of a chiral ester catalyzed by a lipase from 
P. aeruginosa. The hydrolysis of the chiral ester (rac)-A resulted in the (S)-acid (S-B), the 
(R)-ester (R-A) and p-nitrophenol (D) [12] 
 
Reetz subjected the gene encoding the lipase to random mutagenesis by 
epPCR and saturation mutagenesis. Through four generations of mutant 
lipases, the ee of the reaction increased from 2% to 81% at 25% conversion 
for the (S)-enantiomer, corroborating the validity of this strategy [12b]. 
 
2.1.3 Chemogenetic Optimization of Artificial Metalloenzymes 
Though biocatalysts can perform many enantioselective transformations, 
several limitations hamper their widespread application in organic chemistry. 
No enzyme catalyzes reactions such as hydroformylation, allylic substitution, 
or hydrovinylation [13].  
For this reason artificial metalloenzymes, characterized by a homogeneous 
catalyst embedded within a protein environment, constitute a promising 
alternative for the synthesis of enantiopure compounds [14]. 
Inspired by the pioneering work of Whitesides and Wilson [15], our research 
group improved the enantioselectivity of artificial metalloenzymes by 
chemogenetic “fine-tuning” of the hybrid catalyst [16].  
The hydrogenation of acetamidoacrylic acid, using diphosphine rhodium 
complexes within streptavidin as host protein, is the first published example 
of artificial hydrogenases based on biotin-(strept)avidin technology [17]. The 
chemogenetic approach has improved the yields of the reaction through a 
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combination of rational protein design of the second coordination sphere by 
site-directed mutagenesis and chemical modification of the homogeneous 
catalyst.  
The substitution of a serine by a glycine residue at position 112 of 
streptavidin increased the ee of the reaction from 94% to 96% in favour of the 
(R)-product. On the contrary, enantioselectivity was reversed to the (S)-
product by using avidin as host protein [18].  
A meta-substituted aromatic amino acid spacer (4meta) was introduced between 
biotin and the diphosphine moiety. This [Rh(Biot-4meta-1)COD]+ ! WT Sav  
catalyst afforded (S)-reduction products [14a]. 
 
2.1.4 First Round Evolution of Artificial Transfer Hydrogenases  
Inspired by Noyori-type asymmetric transfer hydrogenation of ketones [19] 
previous members of our research group invested a significant effort to 
optimize artificial transfer hydrogenases (ATH) based on the biotin-
streptavidin technology.  
Biotinylated catalyst precursors (["6-(arene)Ru(Biot-q-L)Cl]) were implanted 
into streptavidin as host scaffold to perform asymmetric transfer 
hydrogenation reactions [16c, 20].  
In Noyori’s system, the enantioselectivity of the reduction was indirectly 
controlled by the enantiopure ligand, which determined the absolute 
configuration at the Ru centre [21]. By contrast, in artificial metalloenzymes, 
the enantioselection was controlled by second coordination sphere 
interactions with the metal complex. In the absence of an enantiopure ligand, 
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the protein scaffold provides a chiral environment. Racemic-reduction 
product is formed in the absence of streptavidin. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3 Schematic representation of a) Noyori’s (R,R)-TsDPEN catalyst and b) artificial 
transfer hydrogenases based on biotin-streptavidin technology. a) (R,R)-diamine ligand 
generates (S)-metal and (R)-reduction product in Noyori’s system; b) (["6-(arene)Ru(Biot-q-
L)Cl]) precatalyst (arene = p-cymene or benzene, q = ortho-, meta- or para-) performs the 
asymmetric reduction of acetophenone derivatives, in the presence of HCOONa as hydrogen 
source, B(OH)3, MOPS and DMF as buffer and organic co-solvents, when it is embedded into 
WT Sav scaffold, which determines the enantioselectivity of the reaction [20, 22] 
 
A library of hybrid transfer hydrogenases was generated with the aim of 
optimizing the activity and selectivity of the artificial metalloenzymes, 
through minimal modifications of three important factors: chemical, genetic 
and substrate diversity [20].  
 
CHEMICAL DIVERSITY 
The chemical diversity was varied as follows: 
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Metal Centre: Ru, Rh, Ir 
 
GENETIC DIVERSITY 
19 Sav variants were produced by saturation mutagenesis at S112 position. 
 
 
SUBSTRATE SCOPE 
The following substrates were used in transfer hydrogenation reactions 
catalyzed by artificial metalloenzymes: 
 
 
 
 
 
 
2.1.4.1 Chemical Optimization of ATH 
21 catalyst precursors were produced by varying the arene cap, the biotin 
anchor position and the metal centre. In a first screening, performed in the 
presence of two streptavidin isoforms (WT and P64G), only five metal 
complexes, bearing the Biot-p-L ligand, were found promising for the 
reduction of acetophenone derivatives 1-3: (["6-(p-cymene)Ru(Biot-p-L)Cl]), 
(["6-(benzene)Ru(Biot-p-L)Cl]), (["6-(durene)Ru(Biot-p-L)Cl]), (["6-
(C5Me5)Ir(Biot-p-L)Cl]) and (["
6-(C5Me5)Rh(Biot-p-L)Cl]) 
[16c].  
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2.1.4.2 Saturation Mutagenesis at Position S112 
The subsequent optimization involved the second coordination sphere 
through saturation mutagenesis at position S112 of streptavidin. Docking 
studies, performed in collaboration with Dr. Sylwester Mazurek at the 
University of Ljubljana, identified residue S112 for genetic optimization due 
to close contacts between the side chain and the biotinylated metal. 
The most stable docked structure of the artificial transfer hydrogenases ["6-
(p-cymene)Ru(Biot-p-L)H] ! WT revealed an average distance Ru-C! < 8 Å 
for two amino acid residues: S112 and S122. However, position S112 was 
selected for mutagenesis because its side chain points towards the piano-stool 
fragment in contrast with serine 122, which is oriented away from the 
complex (Fig. 2.4) [20]. 
 
Fig. 2.4 Docking studies between [!6-(p-cymene)Ru(Biot-p-L)H] and WT Sav. The 
biotinylated ruthenium complex is shown as ball-and-stick. WT streptavidin is represented by 
blue, green, yellow and violet subunits corresponding to A, B, C and D monomers, 
respectively. The secondary structure of monomers A and C is schematically drawn. The 
close lying S112 and S122 residues point towards the piano-stool moiety and away, 
respectively [20] 
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2.1.4.3 Results of Chemogenetic Optimization  
The 20 streptavidin variants derived from saturation mutagenesis at position 
S112 were evaluated in conjunction with the five most promising metal 
catalysts for the reduction of acetophenone derivatives 1-3. The results of this 
screening were summarized in a fingerprint display, a color-coded format that 
permits rapid identification of enantioselectivity and conversion of the 
reaction, depending on substrate-protein-ligand combinations (Fig. 2.5).  
Chemogenetic optimization evidenced that: 
• The capping arene controls the enantioselectivity:  "6-(p-cymene)- and 
"6-(durene)-complexes afforded (R)-reduction products, whereas "6-
(benzene)-complex produced (S)-enantiomers.  
• Changing the residue of position S112 drastically influenced 
enantioselectivity and conversion: coordinating residues at position 
S112 (e.g. S112C, S112M, S112D, S112E or S112H) almost 
completely inhibited the transfer hydrogenation catalyzed by the 
artificial metalloenzyme, while cationic residues (e.g. S112K and 
S112R) and hydrophobic amino acids (e.g. S112Y, S112F, S112V, 
S112A) favoured (S)- and (R)-products, respectively, with relatively 
high conversion. 
 
 
 
!
!
!
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Fig. 2.5 Fingerprint display of the results for the chemogenetic optimization of the 
artificial transfer hydrogenases. Five biotinylated piano-stool ruthenium complexes were 
incorporated into 20 streptavidin isoforms S112X to perform the transfer hydrogenation of 
three prochiral ketones: acetophenone 1, p-bromoacetophenone 2 and p-methylacetophenone 
3 [20] 
 
The ["6-(p-cymene)Ru(Biot-p-L)Cl] was the most promising (R)-selective 
metal complex, while the ["6-(benzene)Ru(Biot-p-L)Cl] catalyst resulted in 
(S)-products. 
 
2.1.5 X-Ray Crystal Structure of an Artificial Transfer Hydrogenase 
A structural and functional insight into the hybrid hydrogenase was an essential 
prerequisite to perform the second round evolution of artificial transfer 
hydrogenases. For this reason, the most promising hybrid protein catalysts 
involved in transfer hydrogenation were proposed for crystallization and 
structural analysis.  
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In 2007, the catalytically active ["6-(benzene)Ru(Biot-p-L)Cl] was co-
crystallized with the S112K streptavidin mutant [23]. 
The crystal structure was solved by Dr. Isolde Le Trong and Prof. Ronald 
Stenkamp (University of Washington). 
In this discussion of the refined model we focused mainly on the close contacts 
between the biotinylated Ru complex and amino acid residues in the protein 
scaffold. 
A partial occupancy (only 20%) of the ruthenium complexes could be 
interpreted in several ways:  
i. Conformational flexibility inside the host protein. 
ii. Ruthenium decomplexation during co-crystallization in the presence of 
sodium citrate (0.1 M). 
iii. Steric clash between two neighboring biotinylated complexes, 
simultaneously present in two adjacent subunits of the S112K scaffold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6 Close up view of two neighboring biotinylated Ru complexes within two adjacent 
subunits. Simultaneous presence of ["6-(benzene)Ru(Biot-p-L)Cl] complex in two adjacent 
monomers (A and B) of 112K Sav is hindered by close contacts between the two biotinylated 
complexes. The structural model focuses on the position of the metal moiety, located near a 
subunit-subunit interface (Ru""""Ru distance: 4.44 Å) 
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This processed model, consistent with the docking results (described in 
subsection 2.1.4), confirmed the immediate vicinity between amino acid 
residue S112 and the ruthenium centre. 
Other amino acid side chains were shown to lie in the proximity of the 
biotinylated complex. G48 (in the L3,4 loop) and H87 (in the L5,6 loop) of 
monomer A interact with the Ru catalyst. Position K121 was of particular 
interest, as this residue in subunit B (K121B) interacts with the "
6-(arene), 
while K121 of subunit A (K121A) may interact with the incoming substrate. 
The substrate can also be influenced by interactions with other amino acid 
residues, identified along the expected trajectory of the substrate (i.e. N118, 
A119, W120 in the L7,8 loop). Additionally, the side chain of residue L124 
lies close to the SO2 moiety (linking the ruthenium piano-stool complex and 
the biotin anchor). It thus may influence the position of biotinylated ruthenium 
complex within the hydrophobic pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 X-ray crystal structure of  [!6-(benzene)Ru(Biot-p-L)Cl] !  S112K. Close up view 
of the biotinylated ruthenium complex bound to the S112K monomer A (blue) and partially 
interacting with the other subunit B (orange). Residues K112A, K121A and L124A (monomer A) 
as well as K112B and K121B (monomer B), which lie close to the ruthenium metal, are 
highlighted as sticks. Residues G48, H87, N118, A119 and W120 are depicted as light blue 
lines 
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2.1.6 Expression and Purification of T7-Sav in Large-Scale 
Chemogenetic optimization of artificial metalloenzymes requires large 
amounts of protein to carry out experiments, in the absence of a high-
throughput screening (HTS) assay [14a, 16c, 17]. 
Overexpression of streptavidin in the native host (i.e. Streptomyces avidinii) 
suffers from numerous restrictions including a relatively long time to culture 
and a final heterogeneous product. For these reasons, previous co-workers 
have invested much effort to optimize critical parameters of recombinant 
streptavidin expression in a soluble form. 
The choice of E. coli as expression strain was motivated by many factors such 
as, for example, low cost, simple transformation protocol, easy fermentation 
and high protein yields. However, streptavidin overexpression in E. coli leads 
to several problems, for example, formation of inclusion bodies and biotin 
depletion, which ultimately inhibits the bacterial growth. 
In order to overcome these problems, Dr. Nicolas Humbert in the Ward group 
carried out several experiments to increase protein solubility and cell growth. 
The pET11b-Sav plasmid (provided by Prof. Santambrogio from University 
of Milan), where the protein gene was cloned between two phage promoters 
(T7 and T7term) in opposite orientations, was used as expression vector for 
recombinant T7-tagged streptavidin. This protein construct consists of 159 
residues with the first 13 N-terminal amino acids replaced by a T7 epitope 
tag, an immunological marker that increases streptavidin solubility in the 
cytoplasm of E. coli.  
! -45- 
The host BL21(DE3)pLysS E. coli strain, transformed by the recombinant 
vector pET11b-Sav, was selected as the system for high-level expression of 
streptavidin in a soluble form [24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8 High-level expression of cloned streptavidin gene controlled by T7 RNA 
polymerase in BL21(DE3)pLysS E. coli strain. In the absence of IPTG (a molecular mimic 
of allo-lactose), the lac repressor binds to the lac operon, preventing E. coli RNA polymerase 
binding and, consequently, T7 RNA polymerase and streptavidin gene transcription (figure 
modified from sbl website) 
 
Bacterial growth was, finally, optimized by raising the temperature from 
30 °C to 37 °C.  
Under these conditions, cultivation of the cells in a 10L fermentor yielded 
230 mg/L of soluble streptavidin [25]. 
The protein was purified by imino-biotin affinity chromatography. After 
lyophilisation, the biotin-binding sites were quantified by biotin-4-fluorescein 
titration [26]. 
This complete process of streptavidin expression and purification requires a 
minimum of three weeks and is an extremely time-consuming process. 
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2.2 Aim of the Work 
In the context of artificial metalloenzymes, this work was aimed at improving 
hybrid catalysts through genetic evolution of the biotin-binding protein 
scaffold.  
The broad aim of this chapter was to explore the influence of the second 
coordination sphere on enantioselective trends and catalytic performance of 
artificial transfer hydrogenases.  
Having identified by X-ray crystallography two additional close lying residues, 
we speculated that saturation mutagenesis at those positions (K121 and L124) 
could improve the performance of the hybrid catalysts involved in the transfer 
hydrogenation through a “designed” evolution scheme. 
To achieve this goal, we strived to implement a straightforward protein 
production and purification scheme, amenable to HTS.  
For this purpose both streptavidin immobilization and thermal treatment of 
crude cell extracts were investigated. 
 
 
2.3  Results and Discussion 
2.3.1 Saturation Mutagenesis at Positions K121 and L124 
The X-ray crystal structure, described in subsection 2.1.5, provided a 
fascinating description of a hybrid catalyst involved in the transfer 
hydrogenation, highlighting the organization of the active site and the 
interactions between the ruthenium complex and protein scaffold.  
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Further rounds of optimization of the artificial metalloenzyme were performed 
by “designed evolution”. This term, coined by Dr. Marc Creus, alludes to a 
combination of rational choices related to metal ligands and protein residues 
with rounds of screening in order to fine-tune the best catalytic features that are 
unpredictable a priori [27]. 
To implement “designed evolution” we selected the (R)- and (S)-selective 
variants (112A Sav and 112K Sav, respectively, identified in the first 
optimization round, see subsection 2.1.4), and additionally targeted two of the 
close-lying amino acid residues identified in the crystal structure. 
The first chemogenetic optimization step yielded high (R)-selective and 
moderate (S)-selective combinations for the reduction of aromatic ketones. In 
contrast, very modest selectivities were obtained for the reduction of dialkyl 
ketones.  
A designed evolution approach was performed to improve the 
enantioselectivity of enantioselective artificial transfer hydrogenases and to 
generate novel systems for the reduction of challenging dialkyl ketones. 
Saturation mutagenesis at position S112 revealed a modest influence on dialkyl 
substrates. The enantiodiscrimination was weakly controlled by the interactions 
between dialkyl substrates and side chains at position 112. 
Therefore, we performed a saturation mutagenesis at two unexplored positions 
of particular interest: K121, which possibly interacts both with the "6-arene 
(K121B) and with the substrate (K121A) as well as L124, which may alter the 
position of the metal complex within the hydrophobic pocket. 
Saturation mutagenesis at positions K121 and L124 was carried out in 
collaboration with Dr. Anita Ivanova and Dr. Marc Creus, by using the genetic 
! -48- 
backgrounds of WT Sav (to generate single mutants) and S112A Sav or S112K 
Sav (to generate double mutants) for a total of 117 Sav isoforms. 
For the second evolution round we chose the S112A mutant for its promising 
(R)-selectivity for the reduction of acetophenone derivatives as well as the 
S112K mutant for its promising (S)-selectivity. 
 
 
 
 
 
Fig. 2.9 Second coordination sphere interactions between protein scaffold, biotinylated 
ruthenium catalyst and substrate 
 
A total of 117 streptavidin isoforms were produced and screened in 
combination with either ["6-(p-cymene)Ru(Biot-p-L)Cl] or ["6-
(benzene)Ru(Biot-p-L)Cl] complexes, for the reduction of p-
bromoacetophenone 2 and 4-phenyl-2-butanone 6 (see subsection 2.1.4). 
The successful insertion of mutations into the plasmids was verified by two 
methods: a restriction digest, to detect an inserted silent mutation (24/117 
plasmids were analyzed), and DNA sequencing (Microsynth, Switzerland) 
(14/117 different plasmids were tested). Results confirmed a successful 
insertion in > 90% of mutations of the sequence analyzed. 
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2.3.2 Streptavidin Isoforms Expression in Small-Scale Cell Culture 
The first round of ATH screening was performed with 3-4 mg (per catalytic 
experiment) of each of the 20 purified streptavidin mutants (S112X).  
The second screening experiments called for a HTS approach to test the most 
promising catalysts in combination with the 117 protein variants. Indeed, the 
large-scale expression and purification was too lengthy to produce and purify 
these 117 mutants.  
Thus, streptavidin production was scaled-down from 10 L of E. coli cell 
culture (previously performed in a 10 L fermentor) to 50 mL of culture (carried 
out in 250 mL baffled Erlenmeyer flasks).  
However, high levels of protein expression were an important prerequisite to 
perform a HTS strategy. 
Hence, in close collaboration with Dr. Anita Ivanova and Dr. Marc Creus, we 
optimized critical parameters of small-scale streptavidin expression. 
Many variables, including medium, volume, speed, temperature and glucose 
supplement to cell culture, were reassessed and improved. 
We devised a screening strategy for the selection of the most suitable medium 
for streptavidin expression, which led to the choice of Tryptone Phosphate 
(TP) Broth.  
Different shaking-speeds and thermal conditions were screened to fine-tune 
high-yields streptavidin expression. At the end, cultures were incubated on an 
orbital shaker (415 rpm) and grown in baffled Erlenmeyer flasks for 6 hrs at 
34.5 °C, in the absence of glucose supplement. 
Harvested cells were frozen-thawed and resuspended in 1.5 mL of extraction 
buffer (pH 7.4) in the presence of DNase1. Pooled supernatants were titrated 
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for biotin-fluorescein binding activity in 96-well plates, from which the 
concentration of free streptavidin active sites was calculated.  
The 117 Sav isoforms were directly screened for catalysis as crude cell 
extracts, alleviating the time-consuming process of protein purification and 
lyophilization.  
Typically, 100 mL of culture (e.g. 2 x 50 mL) was sufficient for catalysis, 
although 24/117 new mutants did not express sufficient soluble protein for 
catalytic reactions and were not tested further. 
Expression levels of single and double mutants per volume of culture are 
summarized in a fingerprint display. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.10 Expression levels of streptavidin isoforms per volume of culture. Pooled extracts 
from a minimum of 100 mL cultures were titrated for biotin-fluorescein binding activity in 96-
well plates. The active-site concentration was determined using a B4F titration [26] 
 
! -51- 
2.3.3 Immobilization as HTS Approach 
The presence of catalyst inhibitors in the cell extract has hampered the 
screening of crude cell supernatants for their catalytic performance in the 
presence of biotinylated catalysts. 
Thus far, only pure streptavidin samples gave active metalloenzyme systems. 
However, the long streptavidin purification protocol represents a bottleneck for 
the evolution round and, ipso facto, a new production and purification protocol 
was sought to test the 117 new Sav mutants.  
We addressed this challenge in collaboration with Dr. Anca Pordea and Mr. 
Thibaud Rossel (Ward group) by performing a Sav immobilization protocol 
with biotin-sepharose. In this straightforward approach streptavidin isoforms 
were directly immobilized from crude cell extract thanks to the exquisite 
affinity of the protein for biotin. 
The tetrameric structure of streptavidin allowed to utilize one biotin-binding 
site for immobilization on biotin-sepharose, leaving the other three biotin-
binding sites free to accommodate biotinylated catalyst.  
The immobilized streptavidin was initially washed with guanidinium chloride 
(1 M) to remove other bacterial proteins and was mixed with the most 
promising precursor complexes (["6-(benzene)Ru(Biot-p-L)Cl] or ["6-(p-
cymene)Ru(Biot-p-L)Cl]). In the presence of HCOONa • B(OH)3 mixture as 
hydrogen source and substrates 2 and 6 (see subsection 2.1.4), catalysis was 
performed at 55 °C for 64 hrs. 
Although the purification-immobilization strategy slightly compromised 
activity and selectivity of the transfer hydrogenation reaction, this protocol 
allowed a rapid screening to identify trends. 
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The enantioselective trends, observed with the immobilized ATH and 
summarized in a fingerprint display, revealed that: 
• The capping arene influences enantioselectivity of the reaction. The 
substitution of "6-(p-cymene) by "6-(benzene) moiety results frequently 
in an inversion of the absolute configuration of the product. 
• The artificial metalloenzymes incorporating S112A mutation give 
better enantioselectivities than WT and S112K derived isoforms. 
• Saturation mutagenesis at position K121 brings more diversity than 
mutations in positions L124, probably due to the influence of the K121 
side chain both on the piano-stool moiety and on the trajectory of 
incoming substrate. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.11 Fingerprint display of results for the chemogenetic optimization of immobilized 
ATH. Catalyses were performed on crude cell extracts in the presence of biotin-sepharose-
immobilized ATH. The most promising (S)- and (R)-selective precatalysts, ["6-
(benzene)Ru(Biot-p-L)Cl] and ["6-(p-cymene)Ru(Biot-p-L)Cl] respectively, were 
incorporated in 117 streptavidin isoforms to perform the asymmetric reduction of two 
substrates (2 and 6) [23] 
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The most promising results in term of enantioselectivity and conversion were 
reproduced with purified streptavidin mutants. In most cases, an increase in ee 
and activity was observed with the purified protein. 
 
2.3.4 Thermo-denaturation as Straightforward Purification Strategy 
2.3.4.1 Thermo-Stability of Pure Streptavidin Variants 
Another strategy aimed at simplifying the lengthy streptavidin purification and, 
consequently, at maximizing high throughput catalytic screening was based on 
a thermo-denaturation protocol. This approach was inspired by Reetz’s 
suggestion, where a thermo-stable enzyme (tHisF), easy to purify, was selected 
as scaffold for hybrid catalysts [28]. 
We reasoned that the high thermal stability of streptavidin could be exploited 
to purify the protein by simple heat treatment [29].  
However, thermo-modification of the protein scaffold could negatively affect 
performance of artificial metalloenzymes in several transformations.  
Thus, first we investigated thoroughly the relationship between heating and 
pure streptavidin folding and catalytic performance on pure streptavidin 
samples.  
Three pure streptavidin isoforms were heated at increasing temperature for 5, 
10 and 30 minutes. Long exposition-time and high temperature modified 
quaternary protein structure, as monitored by B4F titration [26] and SDS-PAGE 
assay.  
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Fig. 2.12 Thermo-stability of pure streptavidin variants monitored by non-denaturing 
SDS-PAGE. After heat treatment, heated supernatants were loaded into the gels. From left to 
right temperature and exposition-time were reduced. a) and c) electrophoretic assays highlight 
biotin-fluorescein binding activity of proteins. The activity is compromised at 85 °C-5 min and 
at 75 °C-30 min, as evidenced by reduced fluorescence. b) and d) gels were stained in 
Coomassie Blue. The destaining reveals that tetrameric form of S112A and S112Q mutants is 
converted into monomer at 85 °C-5 min and at 75 °C-30 min 
 
As template, we chose artificial allylic alkylases to perform catalytic reaction 
after heat treatment on pure streptavidin samples. “Fitness” of these hybrid 
catalysts was compromised by high temperature, as revealed by a reduced 
enantioselectivity (Table 2.1), which is consistent with loss of free active sites 
(Table 2.1) as well with a weak biotin-affinity (Fig. 2.12) observed after 
thermo-denaturation. 
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Table 2.1 Results of [Pd(Ph2Allylic)Cl]2 – catalyzed asymmetric allylic alkylation 
performed in the presence of heated pure protein. Sav-WT was chosen as reference 
scaffold, whereas S112A and S112Q were selected, respectively, as the most promising (R)-
and (S)-selective protein host, under standard conditions  
 
 
Entry Protein Condition Active Site ee[%] Conv[%] 
1 Standard 3.6 65 87 
2 75 °C, 5 min 3.6 65 86 
3 75 °C, 10 min 3.6 64 85 
4 75 °C, 30 min 3.6 30 77 
5 
WT 
85 °C, 5 min 3.6 34 77 
6 Standard 4 92 90 
7 75 °C, 5 min 4 92 87 
8 75 °C, 10 min 2 93 88 
9 75 °C, 30 min < 1.6 27 82 
10 
S112A 
85 °C, 5 min < 1.6 37 80 
11 Standard 4 -35 99 
12 75 °C, 5 min 4 -33 98 
13 75 °C, 10 min 4 -35 99 
14 75 °C, 30 min 2.8 -19 89 
15 
S112Q 
85 °C, 5 min 4 -35 99 
 
These trials provided useful information to perform a correct protocol of 
streptavidin purification based on thermo-denaturation on cellular extracts 
containing streptavidin.  
Since high temperature destabilizes streptavidin mutants, we selected moderate 
conditions for thermal treatment of cell lysates in order to preserve protein 
folding and potentially high catalytic performance.  
 
2.3.4.2 Hybrid Catalysts in Crude Cell Extract 
After these preliminary trials on heat-denaturation of pure streptavidin, we 
investigated streptavidin purification in cell extract via thermo-treatment 
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ranging from 65 °C to 95 °C. Different cellular components, such as unwanted 
mesophilic proteins, were removed by this step. 
After expression, the cell lysate was exposed to high temperature for 10 
minutes and the resulting cloudy suspension was centrifuged to separate the 
pellet from the supernatant.   
Heated supernatants were loaded on polyacrylamide gels, which revealed high 
protein purity and strong biotin-fluorescein binding activity. The pellets were 
also analyzed and revealed increasing amounts of inactive monomer in a 
background of many protein species. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.13 Thermo-denaturation as purification strategy estimated by non-denaturing 
SDS-PAGE. The polyacrylamide gel was run after heating ranging from 65 °C to 95 °C for 10 
minutes. Lane 1: protein marker (220 kDa). Lane 2: crude cell extract before heating. Lanes 3, 
5, 7, 9, 11, 13: pellet after heat-treatment at different temperature (65 °C, 71 °C, 77 °C, 83 °C, 
89 °C, 95 °C, respectively). Lanes 4, 6, 8, 10, 12, 14: supernatant post heating at different 
temperature (65 °C, 71 °C, 77 °C, 83 °C, 89 °C, 95 °C, respectively). Gel a. reveals B4F 
binding activity of streptavidin, which is compromised at very high temperature due to protein 
denaturation. Gel b. highlights increasing level of streptavidin purity in supernatant at rising 
temperature 
 
Thus, the results of SDS-PAGE suggested that heat treatment of supernatants 
from cell lysates yielded reasonably pure streptavidin. We anticipated that this 
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straightforward purification protocol might be used to significantly simplify the 
screening effort. 
Contrary to enzymes, which are naturally evolved as biocatalysts in living 
cells, organometallics and artificial metalloenzymes are not designed to 
catalyse reactions in vivo or in the presence of cell debris.  
The presence of many cellular components, such as thiols, anionic nucleic 
acids or other metal-binders, can inhibit catalysis in crude cell extract. 
However, stimulated by this challenging perspective and encouraged by recent 
work of Streu and Meggers, who described a “ruthenium-induced 
allylcarbamate cleavage in living cells”, we tested artificial metalloenzymes 
using crude cell extract [30]. 
In 2009 Adriaenssens et al. published the first example of catalyzed C-C bond 
formation in E. coli cell lysate [31]. Consequently, we chose palladium-
catalyzed asymmetric allylic alkylation as the reaction to be performed directly 
in heated crude cell extract, in collaboration with Mr. Cheikh Lo (Ward group) 
[14c].  
 
 
Fig. 2.14 Asymmetric allylic alkylation catalyzed by artificial metalloenzymes [14c] 
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The results of catalytic runs are summarized in Table 2.2. In light of the 
disappointing results obtained with heat-treated cell supernatants, we 
hypothesized that: 
i. The presence of DNA may inhibit catalysis 
ii. The presence of glutathione may also poison the precious 
metal [32]. 
To alleviate these potential metal-binding macromolecules, the cell lysates 
were treated with DNaseI and dialysed against mQ-H2O, thus removing all low 
molecular weight species. 
Despite these additional purification steps, the results remained disappointing, 
revealing a drastic reduction of catalytic activity (conversion) in crude cell 
extract.  
These reactions were performed under classical conditions, although slightly 
more dilute. Dilution was necessary owing to a low streptavidin concentration 
in the crude cell extract.  
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Table 2.2 Results of [Pd(Ph2Allylic)Cl]2 – catalyzed asymmetric allylic alkylation 
performed in heated crude cell extract. Catalysis performed in H2O in the absence of 
streptavidin leads to formation of racemic-allylic product with a modest conversion (entry 1). 
Pure streptavidin variants, acting as protein scaffold, afford enantioselective allylic alkylase in 
H2O (entries 2, 9, 12). Low conversion is constantly observed in the presence of crude cell 
extract expressing streptavidin. “Empty” extract is defined as E. coli cell extract not-expressing 
streptavidin, but from cells containing the plasmid without a gene insert, treated in the same 
way as for cells expressing Sav 
 
 
Entry 
Protein 
(Sav) 
Condition ee[%] Conv[%] 
1 Metal complex  2 39 
2 Catalyst in crude "empty" extract 57 3.1 
3 Catalyst in heated "empty" extract (75 °C, 10') 4 3.0 
4 
No 
Catalyst in heated "empty" extract (75 °C, 10', 
dialysis) 
3 25 
5 Catalyst into pure streptavidin 79 59 
6 Catalyst in crude extract 68 0.8 
7 Catalyst in heated extract (75 °C, 10') 71 1.0 
8 Catalyst in heated extract (75 °C, 30') 62 2.9 
9 Catalyst in heated extract (75 °C, 10', dialysis) 79 3.0 
10 Spiking with pure protein (75 °C, 10') 57 1.4 
11 
WT 
Spiking with pure protein (75 °C, 10', dialysis) 78 5 
12 Catalyst into pure streptavidin  91 98 
13 Catalyst in heated extract (75 °C, 30') 9 15 
14 
S112A 
Spiking with pure protein (75 °C, 10', dialysis) 89 9 
15 Catalyst into pure streptavidin  -31 100 
16 Catalyst in heated extract (75 °C, 30') 40 1.0 
17 
S112Q 
Spiking with pure protein (75 °C, 10', dialysis) 34 22 
 
On the basis of this screening, several features were identified: 
• High conversion was observed when the catalytic reaction was 
performed in H2O in the presence of homogeneous catalyst (entry 1) as 
well as artificial allylic alkylase (entries 5, 12, 15), even under diluted 
conditions. 
• The presence of crude cell extract inhibited catalysis in all cases, as 
confirmed by a very low conversion (entries 2, 3, 6, 7, 8, 9, 10, 11, 13, 
14, 16, 17).  
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• Reduced catalytic activity was also observed with spiked protein on 
crude cell extract (entries 10, 11, 14, 17). This result confirmed a clear 
correlation between low conversion and components present in the cell 
lysate.  
• No (S)-alkylation product, which is normally favoured by S112Q 
mutant (entry 15), was observed in the presence of E. coli cell lysate, 
expressing S112Q isoform (entries 16, 17) [14c]. 
Compared to catalytic experiments using pure protein under otherwise identical 
conditions (concentration, temperature, pH, etc.), the results with thermo-
treated cell lysates were disappointing (compare Table 2.1 and Table 2.2). 
Catalytic inhibition could be related to the presence of unknown high-
molecular-weight molecules (e.g. liposome or nucleic acids), which absorb at 
250 nm, as revealed by the UV-VIS. A possible interaction between these 
macromolecules and the artificial metalloenzymes could hinder the reaction.  
 
 
Fig. 2.15 Adsorption spectrum (800-200 nm) of pure streptavidin and crude cell extract. 
The black spectrum is typical of a pure protein, absorbing at 280 nm (final concentration 5 
"M). The red spectrum, resulting from cell extract analysis, displays a maximum at 250 nm, 
which suggests the presence of unknown non-protein components. In cell lysate, the protein 
peak (0.11 "M), whose presence is confirmed by SDS-PAGE, is masked by the large peak at 
250 nm  
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Extraction with organic solvents (n-butanol and ethyl acetate) was the last 
attempt aimed at removing eventual lipids from crude cell extract, which did 
not improve, however, catalytic activity. For all these reasons, we decided to 
shelve this challenging project. 
 
2.3.4.3 Streptavidin Refolding 
As previous trials revealed, streptavidin is stable under thermal denaturation. 
Comparing thermal stability of three streptavidin isoforms (WT, S112A, 
S112Q), we identified a thermal vulnerability of S112A and S112Q mutants, 
whose tetrameric form is converted into monomer at 75 °C, and a highly stable 
tetrameric structure of WT, whose transition temperature (from tetramer to 
monomer) is superior to 90 °C.  
A closely packed !-barrel may also warrant high stability of streptavidin over 
wide pH and in the presence of chaotropic reagents. 
Over decades many researchers have carefully investigated relationship 
between denaturant agents and streptavidin integrity. 
In 1990 Sano and Cantor argued that high concentrations of urea (6 M) induced 
conversion of tetrameric streptavidin into two dimers [33]. In 1991 this finding 
was refuted by Kurzban, who claimed the stability of the tetrameric form even 
in the presence of 6 M urea [34].  
Inspired by these findings, we tested streptavidin denaturation conditions, 
leading to full denaturation of the protein. This required protein dissolution in 
guanidinium cloride (6 M, pH 1.5) and heating at 95 °C for 5 minutes.  
Previously in the group, denaturation was performed by a dialysis treatment in 
guanidinium cloride (6 M, pH 1.5) at room temperature, which was believed to 
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lead to streptavidin unfolding and biotin release [25]. Probably, extreme pH and 
chaotropic agent weakened biotin-binding affinity, but they did not affect 
tetrameric structure of streptavidin as revealed by SDS-PAGE assays.  
A denaturation process implies inevitably a protein refolding protocol. 
Properly folded proteins can be produced from denatured proteins or naturally 
insoluble aggregates. 
Genetic modifications of streptavidin revealed that point mutations could 
drastically affect protein solubility. For this reason, heterologous expression of 
streptavidin mutants leads sometimes to the formation of insoluble forms, 
called inclusion bodies [35].  
In collaboration with Ms. Karoline Kersten we performed expression of 
streptavidin mutant N23A/S27D/S45A, selected for its reduced biotin-affinity 
(Kd = 1.2 • 10
-3 M), which led to the formation of inclusion bodies, as revealed 
by SDS-PAGE assay. 
 
 
 
 
 
 
 
 
Fig. 2.16 Heterologous expression of N23A/S27D/S45A mutant as inclusion body in the 
cytoplasm of E. coli, monitored by non-denaturing SDS-PAGE. Lane 1, protein marker 
(220 kDa). Lane 2, protein reference, represented by Sav-His tagged, which is a soluble and 
tetrameric variant of streptavidin. Insoluble fractions, taken during culture, display increasing 
concentrations of streptavidin mutant as monomer, after IPTG induction. Soluble fractions are 
completely devoid of this protein 
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Refolding of this insoluble mutant was performed at 4 °C by adding the 
unfolded protein into the vortexing PBS, not in Tris/HCl (20 mM, pH 7.4) as 
proposed by previous co-workers [25]. Electrophoretic assays revealed the 
presence of a refolded tetrameric protein (N23A/S27D/S45A) in the 
supernatant fraction, after Coomassie staining (Fig. 2.17b) and a low biotin-
affinity even in the active form, as confirmed by absence of B4F fluorescence 
(Fig. 2.17a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.17 Successful refolding of N23A/S27D/S45A mutant, monitored by electrophoretic 
assay. Lane 1, protein marker (220 kDa). Lane 2, Sav-His tagged as reference. Lane 3, 
refolded mutant N23A/S27D/S45A, displaying weak biotin affinity as revealed by B4F agent 
(gel a.) and a tetrameric structure (gel b.)  
 
 
a. 
b. 
B4F revealing agent 
Coomassie Blue Staining  
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2.3.5 High-Throughput Expression in 96-Well Plate  
Over the years, we implemented evolutionary approach on streptavidin 
framework to provide hybrid protein catalysts “made to order”.  
However, finding improved variants in the immensity of protein space is a 
major challenge. Even a small change in sequence can be deleterious for 
protein expression and solubility, as revealed in fingerprint display of the 
level expression for 117 streptavidin isoforms in fig. 2.10.  
To simplify streptavidin selection of the most promising mutants, protein 
expression was performed in 96-well plate with optimized characterization of 
protein. This high throughput system allowed a rapid screening of a 
streptavidin library to select the most promising mutants for high-level 
expression and biotin-binding, monitored by straightforward SDS-PAGE 
assays.  
Exploration of distant “functional space” in streptavidin network led, for 
example, to useful variants, which are very different from wild-type protein. 
We introduced a phenotypic diversity by means of large mutations on the 
flexible loop L3,4 that is close to the binding site. This diversity was easily 
accessed by the new high-throughput approach, which identified two highly 
diversified variants (48T-49K-50N-51P mutant and 48T-49D-50P-51G 
mutant) with high expression and biotin binding activity.  
Amino acid residues G48-N49-A50-E51 were randomly replaced by T-K-N-P 
in the homonymous mutant and T-D-P-G in the other one. Their high levels 
of expression revealed that the loop structure is not so critical for streptavidin 
folding. For this reason, this functional space can be explored to afford 
improved scaffold for hybrid protein catalysts. 
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In constrast, this new approach focused also on unsuccessful expression of 
different streptavidin isoforms, such as mutants at position H87. This amino 
acid residue is critical for streptavidin folding, as revealed by SDS-PAGE of 
H87 mutants performed after 96-well plate expression.  
The power of pre-selection was linked with an optimized combinatorial 
screening of hybrid catalysts library.  
In recent years, Dr. Nicolas Humbert (from Ward group) strove to express 
streptavidin in 96-well plate, but inadequate shaking and insufficient aeration 
hindered a successful result. 
A 96-deep well plate with tips inside during culture was found to significantly 
increase the production levels thus allowing a faster screening approach to 
assess production levels of streptavidin mutants. 
 
 
2.4  Materials and Methods 
2.4.1 Chemicals 
Solvents used were all of analytical grade. All solutions were prepared using 
deionised water. 
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Table 2.3 List of chemical and supplier  
Chemical  Supplier 
Acrylamide 
Glucose 
SDS 
Chloramphenicol 
Ampicillin 
PMSF 
IPTG 
Glycerol 
Tris 
AppliChem 
  
Bactoyeast extract Merck 
  
Bactotryptone BD 
  
NaCl 
DMSO 
DTT 
KH2PO4 
Coomassie Brilliant Blue 
Triton X-100 
Lysozyme (from egg white) 
TEMED 
Fluka 
  
Acetic acid 
Urea 
VWR 
  
APS 
Na2HPO4 
B4F 
DNaseI 
Sigma 
  
Guanidinium/HCl Acros Organics 
  
BenchMarkTM Protein Ladder Invitrogen 
  
Bromophenol Blue Riedel-de Haën 
  
dNTP Promega 
  
Dpn1 
DNA ladder 
Biolabs 
  
Pfu Turbo Stratagene 
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2.4.2 Technical Equipment 
• Protein expression in 20 L of E. coli cell culture was 
peformed in a fermentor NLF22 (Bioengineering®). 
• Protein expression in 50 mL of E. coli cell culture was 
performed in 250 mL baffled Erlenmeyer flasks within an 
incubator shaker (New Brunswick Scientific Co Inc, USA). 
• Protein expression in 96-well plate was performed in an 
incubator shaker (Ecotron®, Switzerland). 
• PCR was performed in an eppendorf mastercycler gradient 
• DNA concentration was determined by nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
• SDS-PAGE was analyzed with Molecular Image Gel Doc 
XR (Bio-Rad®, Switzerland). 
• Protein was lyophilized in a lyophilizer FreeZone 2.5 L 
(benchtop of Labconco, USA). 
• The active sites of proteins were determined with the 
Fluorescence Reader Safire (Tecan®) 
• FPLC was performed by using äkta prime machine  
 
2.4.3 Mutagenesis 
Site-directed mutagenesis was carried out using the Quick-Change 
mutagenesis kit (Stratagene, Switzerland) on the pET11b-Sav plasmid. The 
forward (positive) and the reverse (negative) primers were partially 
overlapped with each other and fully complementary at the mutation site.  
! -68- 
In many cases, a silent Sca1 restriction site was introduced to distinguish 
mutated clones from the template DNA. 
Saturation mutagenesis at positions K121 and L124 was carried out by 
using the genetic background of WT Sav (to generate single mutants) and 
S112A Sav or S112K Sav (to generate double mutants) for a total of 117 
Sav isoforms. 
 
Table 2.4 List of mutagenic primers used for saturation mutagenesis on positions K121 
and L124 
 
Mutation Primers (5'-3') 
Silent 
Mutation 
Upper 
GCCTGGGCGTCCACGCTGGTCGGCCACGACACC 
Lower 
K121A 
CGTGGACGCCCAGGCGTTGGCCTCGGTGGTGCC 
None 
   
Upper 
GCCTGGGAGTCCACGCTGGTCGGCCACGACACC 
Lower 
K121E 
CGTGGACTCCCAGGCCTTGGCCTCGGTGGTGCC 
None 
   
Upper 
GCCTGGTATTCCACGCTGGTCGGCCACGACACC 
Lower 
K121Y 
CGTGGAATACCAGGCGTTGGCCTCGGTGGTGCC 
None 
   
Upper 
CGCCTGGGGGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121G 
GCCGACCAGAGTACTCCCCCAGGCGTTGGCCTCGG 
None 
   
Upper 
CGCCTGGACGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121T 
GCCGACCAGAGTACTCGTCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CGCCTGGGTGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121V 
GCCGACCAGAGTACTCAGCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CGCCTGGTGGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121W 
GCCGACCAGAGTACTCCACCAGGCGTTGGCCTCGG 
ScaI 
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Upper 
CGCCTGGATGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121M 
GCCGACCAGAGTACTCATCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CGCCTGGCAGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121Q 
GCCGACCAGAGTACTCTGCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CGCCTGGAGGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121R 
GCCGACCAGAGTACTCCTCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CGCCTGGTGCAGTACTCTGGTCGGCCACGACACC 
Lower 
K121C 
GCCGACCAGAGTACTGCACCAGGCGTTGGCCTCG 
ScaI 
   
   
Upper 
CGCCTGGCACAGTACTCTGGTCGGCCACGACACC 
Lower 
K121H 
GCCGACCAGAGTACTGTGCCAGGCGTTGGCCTCG 
ScaI 
   
Upper 
CGCCTGGATCAGTACTCTGGTCGGCCACGACACC 
Lower 
K121I 
CCAGAGTACTGATCCAGGCGTTGGCCTCGGTGG 
ScaI 
   
Upper 
CGCCTGGCCGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121P 
GCCGACCAGAGTACTCGGCCAGGCGTTGGCCTCG 
ScaI 
   
Upper 
CGCCTGGGACAGTACTCTGGTCGGCCACGACACC 
Lower 
K121D 
GCCGACCAGAGTACTGTCCCAGGCGTTGGCCTCG 
ScaI 
   
Upper 
CGCCTGGAACAGTACTCTGGTCGGCCACGACACC 
Lower 
K121N 
GCCGACCAGAGTACTGTTCCAGGCGTTGGCCTCG 
ScaI 
   
Upper 
CGCCTGGTTGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121L 
GCCGACCAGAGTACTCAACCAGGCGTTGGCCTCG 
ScaI 
   
Upper 
CGCCTGGTCGAGTACTCTGGTCGGCCACGACACC 
Lower 
K121S 
GCCGACCAGAGTACTCGACCAGGCGTTGGCCTCG 
ScaI 
   
K121F Upper ScaI 
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CGCCTGGTTCAGTACTCTGGTCGGCCACGACACC 
Lower 
 
GCCGACCAGAGTACTGAACCAGGCGTTGGCCTCG 
 
   
Upper 
GGAAGAGTACTCAGGTCGGCCACGACACCTTCACC 
Lower 
L124Q 
CCGACCTGAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTTCGGTCGGCCACGACACCTTCACC 
Lower 
L124S 
CCGACCGAAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTACGGTCGGCCACGACACCTTCACC 
Lower 
L124T 
CCGACCGTAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTGTGGTCGGCCACGACACCTTCACC 
Lower 
L124V 
CCGACCACAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
Upper 
GGAAGAGTACTTGGGTCGGCCACGACACCTTCACC 
Lower 
L124W 
CCGACCCAAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTATCGTCGGCCACGACACCTTCACC 
Lower 
L124I 
CCGACGATAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTATGGTCGGCCACGACACCTTCACC 
Lower 
L124M 
GGCCGACCATAGTACTCTTCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CTGGAAGAGTACTAACGTCGGCCACGACACCTTCACC 
Lower 
L124N 
GGCCGACGTTAGTACTCTTCCAGGCGTTGGCCTCGGCG 
ScaI 
   
Upper 
GGAAGAGTACTCGGGTCGGCCACGACACCTTCACC 
Lower 
L124R 
CCGACCCGAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTTGCGTCGGCCACGACACCTTCACC 
Lower 
L124C 
CCGACGCAAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GGAAGAGTACTTTCGTCGGCCACGACACCTTCACC 
Lower 
L124F 
CCGACGAAAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
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Upper 
GGAAGAGTACTCACGTCGGCCACGACACCTTCACC 
Lower 
L124H 
CCGACGTGAGTACTCTTCCAGGCGTTGGCCTCGGTG 
ScaI 
   
Upper 
GCCTGGGCGTCCACGCTGGTCGGCCACGACACC 
Lower 
L124A 
CAGCGTGGACGCCCAGGCGTTGGCCTCGGTGG 
None 
   
Upper 
GGAAGTCCACGGGGGTCGGCCACGACACCTTCACC 
Lower 
L124G 
CGTGGCCGACCCCCGTGGACTTCCAGGCGTTGGCC 
None 
   
Upper 
GGAAGAGTACTCCGGTCGGCCACGACACCTTCACC 
Lower 
L124P 
GCCGACCGGAGTACTCTTCCAGGCGTTGGCCTCGG 
ScaI 
   
Upper 
CCAACGCCTGGAAGAGTACCAAGGTCGGCCACGACACC 
Lower 
L124K 
GCCGACCTTGGTACTCTTCCAGGCGTTGGCCTCGGTGG 
ScaI 
   
Upper 
GGAAGTCCACGTATGTCGGCCACGACACCTTCACC 
Lower 
L124Y 
CGTGGCCGACATACGTGGACTTCCAGGCGTTGGCC 
None 
   
Upper 
GGAAGTCCACGGAGGTCGGCCACGACACCTTCACC 
Lower 
L124E 
GGCCGACCTCCGTGGACTTCCAGGCGTTGGCCTCGG 
None 
 
 
The PCR results were verified on a 1.2% agarose gel containing 1X Tris-
Borate-EDTA (TBE) buffer. Ultra-competent XL1-Blue E. coli cells (in 
house) were transformed by PCR product and the plasmids were extracted 
from bacteria with a Promega miniprep kit (Promega®). 
The successful insertion of mutations into the plasmids was verified by two 
methods: a restriction digest, to detect an inserted silent mutation (24/117 
plasmids were analyzed), and DNA sequencing (Microsynth®, Switzerland) 
(14/117 different plasmids were tested). Results confirmed a successful 
insertion in > 90% of mutations of the sequence analyzed. 
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Clones were used to transform ultra-competent BL21(DE3)pLysS E. coli 
strains. 
For a detailed description of molecular biology see Appendix B. 
 
2.4.4 Expression Strain 
The pET11b-Sav plasmid (provided by Prof. Santambrogio from 
University of Milan) was used as expression vector for recombinant T7-
tagged streptavidin to transform the ultra-competent BL21(DE3)pLysS E. 
coli strain (in house). 
BL21 bacterial cells were chosen because lacking of lon and ompT 
proteases genes. For this reason they limit proteolytic cleavage of 
synthesized proteins. The nomenclature DE3 suggests that bacterial host is 
lysogen of #DE3 (i.e. E. coli cells were infected by the bacteriophage 
DE3) and carries a chromosomal copy of the viral T7 RNA polymerase 
gene.  
The lacUV5 promoter (induced by IPTG and controlled by E. coli RNA 
polymerase) directs the transcription of T7 RNA polymerase gene, which in 
turn transcribes the cloned gene of streptavidin as it is controlled by T7 
promoter [36].  
BL21 cell strains can also contain the pLysS plasmid, conferring resistance 
to chloramphenicol. In the presence of pLysS, basal expression of 
streptavidin during the pre-induction growth is drastically reduced because 
of a low level expression of T7 lysozyme (i.e. a natural inhibitor of T7 
polymerase) [37].  
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2.4.5 Streptavidin Production  
2.4.5.1 Protein Expression in 20 L of E. coli Cell Culture  
Transformed BL21(DE3)pLysS E. coli strain were plated on selective 
Luria-Bertani broth (LB) petri dishes containing ampicillin (60 "g/mL), 
chloramphenicol (34 "g/mL) and glucose (2% w/v) and incubated overnight 
at 37 °C. 
300 mL of tryptone medium (20 g/L Bactotryptone; 2 g/L Na2HPO4, 1 g/L 
KH2PO4; 8 g/L NaCl; 15 g/L Bactoyeast extract), containing antibiotics and 
glucose at the same concentrations as in LB plates, were inoculated with a 
single colony and incubated overnight in an orbital shaker (37 °C, 250 rpm).  
A 20 L cell culture, inoculated with the whole pre-culture, was grown in a 
30 L fermentor (Bioengineering®, Switzerland) at 37 °C, with 1000 rpm 
agitation speed, in the presence of glucose and antibiotics.  
Cells were induced by IPTG (0.4 mM) at OD600nm = 1.8 – 2.2 (approximately 
3 h after inoculation). When expression time was elapsed (# 3 h after 
induction), bacterial cells were harvested and frozen at -20 °C. 
For a detailed description of streptavidin expression in a 20 L bioreactor see 
Appendix C.  
 
2.4.5.2 Protein Expression in 50 mL of E. coli Cell Culture  
5 mL of tryptone medium (20 g/L Bactotryptone; 2 g/L Na2HPO4, 1 g/L 
KH2PO4; 8 g/L NaCl; 15 g/L Bactoyeast extract), containing ampicillin 
(60 "g/mL), chloramphenicol (34 "g/mL) and glucose (2% w/v) were 
inoculated with a single colony or glycerol stock and incubated overnight in 
an orbital shaker (37 °C, 250 rpm).  
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A 50 mL cell culture, inoculated with the whole pre-culture, was grown in 
250 mL baffled Erlenmeyer flask at 34.5 °C, with 415 rpm agitation speed, 
in the presence of antibiotics.  
Cells were induced by IPTG (0.4 mM) 3 h after inoculation and harvested 3 
h post induction.  Pellet was frozen at -20 °C. 
For a detailed description of streptavidin expression in 250 mL baffled 
flasks see Appendix D.  
 
2.4.5.3 Protein Expression in 96-Well Plate Format 
100 "L of tryptone medium (20 g/L Bactotryptone; 2 g/L Na2HPO4, 1 g/L 
KH2PO4; 8 g/L NaCl; 15 g/L Bactoyeast extract), containing ampicillin 
(60 "g/mL), chloramphenicol (34 "g/mL) and glucose (2% w/v) were 
transferred in each well of a 96-well plate. 
After inoculation with a single colony or glycerol stock, the 96-well plate 
was covered with tin foil and incubated overnight in an orbital shaker 
(37 °C, 250 rpm).  
A 500 "L cell culture, inoculated with the whole pre-culture, was grown in 
a 96-deep well plate at 37 °C, with 250 rpm agitation speed, in the presence 
of antibiotics.  
Cells were induced by IPTG (0.4 mM in TP medium) 3 h after inoculation 
and harvested 3 h post induction.  Pellet was frozen at -20 °C. 
For a detailed description of streptavidin expression in 96-well plate format 
see Appendix E. 
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2.4.6 Streptavidin Purification 
2.4.6.1 Purification on an Imino-Biotin Column  
After thawing, cell lysate was resuspended in 500 mL of resuspension 
buffer (Tris/HCl 20 mM, pH 7.4; PMSF 87 mg in 5 mL EtOH; mQ-H2O up 
to 500 mL) and incubated with DNaseI until complete degradation of nuclei 
acids. Afterwards, three dialysis steps performed in guanidinium 
hydrochloride (6 M, pH 1.5), Tris/HCl (20 mM, pH 7.4) and imino-biotin 
buffer (NaHCO3, 50 mM, pH 9.8; NaCl, 500 mM) preceded protein 
purification. 
Streptavidin was applied in imino-biotin column, previously equilibrated at 
pH 9.8, to be successively eluted with an acetate buffer (pH 4) in a pure form. 
Purified protein was successively dialyzed against a neutralization solution 
(Tris/HCl, 10 mM, pH 7.4) and against distilled and nanopure water in order 
to remove salts from protein solution. 
Lyophilized protein was finally titrated for biotin-fluorescein binding 
activity and free active sites per tetramer were calculated [26]. 
For a detailed description of streptavidin purification on imino-biotin 
column and quantification with B4F see Appendix C.  
 
2.4.6.2 Streptavidin Extraction for Immobilization  
After expression in 50 mL of E. coli cell culture, harvested cells were 
frozen-thawed and resuspended in 1 mL of extraction buffer at pH 7.4 
(Tris/HCl 20 mM; NaCl 100 mM; PMSF 1 mM). After addition of 10 "l of 
DNaseI (10 mg/mL,! from bovine pancreas; Roche, Switzerland), extracts 
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were! incubated for 30-90 min at room temperature and micro-centrifuged 
(14 000 rpm, 5 min). 
Pellet was re-extracted!with 0.5 mL extraction buffer. Pooled supernatants 
(approx!1.5 mL) were titrated for biotin-fluorescein binding!activity in 96-
well plates, from which the concentration of! free streptavidin active sites 
was calculated. 
For a detailed description of streptavidin extraction see Appendix D. 
 
2.4.6.3 Streptavidin Purification by Thermo-Denaturation  
After expression in 50 mL of E. coli cell culture, harvested cells were 
frozen-thawed and resuspended in 1 mL of extraction buffer at pH 7.4 
(Tris/HCl 20 mM; NaCl 100 mM; PMSF 1 mM). After addition of 10 "l of 
DNaseI (10 mg/mL,! from bovine pancreas; Roche, Switzerland), extracts 
were! incubated for 30-90 min at room temperature and micro-centrifuged 
(14 000 rpm, 5 min). 
Pellet was re-extracted!with 0.5 mL extraction buffer. Pooled supernatants 
were heated at 75 °C for 10 minutes and micro-centrifuged (10 000 rpm, 25 
min, 4 °C). 
After heat-treatment, supernatant (transparent yellow solution) was transferred 
in a dialysis bag and dialyzed against mQ-H2O (4 °C, 3 days). Whereafter it 
appeared as a cloudy solution. 
In treated crude cell extract, streptavidin was quantified by B4F titration (to 
calculate the concentration of! free streptavidin active sites) and by UV 
absorbance (at 280 nm). The latter strategy required a correction due to the 
presence of other proteins in the cell lysate. Absorbance of the empty cell 
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extract (non-expression of streptavidin) was subtracted from the absorbance of 
streptavidin-containing crude cell extract. 
 
2.4.7 Streptavidin Refolding 
After expression in 500 mL of E. coli cell culture, harvested cells were 
frozen-thawed and resuspended in 12.5 mL of resuspension buffer at pH 7.4 
(Tris/HCl 20 mM; NaCl 100 mM; PMSF 1 mM). After addition of 1 spatule 
of DNaseI (from bovine pancreas; Roche, Switzerland), extracts were!
incubated under vigorous stirring and centrifuged (4400 rpm, 30 min, 4 °C).  
The supernatant was kept just as negative control, whereas the pellet was 
resuspended in 3.25 mL of Tris/HCl (20 mM, pH 7.4). After addition of 
further 3.25 mL of Tris/HCl (20 mM, pH 7.4) and 225 "L of lysozyme 
(10 mg/mL), the solution was incubated for 5 min at room temperature (r.t.), 
under vigorous stirring. 
Afterwards, a spatula of DNaseI was added and the solution was shaken for 
10 min at r.t. In the presence of 12.5 mL of Inclusion Wash Buffer (Trition 
X-100, Cf: 0.5%; Tris/HCl pH 7.4, Cf: 20 mM; NaCl, Cf: 100 mM) the 
solution was mixed by inverting the tube several times and centrifuged 
(4400 rpm, 30 min, 4 °C). The supernatant was always kept for control. 
First wash: 
• The pellet was resuspended in 3.25 mL of Inclusion Wash Buffer 
and shaken vigorously. 
• After addition of 12.5 mL of Inclusion Wash Buffer, the solution 
was mixed by inverting tube and centrifuged at 4400 rpm for 30 
min at 4 °C (keep supernatant for control). 
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Second Wash: 
• We resuspended the pellet in 3.25 mL of Inclusion Wash Buffer and 
shook vigorously. 
• After adding of 12.5 mL of Inclusion Wash Buffer, the solution was 
mixed by inverting tube and centrifuged at 4400 rpm, 30 min, 4 °C 
(keep supernatant for control). 
Third Wash: 
• After resuspension in 3.25 mL of Inclusion Wash Buffer, the pellet 
was well shaken. 
• 12.5 mL of Inclusion Wash Buffer were added and the solution was 
mixed by inverting tube. 
• The solution was centrifuged (4400 rpm, 30 min, 4 °C) and the 
superantant was kept for control. 
Fourth Wash: 
• The pellet was resuspended in 3.25 mL of Inclusion Wash Buffer 
and shaken vigorously. 
• After addition of 12.5 mL of Inclusion Wash Buffer, the solution 
was mixed by inverting tube and centrifuged at 4400 rpm for 30 
min at 4 °C (keep supernatant for control). 
The pellet was resuspended in 2 mL of guanidinium/HCl (6 M, pH 1.5) and 
centrifuged at 4400 rpm, 30 min, 4 °C, to solubilize streptavidin (soluble 
fraction).  
Finally, protein refolding was performed in the cold room at 4 °C by adding 
2 mL of supernatant into 100 mL of vortexing Phosphate Buffer Saline at 
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pH 7.4 (NaCl, 8 g; KCl, 0.2 g; Na2HPO4 (x 12H2O), 3.58 g; KH2PO4, 
0.24 g) by using a micropipette as slowly as possible. 
The refolded protein was dialyzed against imino-biotin buffer at pH 9.8 and 
purified on imino-biotin affinity column. Before lyophilisation, the pure 
protein was dialyzed overnight against first Tris/HCl (10 mM, pH 7.4), then 
distilled water and finally nanopure water. 
For a detailed description of streptavidin refolding see Appendix F. 
 
 
2.5  Conclusions 
Chemo-genetic “fine-tuning” of artificial metalloenzymes led to the creation of 
several hybrid variants with improved features. 
This hybrid catalyst library was generated by designed evolution and a HTS 
system was needed to rapidly evaluate the catalytic performance. Therefore to 
maximize combinatorial screenings the big challenge of simplifying the 
lengthy streptavidin purification process was addressed [23]. 
An immobilization strategy led to a successful streptavidin purification directly 
from crude cell extract thanks to the high affinity of the protein for biotin. This 
approach allowed a rapid screening of the library to identify enantioselective 
trends of immobilized artificial transfer hydrogenases [23].  
As future perspective, this efficient and straightforward protocol can be 
extended to many other catalytic reactions performed by artificial 
metalloenzymes, based on the biotin-streptavidin technology. 
Thermo-denaturation was another strategy scrutinized to simplify streptavidin 
purification by exploitation of its high thermal stability [29]. Although 
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electrophoretic assays confirmed the efficiency of this purification approach, 
allylic alkylation failed in heated crude cell extracts.  
Many factors may be involved in this inhibition of catalytic activity. In the cell 
lysate, we observed a rapid hydrolysis of the substrate, which inevitably 
reduced the catalytic rate of the allylic alkylation. This bottleneck could 
possibly be overcome by replacing the acetate leaving group with less 
hydrolysis prone derivatives (e.g. allyl-chloride derivatives).  
In addition to a different substrate, a new catalytic system could also improve 
efficiency of allylic alkylases under physiological conditions. Ruthenium 
organometallic catalyst, chosen by Adriaenssens to perform C-C bond 
formation in E. coli cell lysate, could, for example, exhibit superior 
performance than the Pd-complex [31]. 
In order to investigate the activity and the enantioselectivity of artificial 
metalloenzymes in crude cell extract, we can alternatively select more robust 
catalytic reactions towards cell debris and potential “in vivo” contaminants, i.e. 
the metathesis reaction.  
In vivo catalysis is an exciting challenge, which presents many challenges. 
Artificial metalloenzymes with a more robust protein scaffold can be an 
attractive alternative to improve catalytic performance in crude cell extract. 
Carbonic anhydrase is a metalloenzyme containing a zinc ion in its active site, 
which catalyzes the reversible conversion of carbon dioxide to bicarbonate. 
This enzyme could be an interesting protein scaffold for in vivo catalysis due to 
its deep binding pocket, which is suitable for protecting the catalytic moiety 
from inhibition [38].  
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In our classical system with streptavidin as second coordination sphere, the 
metal complex is highly exposed to the surrounding environment and, 
potentially, inhibited by many external factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.18 Close-up view of a) carbonic anhydrase and b) streptavidin active sites, 
highlighting a different cavity depth. In figure a) the deep pocket of carbonic anhydrase 
hides the zinc prosthetic group, whereas in crystallographic structure b) ["6-(benzene)Ru(Biot-
p-L)Cl] metal complex is only partially settled in the cavity of S112K Sav mutant
b. a. 
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Chapter 3 
DNA recognition in vitro 
 
Discovery consists of 
seeing what everyone else 
has seen and thinking 
what no one else has 
thought 
 
Albert Szent-Györgyi 
 
3.1 Introduction 
3.1.1 Organometallic Compounds in Cancer Chemotherapy 
DNA is the main molecular target for many drugs used as anticancer agents [1]. 
However, their success is limited by severe toxic side effects and the resistance 
mechanisms of tumor cells. Cells which are refractory to treatment and 
promiscuous binding to non-target molecules reduce, for example, the clinical 
applications of anticancer platinum drugs [2].  
For this reason, intense effort has been made to design novel anticancer metal 
compounds with enhanced selectivity and reduced toxicity. 
More recently, new organometallic compounds have received increasing attention 
due to promising anticancer activity in vitro and in vivo. These compounds also 
display non cross-resistance with platinum drugs [3]. For example, organometallic 
ruthenium (II) arene complexes coordinate selectively to the electron-rich N7 
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nitrogen of the DNA guanine base, forming monofunctional adducts [4] and 
inhibiting the growth of human ovarian cancer cells [5]. The arene ligand stabilizes 
Ru (II) and provides a lipophilic hemisphere to the complex: this hydrophobic 
face allows transport of ruthenium into cancer cells through a transferrin-
mediated process [6].  
Aquation – substitution of bound Cl by H2O – can activate chloro-Ru (II) arene 
complexes within cancer cells prior to reactions with DNA, as for the cisplatin 
reaction. X-ray crystal structures of anticancer Ru (II) arene complexes revealed a 
“piano-stool” geometry (Fig. 3.1), with an arene ring forming the “seat” and three 
other ligands forming the “legs” of the stool [7]. 
 
 
 
 
 
 
Fig. 3.1 X-ray crystal structure of [(! 6-biphenyl)Ru(1,2-ethylenediamine)Cl]PF6 with a 
characteristic “piano-stool” geometry [7] 
 
3.1.2 Metal Complex Binding to Cellular Thiols 
The interaction of reactive metal drugs with endogenous thiols such as glutathione 
(GSH) can be problematic for chemotherapeutic agents. The overexpression of the 
tripeptide GSH ("-L-Glu-L-Cys-Gly; GSH) in cancer cell plays an important role 
in resistance mechanisms of tumor cells against metal drugs [8]. Several binding 
sites are involved in the interaction between GSH and metal ions: the amino and 
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the carboxylate groups at the Glu terminus, the carboxylate at Gly terminus, and 
the thiolate sulfur of the central Cys residue (Fig. 3.2) [9]. 
 
 
 
 
Fig. 3.2 Tripeptide glutathione involved in the interaction with metallo-drugs 
 
Many reactions of the anticancer Ru (II) arene complex with GSH have been 
investigated. Studies reveal that a large molar excess of glutathione induces the 
release of metals from other biological targets, such as DNA [8, 10]. 
 
3.1.3 Affinity modulation via a presenter protein 
Identifying more specific interactions between metallo-drugs and cancer-
associated DNA sequences can minimize the high toxicity of metallo-complexes. 
However, such extensive interactions between small-molecule drugs and 
macromolecular targets are very difficult to achieve.  
The “surface borrowing” concept may lead to effective mechanisms of small 
molecule delivery to preferred targets via a “presenter protein”. In a living cell, 
small molecules can induce the association of different intracellular 
macromolecules, strengthening interactions. The biological consequences of this 
induced proximity depend upon the macromolecules involved [11].  
In the late 90s, Crabtree and Schreiber emphasized the importance of dimerization 
induced by small molecules as a general control mechanism in signal 
transduction [12].  
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Therefore, a small ligand, containing binding sites for a presenter protein and for 
a target, can bind to endogenous presenter protein forming a composite surface 
area, which improves the specificity and affinity of ligand-protein target 
interactions through additional surface contacts. 
In the immune system, “surface enlargement” is observed for the antigenic ligand 
of the T cell receptor (TCR) whereby a presenter protein increases binding 
affinity. Antigenic peptides usually have a very low affinity for TCR. For this 
reason, the ligand is presented to a T cell by the major histocompatibility complex 
(MHC), which increases the surface area available for interactions and improves 
affinity, thus inducing a pronounced immune response [13] (Fig. 3.3).  
 
 
 
 
 
 
 
 
 
Fig. 3.3 TCR-peptide-MHC ternary complex formation. Proteins encoded by class II MHC are 
expressed on the surface of cells and display antigen peptides to T cells via T cell receptors (TCR) 
[14] 
 
Certain soil microorganisms use analogous mechanisms of “surface borrowing” 
to present and enhance the activity of their toxins, such as the 
immunosuppressants cyclosporin, FK506, and rapamycin which have no affinity 
for their targets [11]. 
The clinically useful drugs cyclosporin and FK506 are presented by two different 
cis-trans isomerases (cyclophilin and FKBP, respectively), also called 
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immunophilins [15]. As revealed by crystal structures, both cyclosporin-cyclophilin 
and FK506-FKBP complexes bind to and inhibit calcineurin with high affinity. 
Calcineurin is a target phosphatase involved in cytokine production. The surfaces 
of calcineurin and the presenter protein FKBP are involved in extensive contacts 
that promote the high binding affinity of ligand to its target protein [15]. 
Similarly, the immunosuppressive antibiotic rapamycin forms a complex with 
FKBP to create a composite surface area available for interactions with the target 
FRAP (the FKBP-Rapamycin-Associated Protein) [16] (Fig. 3.4). 
 
 
Fig. 3.4 Three-dimensional structure of FRAP/FKBP/rapamycin complex. The FKBP protein 
(blue ribbon) has five anti-parallel !-sheets wrapping around a short "-helix. Hydrophobic parts 
of rapamycin (green spheres) interact with hydrophobic residues of FKBP situated between the !-
sheet and the "-helix. Rapamycin-FKBP bimolecular complex establishes only few contacts with 
its target FRAP (red ribbon) (www.ch.ic.ac.uk) 
 
As dimerizers with two distinct protein-binding surfaces, the previously described 
antigenic ligands of the immune system and immunophilin molecules (FKBP and 
cyclophilin) are the perfect examples of CIDs (Chemical Inducers of 
Dimerization), small molecules widely used to modulate the activity of different 
cellular proteins [17]. CIDs carry a protein into the close proximity of another 
protein, and increase ipso facto its activity. In general, the ternary complex 
between presenter protein-CID-protein target is more stable than the bimolecular 
complex. 
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Inspired by these natural examples, Pelletier et al. studied a new strategy to target 
RNA with small molecules (CIDs), designed as bifunctional ligands with a 
protein-binding surface and an RNA-binding portion (Fig. 3.5). Biotin represents 
the protein-binding component of CID, with high affinity for avidin and 
streptavidin, and tobramycin constitutes the RNA-binding moiety, specific for 
two RNA aptamers (J6f1 and X1) [17].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5 Biotin/Tobramycin CIDs design. RNA-binding moiety of CID, tobramycin, is linked to 
biotin ureido group through a chemical spacer R of varied length. RNA aptamers (J6fl and X1), 
with tobramycin-binding pocket highlighted by shaded box, are schematically depicted [17] 
 
These bivalent molecules have been engineered to increase RNA-(strept)avidin 
interactions, in order to inhibit eukaryotic translation. However, the cell 
impermeability of biotin-tobramycin conjugate and its interactions with many 
other biotin-binding proteins prevent the application in vivo of this system. In 
order to overcome the limits of this strategy, Plummer et al. proposed a new 
“surface borrowing” approach” for RNA targeting, in which synthetic 
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bifunctional ligands, known as AP1867, 2G, 4G, 8G, 2A, cross the membrane of 
mammalian cells and interact preferentially with an engineered presenter protein 
over the wild-type form (Fig. 3.6) [18]. 
 
 
Fig. 3.6 “Surface borrowing” approach for targeting RNA. Upon entry into the cell, a 
bifunctional small molecule binds to the presenter protein, forming a bimolecular complex with a 
composite surface area available for specific and strong interactions with cellular RNA target [18] 
 
The synthetic ligand AP1867 and its derivatives, containing functionalised 
guanine/adenine nucleobases, possess two binding moieties, which target an 
intracellular protein and RNA (Fig. 3.7).  
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Fig. 3.7 Small synthetic ligands for RNA targeting. Functionalised guanine/adenine 
nucleobases have been conjugated to AP1867 via amide coupling to give the bifunctional ligands 
2G, 4G, 8G, 2A 
 
The presenter protein FKBP has been engineered by introducing positive charges 
on its binding surface in order to increase electrostatic interactions with the 
negatively charged surface of RNA [18]. 
Upon entry into mammalian cells, the bipartite small ligand binds with high 
affinity to the engineered variant of FKBP, forming a composite surface area 
involved in electrostatic, hydrogen bonding and non-polar interactions with RNA 
target. 
 
 
3.2 Aim of the Work 
High toxicity of numerous anticancer drugs, due to non-specific binding to non-
target molecules, is a deterrent to their clinical applications [2b]. 
Recently, “surface borrowing” strategy has been proposed as a promising 
approach to minimize metallodrug-toxicity inasmuch as increases the specificity 
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of interactions between small molecule agents and macromolecule targets via 
presenter protein [11]. 
Inspired by our previous experience on enantioselective artificial metalloenzymes 
[19], we hypothesized that streptavidin could be used as a presenter protein for in 
vitro-DNA recognition. 
The broad aim of this chapter was to test this hypothesis by inserting biotinylated 
ruthenium piano-stool complexes into streptavidin and modulating binding to 
model DNA targets in vitro. 
 
 
3.3  Results and Discussion 
3.3.1 Introduction of a Biotinylated Ru (II) Complex into a Protein  
Inspired by organometallic drugs with demonstrated antitumor activity, 
biotinylated Ru (II) piano-stool complexes 1 (R,R) [(!6-p-cymene)Ru(Biot-L)Cl] 
and 2 (R,R) [(!6-biphenyl)Ru(Biot-L)Cl] were synthesized within the group by 
Mr Malcolm Jeremy Zimbron (Fig. 3.8). 
 
 
 
 
 
 
 
 
Fig. 3.8 Biotinylated Ru (II) piano-stool complexes 1 and 2, used in this study 
 
A second-coordination sphere was provided around the metal by embedding the 
biotinylated Ru (II) piano-stool moiety inside a tetrameric streptavidin in a 2 : 1 
molar ratio.  
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It was anticipated that the resulting supramolecular complex would allow 
extensive interactions with macromolecules such as DNA, through metal 
coordination as well as through non-covalent interactions provided by the 
protein [20]. The streptavidin as “presenter protein” [11] provided a second 
coordination sphere that could enlarge the surface area available for interactions 
between metallo-drug and its macromolecular targets, improving specificity and 
affinity.  
The crystal structure of the biotinylated Ru (II) complex 1 ! streptavidin 
assembly, resolved by Mr Tillmann Heinisch (in collaboration with the Prof. 
Tilman Schirmer, Biozentrum, Universität Basel), confirmed the three-legged 
piano-stool geometry of the complex and provided a fascinating insight into the 
organization of the active site. 
In light of the refined model, we focused mainly on two amino acid residues, 
S112 and K121, close to the active site, as being important for the assembly: the 
side chain hydroxyl of Ser-112, in the L7,8 loop of streptavidin, formed a 
hydrogen-bond with the Ru-bound amine, thus fixing the position of the metal.  
The crystal structure revealed two lysines (K121 residues of the two adjacent 
monomers A and B) within 10 Å of the Ru, at the entrance of the largely 
hydrophobic biotin-binding pocket (Fig. 3.9). 
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Fig. 3.9 X-ray crystal structure of the biotinylated Ru (II) complex 1 !  streptavidin 
assembly. Close-up view of the ruthenium head group of complex 1 bound to a Sav monomer 
(orange) and partially interacting with another Sav monomer (aquamarine) also containing 
complex 1 (upper-left corner). Selected Sav residues are shown with side-chains and are labeled. 
The ruthenium atom is tetrahedrally coordinated by two amino groups of diaminopyrrolidine, the 
p-cymene and a putative chloride ion (shown in green) 
 
In the absence of a neighboring compound 1 in cis, the size and charge of the 
pocket would allow multiple interactions with an incoming DNA molecule. Ionic 
interactions between DNA phosphate groups and positively charged residues on 
the protein surface were conceivable. The orientation of the labile Ru-Cl bond 
was compatible with coordination to electron-rich N1 or N7
 nitrogens of the 
purine bases of single stranded DNA [19]. 
 
3.3.2 Binding of Drug – Protein Assembly to Quadruplex DNA 
The incorporation of a metallodrug within a protein scaffold can generate an 
extended second coordination sphere [19]. This framework can be exploited for 
additional interactions with a specific macromolecular target to increase 
selectivity, via “surface borrowing”. 
As proof-of-concept, the binding of Ru (II) metallodrug ! streptavidin assembly 
to various DNA targets was investigated (Fig. 3.10). Although the target of DNA-
interactive metallodrugs is generally double stranded DNA (dsDNA), 39 bases G-
quadruplexes DNA represented a new class of attractive alternative therapeutic 
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targets [21]. These secondary DNA structures, formed by tandem repeats of short 
guanine tracts, occur under physiological conditions [1]. G-quadruplex structures, 
abundant in telomeres at the end of the chromosome, act as potential regulatory 
elements in genes, including oncogenes [22]. 
 
 
 
 
 
 
 
 
Fig. 3.10 Concept of ruthenium metallodrug !  presenter protein assembly for targeting 
telomeric DNA. The ruthenium drug embedded into the tetrameric Sav in a 2 : 1 ratio forms a 
supramolecular complex that may allow extensive interactions with DNA (here depicted as G-
quadruplex telomeric DNA). Chemogenetic optimization, performed by varying the arene cap of 
the Ru complex or mutating defined Sav residues (e.g. at position K121 and S112), can modulate 
the affinity of the assembly for the DNA target 
 
The supramolecular assembly of wild-type variant streptavidin (WT) with the 
biotinylated Ru (II) piano-stool complexes 1 and 2 produced a concentration-
dependent change in migration of quadruplex DNA (G4A) in electrophoretic 
mobility shift assays (EMSA).  
After incubation of DNA with the drug-streptavidin assemblies, two predominant 
DNA species with very different mobility were identified on agarose gels: the fast 
migrating species coincided with unmodified G-quadruplex DNA, whereas the 
low mobility species was consistent with the formation of the ternary complex 1 
! Sav " G4A or 2 ! Sav " G4A characterized by a defined 1 : 1 stoichiometry. 
The affinity constant was estimated by EMSA analysis (Kd = < 1.6, entry 2, Table 
3.1, subsection 3.3.10). 
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Fig. 3.11 Binding of assembly of metallodrug and presenter protein (1 !  WT-Sav) to G4A 
monitored by EMSA on agarose gel. The gel was run after incubation of 1 ! WT-Sav with 500 
ng of telomeric G4A-DNA. Lane 1, DNA Marker. Lane 2, G4A. Lane 3, G4A (3.3 #M) + Sav 
(39.6 #M). Lane 4, G4A (3.3 #M) + 1 (85.7 #M). Lanes 5-10, G4A (3.3 #M) + 1 ! Sav at 
increasing concentrations: 0.8 #M, 1.6 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, representing a 1 
! Sav : G4A ratio from 0.2 to 12 
 
Chemical modification of the Ru complex by varying the arene-cap p-cymene 
with biphenyl changed the binding affinity of drug-presenter protein for telomeric 
G4A-DNA only weakly (Kd = 6.25, entry 3, Table 3.1). 
 
 
 
 
 
 
Fig. 3.12 Binding of assembly of metallodrug and presenter protein (2 !  WT-Sav) to G4A 
monitored by EMSA on agarose gel. The gel was run after incubation of 2 ! WT-Sav with 500 
ng of telomeric G4A-DNA. Lanes 3-10, G4A (3.3 #M) + 2 ! Sav at increasing concentrations: 
0.2 #M, 0.4 #M, 0.6 #M, 0.8 #M, 1.6 #M, 3.2 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, 
representing a 1 ! Sav : G4A ratio from 0.06 to 12 
 
 
During these trials, we also investigated the influence of the 1 : Sav ratio on the 
binding-affinity for G4A-DNA. Affinities obtained by varying the ratio of 1 : Sav 
from 1 : 1 to 4 :1 were comparable (entries  2-4-5, Table 3.1). 
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Fig. 3.13 Binding of assembly of metallodrug and presenter protein (1 ! Sav), at 1 or 4 
equivalents of Ru metallodrug per tetramer, to G4A monitored by EMSA on agarose gels. 
Lane 1, DNA Marker. Lane 2, G4A. Lane 3, G4A (3.3 #M) + Sav (39.6 #M). Lane 4, G4A (3.3 
#M) + complex 1 (43 #M for 1 Ru/Sav and 160 #M for 4 Ru/Sav, respectively). Lane 5-10, G4A 
(3.3 #M) + 1 ! Sav at increasing concentrations: 0.8 #M, 1.6 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 
#M, representing a 1 ! Sav : G4A ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded 
onto the gel. Lane 11, 1 ! Sav : G4A ratio of 1.2, with 1 equivalent of Ru per tetramer. Lane 12, 1 
! Sav : G4A ratio of 1.2, with 2 equivalents of Ru per tetramer. Lane 13, 1 ! Sav : G4A ratio of 
1.2, with 4 equivalents of Ru per tetramer 
 
The 2 : 1 ratio was selected for all subsequent studies as it yielded a well defined 
1 : 1 stoichiometry (1 ! Sav : G4A) by EMSA and Isothermal Titration 
Calorimetry (ITC), below described. 
The binding of 1 ! Sav to a model quadruplex telomeric DNA (G4A) was also 
monitored by ITC, a powerful method for characterizing the energetics of 
biological interactions. All the ITC titrations presented in this chapter were 
performed in collaboration with Mr Malcolm Jeremy Zimbron. 
The approach yielded the thermodynamic signature of binding (#H, #S and Kd) 
through an analysis of the heat released or absorbed as a ligand was incrementally 
titrated into a solution of its binding partner.  
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Fig. 3.14 Binding of drug-streptavidin assembly (1 !  Sav) to G-quadruplex DNA monitored 
by Isothermal Titration Calorimetry (ITC). ITC profiles were fitted to a single-binding model, 
the simplest binding model consisting of a single set of identical independent binding sites, and 
provided an association constant of (1.35 ± 0.28) • 106 M-1. The enthalpy of binding at 25 °C was 
endothermic (#H = 1.23 " 104 kcal/mol). The stoichiometry approaching was one quadruplex 
bound per Sav tetramer (molar ratio = 0.90). In the upper panel the raw titration data were plotted 
as rate of heating versus time. In the lower panel the integrated heat measurements were plotted as 
kcal/mol of drug-streptavidin assembly injected into telomeric DNA solution 
 
 
The ITC results suggested the formation of a ternary complex between the drug-
presenter protein assembly and G4A-DNA, with sub-micromolar affinity (Kd = 
0.74 #M. A value in the same range was observed in the extrapolated data from 
EMSA, where the observed Kd was < 1.6 #M (entry 2, Table 3.1). 
Thus, ruthenium metallodrug, embedded into a presenter protein, was designed to 
allow extensive interactions with telomeric DNA, through metal coordination as 
well as through non-covalent interactions provided by the protein scaffold.  
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3.3.3 Complex – DNA Interaction in the Absence of Streptavidin 
Telomeric G4A-DNA incubated with complex 1 in the absence of streptavidin 
presented an electrophoretic mobility compatible with the formation of a mixture 
of fast migrating species. These species could not be resolved by EMSA (Fig. 
3.15), presumably due to the small difference in size and charge of the adduct 
mixture and the binding of varying numbers of Ru moieties to each DNA 
quadruplex. 
 
 
 
 
 
 
 
 
 
Fig. 3.15 Different electrophoretic mobility of drug-G4A complex on agarose gel in the 
presence and absence of streptavidin. Lane 1, DNA Marker. Lane 2, G4A. Lane 3, G4A (3.3 
#M) + Sav (39.6 #M). Lane 4, G4A (3.3 #M) + 1 (85.7 #M). Lanes 5-10, G4A (3.3 #M) + 1 ! 
Sav at increasing concentrations: 0.8 #M, 1.6 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, 
representing a 1 ! Sav : G4A ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the 
gel. 
 
The ITC titration of complex 1 with G4A-DNA revealed multiple binding 
equilibria with a large enthalpic contribution, which hampered the definition of 
dissociation constant (Fig. 3.16). 
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Fig. 3.16 Binding of complex 1 to G-quadruplex DNA monitored by isothermal titration 
calorimetry (ITC). ITC profiles were carried out at 25 °C in 75 mM MOPS (pH 6.5) with 10 mM 
KOH. In the upper panel the raw titration data were plotted as rate of heating versus time; in the 
lower panel the integrated heat measurements were plotted as kcal/mol of drug injected into 
telomeric DNA solution 
 
There is ample experimental evidence for related Ru piano-stool complexes that 
display preferential binding to N7 guanine in DNA [23]. 
Fitting the data with a single-binding model did not provide meaningful binding 
information, because it was difficult to interpret a 0.5 : 1 molar ratio between 
metal drug and telomeric DNA. 
Analysis was further hampered by different factors: a model of the real 
stoichiometry was unclear and the equilibrium conditions were not reached 
(return to baseline), as it seems that an endothermic component was superimposed 
on an exothermic component. 
However, under these experimental conditions the extrapolated results 
demonstrated a very different binding from that found for the complex bound to 
streptavidin.   
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In summary, it was proven that presenter protein influenced the mode of binding 
of complex 1 to quadruplex DNA and helped to form a defined ternary complex, 
by borrowing additional surface contacts, according to ITC and EMSA analysis. 
 
3.3.4 Streptavidin – DNA Binding  
The binding of streptavidin with quadruplex DNA was markedly weaker in the 
absence of Ru complex. The lack of detectable binding in EMSA (Fig. 3.17) 
confirmed the low affinity of streptavidin for G4A (Kd = > 145 #M, entry 1, 
Table 3.1). 
Neither increasing concentrations of wild-type streptavidin nor genetic 
modifications of the protein altered appreciably the interaction between 
streptavidin and telomeric DNA, as observed in EMSA gels.  
 
 
 
 
 
 
 
Fig. 3.17 DNA binding of streptavidin in the absence of Ru (II) complexes monitored by 
EMSA on agarose gels. a) EMSA on agarose gel of WT-Sav incubated with 500 ng of G4A-
DNA. Lane 1, DNA Marker. Lane 2, G4A. Lane 3-10, G4A (3.3 #M) + WT-Sav at increasing 
concentrations: 39.6 #M, 47.5 #M, 55.4 #M, 63.2 #M, 71.2 #M, 79 #M, 119 #M, 146 #M, 
representing a Sav : DNA ratio from 12.5 to 46.2. b) EMSA on agarose gel of different Sav 
isoforms incubated with 500 ng of G4A-DNA. Lane 1, DNA Marker. Lane 2, G4A. Lane 3, G4A 
(3.3 #M) + S112D (7.9 #M). Lane 4, G4A (3.3 #M) + S112F (7.9 #M).  Lane 5, G4A (3.3 #M) + 
K121A (7.9 #M). Lane 6, G4A (3.3 #M) + WT (7.9 #M) 
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The binding of streptavidin alone to the telomeric G4A-DNA was also monitored 
by ITC in the absence of metal complex. The affinity was markedly weaker than 
in the presence of Ru (II) complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.18 ITC profile for binding of WT-Sav alone to G4A. The titration was carried out at 25 
°C in 75 mM MOPS (pH 6.5) with 10 mM KOH, injecting 5 #l of streptavidin (375 #M) into 
DNA solution (25 #M) every 10 min. The heat values were plotted as a function of streptavidin to 
G4A molar ratio, to give the corresponding binding isotherms. The resulting isotherms were then 
fitted to a single set of identical sites model and give an association constant of (6.56 ± 2.35) • 106 
M-1, a binding enthalpy of (1.055 ± 0.124) x 103 kcal/mol and a stoichiometry of 1.81 ± 0.09 
 
 
The ITC profile revealed a weak interaction between streptavidin and telomeric 
DNA, as confirmed by the absence of saturation curve (within the titration 
window of the experiment). 
The modest affinity of streptavidin (theoretical pI = 7) for DNA in the absence of 
metal complex has been exploited for biotechnology applications involving 
biotinylated DNA, rather than using the related but very basic protein avidin 
(theoretical pI = 10.4) [24]. 
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3.3.5 Competition Studies with Interfering Glutathione 
Glutathione has been shown to coordinate different anticancer ruthenium drugs in 
vitro [8-10] as well as our biotinylated Ru (II) complex 1, as confirmed by mass 
spectrometry (see APPENDIX G). Glutathione has also been implicated in 
metallodrug inactivation in vivo [2b, 25]. 
To test the selectivity of the drug-presenter protein assembly towards telomeric 
DNA in the presence of potentially interfering macromolecules, competition 
studies with glutathione were carried out. 
The presence of a large molar excess of GSH (300-fold excess compared to 
G4A), with a final concentration of 1 mM, did not appreciably affect the binding 
of the drug-streptavidin assembly to the telomeric G4A-DNA (Kd = < 1.6 #M, 
entry 6, Table 3.1) as evidenced by EMSA. 
 
 
 
 
 
 
 
 
Fig. 3.19 Binding of drug-streptavidin assembly (1 !  Sav) to G-quadruplex DNA monitored 
by EMSA on agarose gels. a) Binding of 1 !  Sav in the absence of glutathione (GSH). b) 
Binding of 1 !  Sav in the presence of 1 mM of GSH. Lane 1, DNA Marker. Lane 2, G4A. Lane 3, 
G4A (3.3 #M) + Sav (39.6 #M). Lane 4, G4A (3.3 #M) + 1 (85.7 #M). Lanes 5-10, G4A (3.3 #M) 
+ 1 ! Sav at increasing concentrations: 0.8 #M, 1.6 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, 
representing a 1 ! Sav : G4A ratio from 0.2 to 12. In all cases 500 ng of DNA was loaded onto the 
gel 
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Therefore, we hypothesized that the protein scaffold may create a steric bulk 
around the metal centre, providing a shielding from competing species such as 
glutathione. 
 
3.3.6 Target Selectivity against Single Stranded DNA 
To test whether metallodrug-presenter protein assemblies recognized structural 
features of G4A-DNA or simply its nucleotide content, we performed binding 
assays in the presence of G4A-Li+ and “scrambled” G4A.  
Since the great stabilization of G4A-DNA in the quadruplex structure requires the 
presence of potassium ions, we decided to perform DNA binding assays in Li+ 
salts instead of K+ in order to prevent the formation of quadruplex DNA [26]. 
However, under these conditions the resulting unstructured ssDNA 
oligonucleotide interacted with the drug-protein assemblies with the same 
apparent affinity as the quadruplex G4A (Kd = < 1.6 #M for 1 !  Sav; Kd = 1.55 
for 2 !  Sav, entries 7-8, Table 3.1) as estimated by EMSA. 
 
 
 
 
 
 
 
Fig. 3.20 Binding of metallodrug-presenter protein assemblies to G4A (in MOPS/LiOH) 
monitored by EMSA on agarose gels. a) Gel was run after incubation of 1 !  Sav with G4A-Li+. 
Lane 1, DNA Marker. Lane 2, G4A-Li+. Lanes 3-11, G4A-Li+ (3.3 #M) + 1 ! Sav at increasing 
concentrations: 0.4 #M, 0.6 #M, 0.8 #M, 1.6 #M, 3.2 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, 
representing a 1 ! Sav : G4A-Li+ ratio from 0.12 to 12. In all cases 500 ng of DNA was loaded 
onto the gel. b) Gel was run after incubation of 2 !  Sav with G4A-Li+. Lanes 12-20, G4A-Li+ (3.3 
#M) + 2 ! WT-Sav at the same ratio and increasing concentrations than gel a) 
 
 -105- 
To investigate the interactions of metallodrug-presenter protein assemblies with 
other unstructured ssDNA, we performed binding assays in the presence of 
scrambled (Sc) G4A.  
Although characterized by the same sequence as G4A, this scrambled DNA is 
unable to form a G-quadruplex structure.  
The EMSA gel revealed that the affinities of 1 ! Sav and 2 ! Sav for the 
scrambled telomere was weakly lower compared to the affinities towards the 
structured G-quadruplex form (Kd = 2.25 #M, entries 9-10, Table 3.1), which was 
bound stoichiometrically in our EMSA assay. 
 
 
 
 
 
 
 
Fig. 3.21 Binding of metallodrug-presenter protein assemblies to scrambled G4A monitored 
by EMSA on agarose gels. a) Gel was run after incubation of 1 !  Sav with scrambled (Sc) G4A. 
Lane 1, DNA Marker. Lane 2, ScG4A. Lanes 3-11, ScG4A(3.3 #M) + 1 ! Sav at increasing 
concentrations: 0.4 #M, 0.6 #M, 0.8 #M, 1.6 #M, 3.2 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, 
representing a 1 ! Sav : ScG4A ratio from 0.12 to 12. In all cases 500 ng of DNA was loaded onto 
the gel. b) Gel was run after incubation of 2 !  Sav with ScG4A. Lanes 12-20, ScG4A (3.3 #M) + 
2 ! WT-Sav at the same ratio and increasing concentrations than gel a) 
 
Slow-migrating species were visible on the EMSA gel, suggesting multiple 
binding. The complexity of binding to unstructured and flexible ssDNA was also 
reflected in ITC experiments. The ITC titration curves (Fig. 3.22) for both 
unstructured ssDNA oligonucleotides could not be fitted to a single set of 
identical sites model, as in the 1 ! Sav into G4A (KOH) titration described 
previously.  
Analysis was further hampered by a superimposition of an endothermic 
component on an exothermic component. 
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b. a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.22 ITC titration of 1 !  Sav assembly into a solution of unstructured ssDNA. a) ITC profile 
of 1 !  Sav assembly into a solution with G4A-Li+. b) ITC profile of 1 !  Sav assembly into a solution 
containing scrambled G4A. The top panels represent the raw data for 50 sequential injections of 1 ! 
Sav into G4A-Li+ and scrambled DNA, respectively. The bottom panels show the plot of the heat 
evolved (kcal) per mole of drug-presenter protein added 
 
The high similarity of these titration curves suggested comparable binding 
mechanisms of drug-streptavidin to each unstructured ssDNA. These mechanisms 
were markedly different and more complicated than the “one site model” binding of 
drug-presenter protein to K+-stabilized quadruplex G4A. 
 
3.3.7 Competition Studies with Single Stranded DNA 
Competition studies were also carried out in the presence of exceeded competing 
ssDNA co-incubated with G4A (up to 157 equivalents of ssDNA vs G4A). 
We selected two different oligonucleotides: single stranded 12mer, with high 
guanine content, and a smaller trinucleotide GGG. 
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Fig. 3.23 Binding of 1 !  Sav assembly to G4A-DNA in the presence of competing ssDNA 
substrates monitored by EMSA on agarose gels. Lane 1, Marker. Lane 2, G4A. Lane 3, G4A (3 
#M) + GGG trinucleotide (206.5 #M) or 12mer (462 #M), respectively. Lane 4, G4A (3 #M) + GGG 
(206.5 #M) or 12mer (462 #M) respectively + complex 1 (76.5 #M). Lane 5-10, GGG (206.5 #M) or 
12mer (462 #M) were incubated with G4A (3 #M) and the 1 !  Sav assembly at increasing 
concentrations: 0.7 #M, 1.4 #M, 3.5 #M, 7 #M, 17.7 #M, 35.3 #M. Under these conditions, the molar 
ratio 1 !  Sav : G4A ranges from 0.2 to 12, while GGG : G4A and 12mer : G4A ratio is 69 and 154, 
respectively. Lane 11, G4A (3 #M) + 1 !  Sav assembly (35.3 #M). Lane 12, GGG (206.5 #M) or 
12mer (462 #M) in the presence of 1 !  Sav assembly (35.3 #M). GGG or 12mer are barely visible by 
ethidium bromide staining due to lack of intercalation of the dye in ssDNA 
 
 
EMSA assays revealed that an excess of these competing ssDNA co-incubated with 
G4A lowered only marginally the binding of the metallodrug-protein assembly to 
G4A (Kd = 2 #M for 1 !  Sav towards G4A co-incubated with GGG; Kd = 5.5 #M for 
1 !  Sav towards G4A co-incubated with 12mer, entries 11-12, Table 3.1). 
As revealed by EMSA-estimated binding affinities, the single stranded 12mer was 
better at inhibiting G4A-binding than GGG due to the existence of a more extended 
interaction with the metallodrug-presenter protein assembly compared with the 
smaller GGG-trinucleotide. These results supported the notion that G4A was a 
privileged target. 
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3.3.8 Genetic Control of the Second Coordination Sphere 
The influence of the second coordination sphere on G4A-binding was 
investigated through site-directed mutagenesis on the gene encoding streptavidin 
and monitored by EMSA.  
The X-ray crystal structure of the complex 1 embedded into the WT Sav (Fig. 
3.9) highlighted mainly on two amino acid residues, S112 and K121, close to the 
active site as being important for the assembly. 
Mutation of two positively-charged lysines (K121A) at the entrance of the largely 
hydrophobic biotin-binding pocket K121 inhibited interactions of the drug-
presenter protein assemblies with the telomeric DNA (Kd estimated by EMSA = 
29 #M, entry 13, Table 3.1). 
This finding suggested that lysines might form a salt-bridge with the phosphate 
backbone of DNA, enhancing the interactions of the ternary complex [26].  
Similarly, the introduction of a negative charge close to the Ru head-group 
(S112D) equally reduced the G4A-DNA binding (Kd = 12.5 #M, entry 14, Table 
3.1), perhaps by charge-repulsion. In contrast, mutating the same residue S112 to 
a large hydrophobic phenylalanine did not appreciably change the binding affinity 
for G-quadruplex DNA (Kd = < 1.6 #M, entry 15, Table 3.1) compared with the 
wild-type. 
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Fig. 3.24 G4A-binding of metallodrugs embedded in different streptavidin isoforms 
monitored by EMSA on agarose gels. a) Gels were run after incubation of 1 !  S112F or 2 !  
S112F with G4A. b) Gels were run after incubation of 1 !  K121A or 2 !  K121A with G4A. C) 
Gels were run after incubation of 1 !  S112D or 2 !  S112D with G4A. Lane 1, DNA Marker. 
Lane 2, G4A. Lanes 3-11, G4A(3.3 #M) + 1 ! Sav isoforms at increasing concentrations: 0.4 #M, 
0.6 #M, 0.8 #M, 1.6 #M, 3.2 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M, representing a 1 ! Sav : 
G4A ratio from 0.12 to 12. Lanes 12-20, G4A (3.3 #M) + 2 ! Sav isoforms at the same ratio and 
increasing concentrations. In all cases 500 ng of DNA was loaded onto the gel 
 
These results were also consistent with the existence of an extended interaction 
between G4A-DNA and drug-protein assembly.  
In light of these results we speculated that a genetic optimization of streptavidin 
might increase the selectivity of the metallodrug-presenter protein assembly 
towards the DNA target. 
 
3.3.9 Chemo – Genetic Optimization with Increased dsDNA Affinity 
To estimate the affinity of drug-presenter protein complex for double-stranded 
DNA on agarose gels, titrations of 1 ! Sav and 2 ! Sav were carried out with a 18 
base pair dsDNA including the sequence of the common Braf V599E oncogenic 
mutation (dsOnc) [27]. 
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As estimated by EMSA, the affinity constant of 1 ! Sav for dsOnc was 
significantly lower (Kd = 37.9 #M, entry 16, Table 1.3) compared to the affinity 
for single-stranded G4A (Kd = < 1.6 #M, entry 2, Table 1.3). We hypothesized 
that a different organization of functional groups as well as the reduced flexibility 
of dsDNA hampered efficient interactions between the ruthenium and 
nucleophilic sites on the bases [28]. 
Chemo-genetic optimization of metallodrug-protein assembly improved the 
binding to dsDNA. As proof-of-the-concept, a chemical modification of the 
Ru (II) complex, with a p-cymene replaced by a biphenyl group in the arene cap, 
was combined with a genetic modification of the second coordination sphere, by 
incorporation of an aromatic residue at the position closest to Ru (S112F). The 
resulting drug-presenter protein complex (2 ! S112F) increased the affinity to 
dsDNA by at least a factor two from 37.9 to 18.2 #M (entries 18-19, Table 1.3) 
compared to 1 ! WT and 2 ! WT  (Kd = 37.9 #M, entries16-17, Table 1.3) as 
best illustrated in lane 20 of Fig. 3.25d.  
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Fig. 3.25 Chemo-genetic optimization of drug-streptavidin assemblies for improved binding 
to dsDNA monitored by EMSA on agarose gels. Comparison of wildtype streptavidin (WT; a 
and c) to a genetic variant S112F (b and d) illustrates that the nature of the metallodrug and 
presenter protein can influence the binding to dsDNA. Lane 1, Marker (M). Lane 2, dsOnc. Lanes 
3-11, dsOnc (3.12 #M) + concentration increase of 1 ! Sav: 0.4 #M, 0.6 #M, 0.8 #M, 1.6 #M, 3.2 
#M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M with a 1 ! Sav : dsOnc ratio from about 0.1 to 13. Lanes 
12-20, dsOnc (3.12 #M) + concentration increase of 2 ! Sav: 0.4 #M, 0.6 #M, 0.8 #M, 1.6 #M, 
3.2 #M, 3.9 #M, 7.9 #M, 19.8 #M, 39.6 #M with a 2 ! Sav : dsOnc ratio from about 0.1 to 13. In 
all cases 500 ng of DNA was loaded onto the gel 
 
 
This result suggested that a chemo-genetically engineering of drug-streptavidin 
assemblies, with a different arene-cap and through point mutations within the host 
protein, might afford more specialized binders with increased target-selectivity. 
 
3.3.10 Summary of Kd Estimated by EMSA and Determined by ITC 
ITC titration and EMSA analysis were important tools to estimate the dissociation 
constants (Kd) of ruthenium metal drug ! streptavidin assemblies for various 
DNA targets (Table 3.1).  
To extrapolate the affinity constants from EMSA analysis, the intensity of the 
bands in which DNA migrates approximately equally-distributed between the 
slow mobility and high mobility species, were fitted to the equation:  
Kd = [Ru-complex !  Sav]0  –  ! [DNA]0 
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with  [Ru-complex ! Sav]0 and [DNA]0 as initial concentrations of drug-presenter 
protein and DNA, respectively. The band intensity was assumed to be 
proportional to the concentration of sample when loaded on the gel.  
In the case of 1 ! Sav binding to G4A, a 1 : 1 stoichiometry of 1 ! Sav to DNA 
target was observed and only an upper estimate of Kd could be determined by EMSA.  
 
 
Table 3.1 Summary of Kd of ruthenium-Sav assemblies for different DNA targets, as 
estimated by EMSA 
 
 
Entry DNA Target Metal complex Sav Ratio Ru:Sav 
Kd estimated by EMSA 
(#M) 
1 G4A None WT / > 145a  
2 G4A 1 WT 2 < 1.6b, c  
3 G4A 2 WT 2 6.25 
4 G4A 1 WT 1 2.3 
5 G4A 1 WT 4 < 1.6c 
6 G4A (GSH)d 1 WT 2 < 1.6c  
7 G4A (Li+) 1 WT 2 < 1.6c  
8 G4A (Li+) 2 WT 2 1.55 
9 ScG4A 1 WT 2 2.25 
10 ScG4A 2 WT 2 2.25 
11 G4A (GGG)d 1 WT 2 2 
12 G4A (12mer)d 1 WT 2 5.5 
13 G4A 1 K121A 2 28 
14 G4A 1 S112D 2 12.2  
15 G4A 1 S112F 2 < 1.6c  
16 dsOnc 1 WT 2 37.9 
17 dsOnc 2 WT 2 37.9 
18 dsOnc 1 S112F 2 37.9 
19 dsOnc 2 S112F 2 18.2 
 
 
a Kd determined by ITC: 15.2 #M 
b Kd determined by ITC: 0.74 #M 
c Binding was stoichiometric and probably beyond the sensitivity of these EMSA 
d In brackets competing species: glutathione (GSH), trinucleotide GGG (GGG), ssDNA 12mer (12mer) 
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3.4 Materials and Methods 
3.4.1 Chemicals 
Solvents used were all of analytical grade. 
All solutions were prepared using deionised water. 
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Table 3.2 List of chemical and supplier  
Chemical  Supplier 
Acrylamide 
Glucose 
SDS 
Chloramphenicol 
Ampicillin 
PMSF 
IPTG 
Glycerol 
KOH 
Tris 
AppliChem 
  
Bactoyeast extract Merck 
  
Bactotryptone BD 
  
NaCl 
DMSO 
DTT 
KH2PO4 
Sucrose 
Coomassie Brilliant Blue 
TEMED 
Fluka 
  
Acetic acid 
NaOH 
HCl 
LiOH 
VWR 
  
APS 
Na2HPO4 
B4F 
DNaseI 
Sigma 
  
Guanidinium/HCl Acros Organics 
  
BenchMarkTM Protein Ladder Invitrogen 
  
Bromophenol Blue Riedel-de Haën 
  
dNTP Promega 
  
Dpn1 
DNA ladder 
Biolabs 
  
Pfu Turbo Stratagene 
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3.4.2 Technical Equipment 
• Protein expression in 20 L of E. coli cell culture was 
peformed in a fermentor NLF22 (Bioengineering®). 
• PCR was performed in an eppendorf mastercycler 
gradient 
• DNA concentration was determined by nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
• Agarose gel was analyzed with Molecular Image Gel 
Doc XR (Bio-Rad®, Switzerland). 
• Protein was lyophilized in a lyophilizer FreeZone 2.5 L 
(benchtop of Labconco, USA). 
• The active sites of proteins were determined with the 
Fluorescence Reader Safire (Tecan®). 
• FPLC was performed by using äkta prime machine. 
• ITC was performed in a VP-ITC titration calorimetry 
(MicroCal, Northampton, MA, USA). 
• Crystallization was initially performed in high-
throughput liquid-handling system (PHOENIX, Art 
Robbins Instruments, California). 
3.4.3 DNA 
Oligonucleotides (desalted) were purchased from MICROSYNTH (Switzerland). 
DNA stocks were dissolved in mQ-water and quantified spectrophotometrically at 
260 nm. 
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DNA was prepared for experiments by heat denaturation at 95 °C for 10 minutes, 
in 75 mM MOPS buffer with KOH or LiOH (10 mM) at pH 6.5, followed by 
cooling down to room temperature. The oligonucleotide sequences were:  
G4A, CATGGTGGTTTGGGTTAGGGTTAGGGTTAGGGTTAACCAC;  
Scrambled-G4A, 
GTGAGTGTTGCTGTGTAGGTGTAGTACGTGTGGAGTCAC;  
Onc, CTAGCTACAGAGAAATCTCGA and complementary strand. 
 
3.4.4 Electrophoretic Mobility Shift Assay  in Agarose Gel 
EMSA were carried out on 1.2% agarose gels containing ethidium bromide (5 #g 
per 100 mL of gel) in standard Tris-Borate-EDTA (TBE) buffer. 
500 ng of DNA, previously refolded after heat denaturation, were incubated at 
37 °C for 30 minutes with the desired amount of protein and complex mixture to 
give a final concentration of 13.7 #M oligonucleotide in 75 mM MOPS buffer, 
with KOH or LiOH (10 mM) at pH 6.5. After incubation, loading buffer 
consisting only of 40% sucrose was added to a final 1/6 of total volume before 
charging the gels. Electrophoresis was typically run at 45 V for 20-30 minutes. 
DNA marker with blue dye (DNA Molecular Weight Marker X, 0.07-12.2 Kb.p., 
Roche) was used to follow DNA migration and to confirm similar running 
conditions between gels. 
The affinity constants, sometimes confirmed by ITC, were estimated by EMSA.  
To extrapolate the affinity constants from EMSA analysis, the intensity of the 
bands in which DNA migrates approximately equally-distributed between the 
slow mobility and high mobility species, were fitted to the equation (1):  
Kd = [Ru-complex !  Sav]0  –  0.5 [DNA]0     (1) 
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The equation (1) was derived from this simplified binding model:  
 
   where    [A] = DNA 
           [B] = Ru !  Sav  
          [AB] = [Ru !  Sav •  DNA]  
 
The affinity constant was described by the equation (2): 
The initial concentrations were defined as: 
C0A = [A] + [AB] = [DNA] + [Ru !  Sav • DNA] 
C0B = [B] + [AB] = [Ru !  Sav] + [Ru !  Sav •  DNA] 
 
By deriving: 
[A] = C0A - [AB]        [DNA] = [DNA]0 - [Ru !  Sav • DNA] 
[B] = C0B - [AB]        [Ru !  Sav] = [Ru !  Sav]0 - [Ru !  Sav •  DNA] 
 
Assuming that at 50% intensity for both bands:   
[AB] = [A] = 0.5 • C0A 
[Ru !  Sav • DNA] = [DNA] = 0.5 [DNA]0 
 
The affinity constant became: 
 
 
A + B AB
Ka =
(0.5 C0A)
(0.5 C0A) (C0B - 0.5 C0A)
Ka =
[AB]
[A] [B]
(2)
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0.5 [DNA]0 
                       Ka =  
0.5 [DNA]0  • ([Ru-complex !  Sav]0  –  0.5 [DNA]0) 
 
 
Finally, considering that:  
 
We derived the equation (1): 
Kd = [Ru-complex !  Sav]0  –  0.5 [DNA]0     (1) 
with  [Ru-complex ! Sav]0 and [DNA]0 as initial concentrations of drug-presenter 
protein and DNA, respectively. The band intensity was assumed to be 
proportional to the concentration of sample when loaded on the gel. Values 
estimated for Table 3.1 assume in all cases a 1 : 1 stoichiometry. 
 
3.4.5 Electrophoretic Mobility Shift Assays in Acrylamide Gel 
Non-denaturing TBE-polyacrylamide gel was also performed to resolve the 
ternary complex drug-streptavidin-DNA from free protein, without nevertheless a 
defined and meaningful stoichiometric resolution of the ternary complex.  
In non-denaturing gels, protein mobility is influenced by molecular weight, 
conformation and charge. Instead, in Sodium Dodecyl Sulphate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE), the major determinant of protein mobility is 
the length of the polypeptide chain, since SDS gives all proteins equal negative 
charge. EMSA was carried out in 6% acrylamide gel (acrylamide, 1X TBE, APS 
and TEMED) in total absence of SDS. Preparation of samples was the same as 
described in subsection “Electrophoretic Mobility Shift Assays (EMSA) in 
agarose gel” (3.3.3). 
Kd =
1
Ka
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Loading buffer consisting of Bromophenol blue and 40% sucrose was added to a 
final 1/6 of total volume before charging the gel.  
The gel, cast between glass plates, was run at 45 V in 1X TBE running buffer and 
stained in Coomassie blue. 
See APPENDIX D for a more detailed picture. 
 
3.4.6 Protein Expression and Purification 
Ultra-competent BL21(DE3)pLysS E. coli strains (in house) were transformed by 
pET11b-Sav plasmid (University of Milan, Prof. Paolo Santambrogio) containing 
a gene encoding recombinant streptavidin. Transformed bacteria, plated on 
selective Luria broth (LB) petri dishes containing ampicillin (60 mg/mL), 
chloramphenicol (34 mg/mL) and glucose (2% w/v), were incubated overnight at 
37 °C. 
300 mL of tryptone medium (20 g/L Bactotryptone; 2 g/L Na2HPO4, 1 g/L 
KH2PO4; 8 g/L NaCl; 15 g/L Bactoyeast extract), containing antibiotics and 
glucose at the same concentrations as in LB plates, were inoculated with a single 
colony and incubated overnight in an orbital shaker (37 °C, 250 rpm).  
A 20 L cell culture, inoculated with the whole pre-culture, was grown in a 30 L 
fermentor (Bioengineering, Switzerland) at 37 °C, with 600 rpm agitation speed, 
in the presence of glucose and antibiotics.  
For a detailed description of streptavidin expression and purification see 
Appendix C.  
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3.4.7 Site – Directed Mutagenesis 
Site-directed mutagenesis was carried out using Quick-Change mutagenesis kit 
(Stratagene, Switzerland) on the pET11b-Sav plasmid. The forward (positive) and 
the reverse (negative) primers (Microsynth, Switzerland) were partially 
overlapped with each other and fully complementary at the mutation site. 
Ultra-competent XL1-Blue E. coli cells (in house) were transformed by PCR 
product. The plasmids were extracted from bacteria with a Promega miniprep kit 
(Promega®) and clones were used to transform ultra-competent 
BL21(DE3)pLysS E. coli strains. 
For a detailed description of molecular biology see Appendix B.  
 
3.4.8 Isothermal Titration Calorimetry (ITC) 
All ITC experiments were carried out using a VP-ITC titration calorimeter 
(MicroCal, Northampton, MA, USA) at 25 °C with MOPS buffer (75 mM) 
prepared with 10 mM KOH or LiOH at pH 6.5. Prior to each experiment, all 
solutions were thoroughly degassed and the ITC sample cell washed several times 
with MOPS buffer solution (containing KOH or LiOH).  
The titration was carried out using a 300 #L syringe filled with the 1 ! Sav 
solution or Sav solution. Injections began after baseline stability had been 
achieved. A typical titration experiment consisted of 50 consecutive injections of 
10 #L volume and 10 s duration, with a 10 min interval between each injection 
and stirring at 300 rpm. 
The titration was carried out with a 1 ! Sav or Sav concentration of 0.375 mM. 
Heats of dilution of 1 ! Sav solution into the buffer alone were used to adjust 
total observed heats of binding. At least two titration experiments were performed 
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for each sample set to evaluate reproducibility. The resulting data were fitted 
using MicroCal ORIGIN software supplied with the instrument. 
 
3.4.9 Crystallization 
Initial screening trials were set up in a high-throughput liquid-handling system 
(PHOENIX, Art Robbins Instruments, California) equipped with 96 well sitting 
drop plates. Classical screens in kit form, such as Crystal Screen and Crystal 
Screen 2 (Hampton Research, California), were used as crystallization solutions. 
In order to optimize crystal growth, microbatch under oil crystallization 
experiments were carried out manually. Trials were conducted in 96-well plates, 
filled up with 50 #L of mineral or paraffin oil [29]. 1 or 2 #L of the sample, 
consisting of pure streptavidin (26 mg/mL in H2O) with biotinylated Ru (II) 
metal-complex 1 (0.15 mM in H2O), was mixed with different crystallization 
solutions in a ratio 1:1, 1:2, 2:2 (v/v in #L).  
Successful crystallizations were obtained with 2.99 M NaCl, 0.1 M Na Citrate, pH 
4; 0.1 M LiBr, 0.1 M Na Citrate, PEG 8000 40%, pH 4; 0.1 M citric acid, PEG 
3350 25%, pH 3.5. Crystals were not exposed to cryo solutions before freezing in 
liquid nitrogen. However, diffraction data were not collected due to low 
diffraction quality. Crystal structure of drug-streptavidin assembly (complex 1 ! 
Sav) was resolved by Tillmann Heinisch (in collaboration with the Prof. Tilman 
Schirmer, Biozentrum, Universität Basel). Apo-streptavidin was crystallized using 
the hanging drop vapor diffusion technique [30]. Rhombohedral crystals were 
obtained by mixing 5 #L protein solution (26 mg/mL in H2O) with 5 #L 
crystallization buffer (2 M (NH4)SO4, 0.1 M Na Acetate , pH 4.0) and 
equilibrating the droplet against a reservoir of 500 #L crystallization buffer for 24 
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h at room temperature. The ligand soaking solution was prepared by mixing 9 #L 
stabilization buffer (3 M (NH4)SO4, 0.1 M Na Acetate, pH 4.0) with 1 #L ligand 
solution (50 mM [(!6-p-cymene)Ru(Biot-L)Cl]CF3SO3  in water). Lyophilized 
streptavidin (about 100-300 #g) was added to the ligand soaking solution 
subsequently to scavenge non-modified biotin. A single apo-streptavidin crystal 
was soaked for 24 h at room temperature. Then, the crystal was placed into cryo 
buffer (1.5 M (NH4)SO4, 0.1 M Na acetate, pH 4.0, 25% glycerol) for 30 s before 
to be frozen in liquid nitrogen. 
 
 
 
 
3.5 Conclusions 
The streptavidin presenter protein [11] provided an additional surface area available 
for interactions between metallo-drug and its macromolecular target, improving 
affinity and specificity for telomeric G4A. Further structural studies of ternary 
complexes will be of great assistance in achieving sequence selectivity by rational 
design. 
Supramolecular assembly of a drug with a host protein may be proposed as a new 
attractive alternative to the current anti-cancer therapeutic agents. The binding of 
metal complex with a presenter protein protects the drug from unwanted 
interactions and chaperones its specific delivery to desired macromolecular 
targets. 
The exploitation of an endogenous protein, such as an overexpressed protein in 
cancer cells, as a presenter protein for metallo-drugs can be a new outlook for 
rational drug-design. 
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Although these studies were carried out in vitro, it could be possible to engineer 
hybrid organometallic species with improved binding and selectivity in vivo. The 
intracellular delivery of chaperoned metallo-drugs still remains a challenge, due to 
the poor uptake of hydrophilic compounds by the cells. Over the past decade, 
numerous strategies to overcome the cell membrane barriers have been proposed, 
including electroporation, microinjection, viral vectors and liposome 
encapsulation, but these still have low delivery efficiencies [31]. 
Therefore, naturally occurring, short, cell-penetrating peptides (CPPs) have 
attracted considerable interest in the field of drug delivery for their ability for 
direct cellular uptake. CPPs are oligopeptides containing cationic and hydrophilic 
residues and are able to deliver an array of pharmacological cargoes into the cells 
[32]. 
Streptavidin and related avidins have previously been used in clinical trials as 
drug carriers, but unfortunately with difficult cellular uptake and low intracellular 
delivery [33]. In order to increase the internalization of these therapeutic proteins, a 
cell penetrating peptide, known as TAT, has been attached to the N-terminus of 
each streptavidin monomer. This system acted as carrier of biotinylated 
complexes into the nucleus of human cells to interact with the target DNA [31, 34]. 
The extension of the ruthenium metallodrug-protein concept to other molecular 
targets, such as RNA, is an interesting perspective for future applications. RNA 
plays an important role in biological processes, as the carrier of necessary 
information for biological functions. It offers several advantages as a drug target: 
lack of cellular repair mechanisms, structural diversity, and direct influence on 
gene expression [35].  
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A few years ago, Verdine [18] and Pelletier [17] developed RNA-targeting systems, 
in which a small molecule was presented to RNA in complex with a protein. This 
approach allowed modulation of gene expression. 
Furthermore chaperoned metallodrugs were defined as high-affinity binders 
specific for ssDNA. This high affinity could be exploited to label and detect 
telomeric structures in vitro and in vivo, providing alternatives to antibodies [35].
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Chapter 4  
Novel Avidin from B. pseudomallei 
 
The whole of science is 
nothing more than a 
refinement of everyday 
thinking 
 
Albert Einstein 
 
 
4.1 Introduction 
4.1.1 Avidins Useful in Biotechnology 
Avidins have been widely exploited as important tools in a plethora of 
medical and biotechnological applications, owing to the exceptionally high 
affinity for biotin through non-covalent interactions [1]. 
The extremely low dissociation constants of the interaction (avidin has a Kd = 
1.3 • 10-15 M) [2] have also proven to be an incredible useful model system for 
the exploration of biomolecular interactions [3]. 
Over the years a wide variety of novel and engineered forms of (strept)avidin 
have been produced leading to their routine use in many applications, 
including affinity chromatography, immunoassays, cytochemistry [4], 
nanotechnology [5] and drug delivery [6]. 
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4.1.2 Avidins from Different Organisms 
The two most widely studied avidins are Avidin (Avi) and Streptavidin (Sav), 
which like most avidins studied to date are homotetrameric proteins 
consisting of four antiparallel !-barrels [7]. 
As widely described in the introduction, Avi is naturally glycosylated and 
positively charged (pI = 10.5), whereas Sav is a non-glycosilated protein with 
a less basic pI than avidin. 
Notwithstanding a similar organization of amino acid residues in the biotin-
binding pocket, Avi and Sav differ in many aspects, which render them useful 
for different applications [7-8].  
Consequently, many avidins other than Avi and Sav have also been 
investigated for potential biotechnological applications. 
Avidin-related gene (AVR), isolated in chicken, encodes protein with a 
different glycosilation pattern, immunological activity, isoelectric point, 
stability and biotin-binding pathway than chicken avidin [9]. 
A novel biotin-binding protein A (BBP-A) has been recently described as an 
avidin-like protein with similar tetrameric structure and high affinity for 
biotin, but with a different stability and immunological reactivity [10].  
New bacterial avidin-like proteins, characterized by a reduced 
immunogenicity, were isolated from nitrogen-fixing symbiotic bacteria, such 
as Bradavidin and Rhizavidin. Rhizavidin is also the first dimeric member of 
the avidin family, which maintains high affinity towards biotin [11]. 
Avian avidins, isolated from egg-white of duck, goose and ostrich, display a 
different immunological features and potential in pretargeting cancer 
treatment [6b]. 
! -129"
Studies of different Streptomyces strains led to the discovery of two novel 
streptavidin forms (Streptavidin v1 and Streptavidin v2), purified from 
Streptomyces venezuelae. As revealed from sequence alignment, these new 
biotin-binding proteins shared a sequence homology of 98% with 
streptavidin [12].  
Tamavidin [13] and Xenavidin [14] were isolated from fungi and frogs, 
respectively. 
Many other genes, probably encoding biotin-binding proteins, have been 
identified over the years. 
 
 
4.2 Aim of the Work 
The broad aim of this chapter was to express novel bacterial avidins 
recombinantly in E. coli and to purify and characterize the proteins in view of 
their potential in biotechnological applications. 
We aimed to characterize novel avidins in term of their biotin-binding activity 
and their stability over temperature ranges and in the presence of proteases 
and chaotropic reagents.  
Inspired by our previous experience on artificial metalloenzymes, we 
hypothesized that novel biotin-binding proteins could be used as scaffold for 
hybrid catalysts.  
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4.3 Results and Discussion 
4.3.1 Overexpression and Purification of Novel Avidins 
Homology searches in DNA databases can be used to identify many putative 
avidin-like proteins. Of these, three candidates from bacteria were chosen for 
further investigation following recombinant expression in E. coli: one from 
Rhodopseudomonas palustris [15], here called Rhod, and two from the human 
pathogen Burkholderia pseudomallei [16], named Burk1 and Burk2.  
The natural functions of these novel avidins remained speculative, although 
they might have a similar antimicrobial function to other avidins, through 
biotin depletion [17]. 
To study the characteristics of these novel biotin-binding proteins, the genes 
were cloned by PCR from genomic bacterial DNA into pET11b for 
recombinant overexpression of the native (untagged) open reading frames in 
E.coli.  
Envisaging the existence of either N-terminal secretion peptides or alternative 
start codons, several truncated forms of the genes were chosen. Protein 
extracts were analyzed with a functional screening assay for biotin-binding 
proteins [18], which revealed functional expression of one construct of each 
protein. 
Whereas Rhod and Burk2 migrated in the SDS-PAGE as functional and 
stable tetramers, Burk1 tended to form dimers.  
 
 
 
 
 
 
! -131"
 
 
Fig. 4.1 Functional assay of biotin-binding, monitored by SDS-PAGE in the presence of 
B4F. Lane 1, protein ladder (220 KDa). Lane 2, Rhodavidin (good expression). Lane 3, 
Burk1 (MARPA isoform; no expression). Lane 4, Burk1 (MTGAP isoform; no expression). 
Lane 5, Burk1 (MQRLE isoform; (modest expression and probably dimeric). Lane 6, Burk2 
(MPIQE, good expression). Lane 7, Burk2  (MDTSTA, no expression) 
 
Visible leaching of the biotinylated fluorophore (B4F) from Rhod and Burk1 
(Fig. 4.1, Lanes 2 and 5) during electrophoresis probably suggested fast 
dissociation and weak B4F-binding activity. Low affinity for biotin of these 
two proteins was confirmed by their inability to bind on iminobiotin-
sepharose.  
By contrast, Burk2 was the only protein purified successfully by means of its 
strong iminobiotin-binding, following protocols previously established for 
Sav [19]. About 5 mg of purified lyophilized protein per liter of culture were 
obtained, without further protocol optimization. 
 
4.3.2 Sequence Alignments and 3D-Modelling 
These three novel avidins presented a very low sequence similarity with each 
other or with either Sav or Avi. The paired-alignments revealed less than 25% 
sequence identity and only 12 residues from the five proteins (including Sav 
and Avi) aligned perfectly overall. These conserved residues were mostly 
implicated in biotin-binding in Sav and Avi [11a]. 
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A conserved tryptophan residue (Trp-120 of Sav) on a loop was involved in 
an inter-monomeric contact, effectively “closing” the lid of the active site 
upon biotin-binding [20]. However, not all biotin-binding residues were 
perfectly conserved and, for example, Burk2 had a leucine (Leu-106) at the 
equivalent position of Trp-108 of Sav, both presumably providing a 
hydrophobic lining inside the biotin pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Multiple sequence alignment of novel biotin-binding proteins. Primary structures 
of burkavidin-2 (Burk2), T7-tagged streptavidin (T7-Sav), avidin (Avi), burkavidin-1 
(Burk1) and rhodavidin (Rhod) are ligned. Black arrows indicate the positions of the eight !-
strands. The secretory signal peptide of Burk2 is written in italic. The T7-tag peptide of 
recombinant streptavidin (T7-Sav) is underlined [21]. The residues directly involved in biotin-
binding, identified in the crystal structure of “core” Avi and T7-Sav, are shaded in blue. The 
cysteines of Burk2 and Avi, which form a disulphide bridge, are circled. Perfectly conserved 
residues are marked by stars 
 
By comparing these novel avidins that we expressed recombinantly in E. coli, 
only Burk2 appeared to bind biotin and its derivatives with sufficient affinity. 
The reasons for the low biotin-binding of Rhod and Burk1 were not pursued 
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further, but sequence alignments of the new avidins could provide some 
clues. 
For example, Burk1 was the only avidin having an alanine (Ala-76) at the 
equivalent position of Ser-88 in Sav, thus potentially losing hydrogen 
bonding with the carboxylic group of biotin (or with the carbonyl group of an 
amide in biotinylated derivatives). 
Burk1 also appeared to have shorter loop around the active site, thus probably 
providing a more “open” biotin-binding pocket. 
Finally, the presence of an alanine (Ala-108), at the inter-monomeric surface, 
rather than valine at the equivalent position of Sav (Val-125) could contribute 
to this protein’s tendency to dissociate into dimers. 
In contrast, Burkavidin (Burk2) bound biotin strongly and formed tetramer of 
very pronounced structural stability, as judged by thermal and chemical 
denaturation assays (see below).  
In addition to important inter-monomeric contacts of residues (e.g. Val-123 
and Trp-118), that are also conserved in Sav, a homology model of 
Burkavidin based on the Sav structure suggested the presence of additional 
hydrophobic residues at the inter-monomeric interfaces in Burkavidin, which 
probably stabilized the tetramer (e.g. Trp-54, Tyr-56, Tyr-107, Tyr-109, Val-
121). 
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Fig. 4.3 Structural comparisons of Burkavidin (Burk2) and Streptavidin (Sav). 
a) Superposition of the crystal structure of Sav monomer bound to biotin (1MK5:A) with a 
structural model of Burk2. The same residues highlighted in the sequence alignment in 4.3c 
(within 4 Å of biotin) are shown in full. Sav: red (backbone) and magenta (residues in full); 
biotin: yellow; Burk2 blue (backcone) and purple (residues in full). Residues W120 in Sav 
and W118 in Burk2 are also highlighted because W120 is known to make a contact with the 
biotin in the neighbouring monomer. The superposition has a RMSD of 0.41 Å over 114 
aminoacids. b) Comparison of quaternary structures of Sav and Burk2 by gel-filtration 
chromatography. Both proteins are tetrameric in solution. c) Sequence alignment of Sav and 
Burk2. The highlighted residues are those contacting biotin (within 4 Å) in the crystal 
structure of streptavidin (pdb code 1MK5:A). Those putative biotin-binding residues that are 
not perfectly conserved are indicated with a dot (•). The cysteines, which form a disulphide 
bridge (conserved in avidin), are circled. In lower case are amino acids not included in the 
structural model 
 
 
 4.3.3 Biotin-Binding Activity  
The facile expression and purification of Burk2, simply called Burkavidin, 
warranted a further exploration of its features, such as, for example, biotin-
binding activity and stability over temperature ranges and in the presence of 
proteinases and chaotropic reagents.  
Despite a very different primary aminoacid sequence compared with Avi and 
Sav, Burkavidin bound biotin strongly, as monitored by Isothermal Titration 
Calorimetry (ITC) analysis and 2-[(4-hydroxyphenyl)azo]benzoic acid 
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(HABA) titration. 
The dissociation constant of Burkavidin, determined by ITC (Kd < 10
-7 M, in 
the sub-micromolar range), was modest. For comparison, the values of Kd that 
we obtained for T7-tagged Sav were only an order of magnitude lower. 
Therefore, these data were likely to be an underestimate considering that they 
approach the sensitivity of the instrumentation. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4 Binding of biotin to Burkavidin (Burk2) and Sav monitored by Isothermal 
Titration Calorimetry (ITC). ITC for the binding of biotin onto a) Sav and b) Burkavidin, 
respectively. Titrations were carried out at 25 °C in 50 mM HEPES, pH 6.5. In the upper 
panels the raw titration data were plotted as heat versus time. In the lower panels, the 
integrated heat measurements are plotted as Kcal/mol of biotin injected into a) tetrameric 
Burkavidin or b) Sav. The data were fitted to a single set of one site model. For Burkavidin, 
the association constant is (1.14 ± 0.319) x 107 M-1, an enthalpy of (-2.83 ± 296.2) x 104 
Kcal/mol, and a stoichiometry of 1.95. For Streptavidin, the association constant is 1.09 ) x 
108 M-1, an enthalpy of -2.102 x 104 Kcal/mol and a stoichiometry of 3.16 
 
The stoichiometric value determined by ITC suggested around two free-biotin 
binding sites per tetramer of Burkavidin. 
Evidence of strong-binding of biotin was also provided by a 
spectrophotometric HABA titration of Burkavidin, which gave a clear 
equivalent point upon biotin addition.  
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Displacement of the chromophore HABA from Burkavidin upon titration 
with biotin caused a decreased absorbance at 506 nm [22]. However, the 
HABA absorption changed only moderately upon biotin-binding to 
Burkavidin compared with Sav or Avi [22]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. Binding of biotin to Burkavidin (Burk2) and Sav monitored by HABA 
titration. HABA titration of a) Streptavidin and b) Burkavidin, respectively. Displacement 
of the chromophore HABA upon titration with biotin causes a decreased absorbance at 506 
nm [22]. Three free active sites per tetramer of Sav and two free active site per tetramer of 
Burkavidin are quantified by HABA titration 
 
A low dissociation constant of Burkavidin was confirmed by additional 
findings: 
i. The protein could be purified easily by iminobiotin-affinity. 
ii. Traces of a biotinylated enzyme from E. coli (acetyl CoA 
carboxylase) were present in some batches, suggesting co-purification 
of the minor contaminant due to the tetrameric nature of Burkavidin. 
iii. Only about two biotin-binding sites per tetramer were quantified, 
suggesting that biotin from yeast extract in rich medium remained 
bound, although this was apparently not a problem encountered when 
recombinant secreted avidin was expressed in rich medium in E. coli 
[23]. 
! -137"
iv. In contrast to Rhod and Burk1, no leaching of B4F was observed in 
SDS-PAGE (Fig. 4.1).  
 
 4.3.4 Protein Stability  
4.3.4.1 Resistance to Proteinase Digestion 
A further characterization round of Burkavidin was aimed to assess its 
stability in the presence of chaotropic agents and proteinases . 
During purification, Burkavidin was dialyzed against 6 M guanidinium 
chloride at pH 1.5 at room temperature, remaining active in SDS-PAGE 
analysis. 
We also performed B4F-binding analysis to test the resistance of Burkavidin 
to Proteinase K digestion (Fig. 4.6). 
In this assay, active Avi did not migrate into the gel, probably due to its very 
high pI, although the inactive monomer in the preparation was visible 
degraded by proteinase K. 
In contrast, both Sav and Burkavidin resisted Proteinase K treatment in an 
active form either in the presence or absence of B4F, albeit with slight 
changes in migration pattern. 
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Fig. 4.6. Burkavidin resistance to proteolysis by Proteinase K monitored by SDS-PAGE. 
Gel a) and b) were run following incubation in the presence of B4F (assaying for functional 
activity). Gel c) was run in absence of B4F (and only Coomassie stained). Lane 1, protein 
ladder (220 KDa). Lanes 2, 4, and 6, Avi, Burkavidin and Sav with Proteinase K, 
respectively. Lanes 3, 5 and 7, Avi, Burkavidin and Sav without Proteinase K, respectively. 
The functional assay (panel a) shows that Burkavidin and Sav remain active upon incubation 
with Proteinase K. Functional Avi does not migrate into the gel under these conditions. 
Binding of the biotin-fluorophore B4F alters sensitivity of Burkavidin against Proteinase K 
(panels b and c). Comparison of lane 5 suggests that oligomerization domains responsible for 
apparent heterogeneity are sensitive to proteolytic cleavage, especially in the presence of B4F 
(panel b) 
 
In certain Burkavidin preparations, high-molecular weight species (probably 
aggregated oligomers) were observed in addition to the tetramer, particularly 
in the absence of B4F (Fig. 4.6c).  
A change in migration of Burkavidin upon Proteinase K treatment, leading 
towards a single species formation, was more evident in more heterogeneous 
preparations. We ascribed this different migration of active Sav and 
Burkavidin to the formation of a “core” (active) tetramer [24]. Then, the 
terminal sequences that were cleaved upon proteolysis in Burkavidin 
probably induced oligomerization in the non-treated species. 
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Increased formation of the tetramer from oligomers in the presence of B4F 
suggested the presence of the apo-protein termini into the biotin-binding site, 
as described for the C-terminus of Sav [25]. 
 
4.3.4.2 Thermal Stability 
The high stability of Burkavidin in the presence of denaturing agents was an 
attractive property for its use in biotechnological applications, in particular as 
a catalytic artificial enzyme. However, many catalytic reactions are carried 
out in the presence of organic solvents or at high temperature. 
Thus, we also explored the thermal stability of Burkavidin through 
electrophoretic assays. 
Burkavidin resisted incubation in an active B4F-bound form upon heat 
treatment up to 99 °C for 10 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7. Thermal stability of Burkavidin (Burk2) assessed by SDS-PAGE. Purified 
Burkavidin samples were electrophoresed after heating at 50 °C to 99 °C for 10 minutes, 
either in the presence of B4F (a and b) or in the absence of B4F (c). a) Activity assay: 
fluorescence of B4F is strongly associated to tetramers and only more weakly to oligomers. 
Disaggregation oligomers occurs with higher temperatures. b) and c) Coomasie-blue staining 
of gels reveals that denaturation into monomers only occurs (weakly) in the absence of B4F 
above at higher temperature (80°C and above). Lanes 1-7, supernatants from heat treatment 
at different temperatures: 50°C, 60°C, 70°C, 80°C, 85°C, 90°C, 99°C, respectively. Samples 
were loaded in the same order in all gels 
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A small amount of monomeric species was observed at the highest 
temperatures tested only in the absence of B4F, in agreement with the notion 
protein stabilization upon ligand-binding [26]. 
Whether in the presence or absence of B4F, dissociation of oligomers towards 
a more defined tetrameric species was observed with higher temperatures. 
 
4.3.4.3 Resistance to Reducing Agents 
As revealed by the sequence alignments, the cysteines that form an intra-
monomeric disulphide bridge in Avi were also conserved in Burkavidin. 
Consequently, to assess the stability of Burkavidin in the presence of 
reducing agents, we carried out denaturing SDS-PAGE analysis in the 
presence and absence of DTT as reductant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 Burkavidin (Burk2) stability in presence of reducing agents assessed by 
denaturing SDS-PAGE. In all cases, proteins were electrophoresed in the absence of B4F. 
a) Heating at 95 °C for 10 min in DTT. b) Heating at 95 °C for 10 min in absence of DTT. 
Lane 1, protein ladder (220 KDa). Lanes 2, 4 and 6, Avi, Burkavidin and Sav in the presence 
of Proteinase K, respectively. Lanes 3, 5 and 7, Avi, Burkavidin and Sav in the absence of 
Proteinase K, respectively. Samples were loaded in the same order in all gels  
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Remarkably, Burkavidin remained tetrameric upon treatment with Proteinase 
K, following by 10 minutes incubation at 95 °C. In contrast, both Avi and Sav 
were degraded mostly into monomers under these conditions. 
Adding a reducing agent to Burkavidin in these assays led to partial 
denaturation into dimers and monomers, although tetrameric Burkavidin 
remained. 
The destabilization of the tetramer upon incubation with a reducing agent 
suggested that the presence of an intra-monomeric disulphide bridge, found 
also in Avi [2], contributed to the extreme stability of Burkavidin to thermal, 
proteolytic and chemical denaturation of the protein. 
To confirm the importance of this disulphide bridge for Burkavidin 
expression, we produced Burkavidin mutant C8A (numbering refers to 
position following the signal peptide). This single point mutation did not lead 
to any detectable expression of active protein, as monitored by SDS-PAGE 
analysis.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.9 Expression of Burkavidin mutant C8A monitored by SDS-PAGE. Functional 
assay of mutant C8A to assess importance of disulphide-bond formation. Lane 1, cell-extract 
of wildtype Burkavidin (WT). Lane 2, C8A-mutant of Burkavidin 
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The presence of the disulphide bridge was crucial for Burkavidin expression 
in an active form as well as contributing to its extremely high stability. 
 
 4.3.5 Protein Secretion into the Periplasm of E. coli 
4.3.5.1 Secretory Signal Peptide 
Sequencing of purified Burkavidin by Edman degradation confirmed the 
sequence DTSTA at the N-terminal, in line with signal-peptide predictions [27].  
In some cases, the sequence MDIRK was also detected as a minor species 
(less than 10 %), corresponding to the N-terminal of acetyl CoA carboxylase 
of E. coli. 
The principal ESI-MS peak was 14249.71 Da (theoretical for Burkavidin 
monomer: 14250.74 Da) and in some cases a peak of 16913.23 Da was also 
detected and attributed to the biotinylated contaminant acetyl CoA 
carboxylase (theoretical mass: 16669 + 244 biotin = 16913 Da), as previously 
found in recombinant avidin preparations [28]. 
 
4.3.5.2 Periplasmic Expression in E. coli 
Since protein sequencing and mass spectra showed a cleavage of the N-
terminus, we sought to explore whether Burkavidin was secreted into the 
periplasm of E. coli, due to the presence of a secretory signal peptide from B. 
pseudomallei [27]. 
Periplasmic extracts of E. coli expressing Burkavidin were enriched in B4F-
binding protein compared with those containing recombinant T7-tagged Sav, 
which was found mostly intracellularly in E. coli in an active form [21]. 
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Fig. 4.10 Functional analysis of Burkavidin (Burk2) periplasmic secretion into the 
periplasm of E.Coli. a) Functional analysis of Burkavidin and Sav expression into the 
periplasmic (Pe) or spheroplastic (Sp) fractions of E. Coli. Lane 1, protein ladder (220 KDa). 
Lanes 2 and 4, Burkavidin and Sav periplasmic extracts, respectively. Lanes 3 and 5, 
Burkavidin and Sav spheroplasmic extracts, respectively. b) Coomasie-blue staining of gel a)  
 
As reported for secreted avidin in E. coli, a large fraction of the protein was 
associated with the non-periplasmic fraction [23]. However, unlike reported for 
Avi, the cellular Burkavidin fraction contained active protein with high 
propensity to form oligomers, while the secreted form tended to be only 
tetrameric.  
We speculated that the presence of the hydrophobic signal peptide, which was 
only cleaved upon secretion, might contribute to Burkavidin oligomerization. 
Expression of a construct lacking the signal peptide, with N-terminal 
sequence MDTSTA led to absence of active protein in E. coli, suggesting that 
the less reducing environment of the periplasm was necessary for S-S bond 
formation and the correct folding of the protein (Fig. 4.1). 
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These experiments suggested that secretion into the periplasm, using 
Burkavidin’s native secretory signal, and the presence of the disulphide 
bridge were crucial for Burkavidin expression in an active form and protein 
stability. 
 
 4.3.6 Burkavidin Homogeneity 
Further optimization of expression and purification conditions of Burkavidin 
may lead to higher yield, more efficient secretion and improved properties, 
such as a decreased oligomerisation propensity and a lower biotin content of 
preparations.  
The best batches of periplasmic Burkavidin showed a single main species in 
isoelectric focusing (IEF) analysis, performed in collaboration with Prof. 
Zoller (Medical University of Innsbruck). Surprisingly, the highly-purified 
T7-tagged Sav was much more heterogeneous than Burkavidin with several 
unidentified isoforms, as judged by IEF [29].  
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Fig. 4.11 Isoelectric focusing (IEF) of Avidin (Avi), T7-tagged Streptavidin (Sav) and 
Burkavidin (Burk2). Marker (left lane), PhastGel IEF 3-9 (GE-Healthcare). Whereas the 
highly-purified T7-Streptavidin (Sav) shows several unidentified isoforms, Burkavidin is 
comparatively homogeneous and with a dominant species that has a lower isoelectric point 
(pI) than either Avi (very basic) or most isoforms of Sav  
 
It was noteworthy that the pI of the T7-tagged Sav tested here was higher 
than expected. Both heterogeneity and the presence of Sav preparations with 
high pI have also been reported previously by others for untagged 
streptavidin [30].  
The low pI of Burkavidin compared with Avi and T7-Sav may render this 
novel protein also useful for specific binding of biotinylated DNA, since the 
negatively charged DNA can bind strongly to avidin non-specifically due to 
electrostatic interactions.  
 
4.3.7 Burkavidin as an Artifcial Metalloenzyme 
To begin exploring the potential of Burkavidin in biotechnology, we chose to 
use the protein for enantioselective hydrogenation of N-acetamidoacrylic acid 
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and N-acetamidocinnamic acid using [Rh(COD)(Biot-1)]+ or [Rh(COD)(Biot-
(R)-Pro-1)]+ as artificial cofactors for the hydrogenation of N-protected 
dehydroamino acids [31], in collaboration with Mr. Lo. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.12 Enantioselective reduction of N-acetamidoacrylic acid and N-
acetamidocinnamic acid catalyzed by artificial hydrogenases. The reaction was catalyzed 
by [Rh(COD)(Biot-1)]+ or [Rh(COD)(Biot-(R)-Pro-1)]+ in the presence of 50 equiv of each 
substrate with respect to the ligand and using T7-Streptavidin (Sav) or Burkavidin (Burk2) as 
protein host. Results are summarized in Table 1. MES buffer is composed of 4-
morpholineethanesulfonic acid that is pH adjusted with sodium hydroxide 
 
The catalyst in the absence of protein catalyzed hydrogenation leading to 
racemic mixture of products. In contrast, the placement of the catalyst within 
the chiral environment of the Burkavidin, through biotin-anchoring, led to 
enantioselective enrichment of the reduced species: up to 39% ee in favour of 
the (R)-product for N-AcAla using [Rh(COD)(Biot-1)]+  catalyst and up to 
65% ee for the (S)-product for N-AcPhe using [Rh(COD)(Biot-(R)-Pro-1)]+ . 
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Table 4.1 Numeric summary of results from catalytic experiments 
 
 
 
 
 
 
 
 
 
[
1] N-AcPhe = N-acetamidophenylalanine; [2] N-AcAla = N-acetamidoalanine 
Catalytic hydrogenation conditions are as detailed in Fig. 4.12. 
WT Sav = wildtype Streptavidin; S112W = mutant S112W of Sav; Burkavidin refers to 
Burk2 
 
The results revealed that: 
i. Conversion in Burkavidin was higher for the smaller substrate 
N-AcAla regardless of the metal complex employed (entries 1-
2). 
ii. For both ligands used, N-AcAla was enriched for the (R)-
product, whereas N-acPhe was enriched for the (S)-product 
(entries 1-2). Such opposite enantioselectivities for both 
substrates were never observed before using either Sav or Avi 
isoforms [31b].  
These observations suggested very different discrimination events for both 
substrates [31a, 32]. The different conversions further supported this hypothesis. 
N-AcPhe[1] N-AcAla[2] 
Entry Protein Ligand 
ee [%] Conv [%] ee [%] Conv [%] 
       
1 Burkavidin Biot-1 -65 18 39 52 
       
2 Burkavidin Biot-(R)-Pro-1 -35 21 15 100 
       
3 WT Sav Biot-1 93 84 94 100 
       
4 S112W Sav Biot-(R)-Pro-1 -95 100 -95 100 
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The finding of enantiomeric enrichment and discrimination against the larger 
substrate when using Burkavidin in hydrogenation was strongly indicative 
that catalysis occurred within the defined-biotin-binding pocket [31a].  
Further, the large differences in catalytic results in term of ee and conversion 
when compared Burkavidin to Sav suggested that the chiral environment 
provided by Burkavidin or Sav around the metal-catalyst were markedly 
different. 
Importantly, the successful use of Burkavidin as an enantioselective artificial 
metalloenzyme for Rh-catalyzed hydrogenation provided proof-of-principle 
that the biotin-binding affinity of Burkavidin was sufficient for its use in 
biotechnological applications. 
 
 
 
4.4 Materials and Methods 
  
4.4.1 Chemicals 
Solvents used were all of analytical grade. 
All solutions were prepared using deionised water. 
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Table 4.2 List of chemical and supplier  
 
Chemical  Supplier 
Acrylamide 
Glucose 
SDS 
Chloramphenicol 
Ampicillin 
PMSF 
IPTG 
Glycerol 
Tris 
AppliChem 
  
Bactoyeast extract Merck 
  
Bactotryptone BD 
  
NaCl 
DMSO 
DTT 
KH2PO4 
Coomassie Brilliant Blue 
Triton X-100 
Lysozyme (from egg white) 
TEMED 
Fluka 
  
Acetic acid 
Urea 
VWR 
  
APS 
Na2HPO4 
B4F 
DNaseI 
Sigma 
  
Guanidinium/HCl Acros Organics 
  
BenchMarkTM Protein Ladder Invitrogen 
  
Bromophenol Blue Riedel-de Haën 
  
dNTP Promega 
  
Dpn1 
DNA ladder 
Biolabs 
  
Pfu Turbo Stratagene 
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4.4.2 Technical Equipment 
• Protein expression in 20 L of E. coli cell culture was peformed 
in a fermentor NLF22 (Bioengineering®). 
• PCR was performed in an eppendorf mastercycler gradient 
• DNA concentration was determined by nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
• SDS-PAGE was analyzed with Molecular Image Gel Doc XR 
(Bio-Rad®, Switzerland). 
• Protein was lyophilized in a lyophilizer FreeZone 2.5 L 
(benchtop of Labconco, USA). 
• The active sites of proteins were determined with the 
Fluorescence Reader Safire (Tecan®). 
• FPLC was performed by using äkta prime machine. 
• ITC was performed in a VP-ITC titration calorimetry 
(MicroCal, Northampton, MA, USA). 
• IEF was performed in a PhastGel IEF, 3-9 (GE-Healtcare). 
 
4.4.3 Vector Generation 
For cloning Burkavidin isoform 2 (Burk2), the following primers were 
designed: GC AGC GCG cat atg CCA ATA CAA GAG ATC (upstream 
primer for expression of full-length isoform translated as MPIQE…); AA 
CCT GCG cat atg GAC ACT TCA ACC GCC C (upstream primer for 
expression of putative mature isoform MDTSTA…, starting at D36 according 
to signalp); CACGTTCAAATggatccTACCGCTTTATGC (downstream 
primer). For cloning Burkavidin isoform 1 (Burk1): G CCG ATA AAA GAA 
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cat atg GCG CGC CC (upstream primer for expression of full-length isoform 
translated as MARPA…); GG AGG CGA catatg CAG CGA TTG GAA C 
(isoform translated as: MQRLE…); TC AAG cat atg ACC GGC GCG CCG 
ATC GAT TTC (isoform translated as: MTGAP…); 
ccgttggatcctcaagtcttcacgaatatatc (downstream primer for all Burk1 isoforms). 
For cloning Rhodavidin (Rhod): A TGG AGT TTT cat atg CTC CGT ATC 
(upstream primer for expression of full-length isoform translated as: 
MLRIV…); TCC GCT GCA cat atg GCG CAA GTC AG (upstream primer 
for expression of putative mature isoform MAQVSW…, starting at aa27 
according to signalp); GACggatccGCGACGATGTTATTTC (downstream 
primer for Rhod isoforms).  
Genomic DNA from R.palustris strain BisB18 was a kind gift from Dr. 
Caroline Harwood at the University of Washington (US). Genomic DNA 
from Burkholderia pseudomallei strain K96243 was kindly provided by Prof. 
Richard Titball from the Defence Science Technology Laboratory, Porton 
Down, Salisbury (UK). In all cases, PCR was carried out using genomic DNA 
as a template and the amplified genes were cloned into expression plasmid 
pEt11b (Novagen) using Nco1 and BamH1 as cloning sites. DNA sequencing 
was carried out by Microsynth (Switzerland) or StarSEQ® GmbH 
(Germany).  
 
4.4.4 Expression and Purification [19] 
Ultra-competent BL21(DE3)pLysS E. coli strains (in house) were 
transformed by pET11b-burkavidin plasmid containing a gene encoding 
recombinant burkavidin. Transformed bacteria, plated on selective Luria 
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broth (LB) petri dishes containing ampicillin (60 mg/mL), chloramphenicol 
(34 mg/mL) and glucose (2% w/v), were incubated overnight at 37 °C. 
300 mL of tryptone medium (20 g/L Bactotryptone; 2 g/L Na2HPO4, 1 g/L 
KH2PO4; 8 g/L NaCl; 15 g/L Bactoyeast extract), containing antibiotics and 
glucose at the same concentrations as in LB plates, were inoculated with a 
single colony and incubated overnight in an orbital shaker (37 °C, 250 rpm).  
A 20 L cell culture, inoculated with the whole pre-culture, was grown in a 
30 L fermentor (Bioengineering, Switzerland) at 37 °C, with 1000 rpm 
agitation speed, in the presence of glucose and antibiotics.  
Isopropyl-!-D-1-thiogalactopyranoside (IPTG) (0.4 mM as final 
concentration) was added to the culture when the OD600 reached a value 
between 1.8 and 2.0. Three hours after induction, the bacterial pellet was 
collected by centrifugation and stored at -20 °C until purification. On the next 
day, the pellet was thawed and resuspended in 20 mM Tris/HCl pH 7.4, 
1 mM PMSF and 2-3 mg DNaseI under vigorous shaking.  
The sample was dialysed against 6 M guanidine chloride at pH 1.5 for 24 h, 
against 20 mM Tris/HCl pH 7.4 for another day and finally against 50 mM 
NaHCO3/500 mM NaCl pH 9.8 for 24 h. The protein extract was loaded onto 
a 2-iminobiotin agarose column, pre-equilibrated with 50 mM 
NaHCO3/500 mM NaCl buffer. At this step, it was observed that Rhod 
(MAQVS isoform) and Burk1 (MQRLE isoform) did not bind to the column, 
as judged by SDS-PAGE of elution fractions. Only Burk2 (containing the 
signal peptide starting with MPIQE) had sufficiently-strong binding to 
iminobiotin-sepharose for affinity purification. The protein was washed with 
the same buffer and eluted with 1% acetic acid.  
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Purified Burkavidin was immediately dialysed against 10 mM Tris/HCl pH 
7.4 for 24 hrs and twice in mQ-water, before lyophilisation.  
For a detailed description of burkavidin expression and purification see 
Appendix C.  
N-terminal sequencing (on an Applied Biosystems Procise Sequencer) and 
mass spectrometry by electrospray ionisation (ESI-MS) were carried out by 
Analytical Research and Services, University of Bern.  
 
4.4.5 Preparation of Periplasmic Proteins from  Bacterial Culture 
One mL of a bacterial cell culture, inoculated with 200 !L of pre-culture, was 
grown at 37 °C in a 15 mL Falcon tube for 2 hrs. The cells, induced by IPTG, 
were harvested by centrifugation at the log phase, one hour after induction. 
The fresh culture was immediately processed as described in the PeriPrepsTM 
Periplasting protocol (Connectorate AG, Switzerland). Spheroplastic and 
periplasmic fractions were analysed by a 12% acrylamide gel. 
 
4.4.6 Site – Directed Mutagenesis 
For generating Burk C8A, site-directed mutagenesis was carried out using the 
Quick-Change mutagenesis kit (Stratagene, Switzerland) on the pET11b-
burkavidin plasmid. The forward (positive) and the reverse (negative) primers 
were partially overlapped with each other and fully complementary at the 
mutation site. 
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Table 4.3 List of mutagenic primers used for generating Burk C8A 
 
 
 
 
 
 
The PCR results were verified on a 1.2% agarose gel containing 1X Tris-
Borate-EDTA (TBE) buffer. Ultra-competent XL1-Blue E. coli cells (in 
house) were transformed by PCR product. Finally the plasmids were 
extracted from bacteria with a Promega miniprep kit (Promega) and clones, 
sequenced by StarSEQ® GmbH (Germany), were used to transform ultra-
competent BL21(DE3)pLysS E. coli strains. 
For a detailed description of molecular biology see Appendix B. 
 
4.4.7 Structural Modeling 
Structural models were carried out by automated homology modeling with 
SWISS-MODEL [33].  
 
4.4.8  Thermostability  
The thermostability of burkavidin was assessed by SDS-PAGE assay. The 
samples (26 !M tetramer) were solubilised in 10 mM CaCl2/50 mM Tris pH 8 
and incubated for 10 minutes at selected temperature (from 50 °C to 99 °C) in 
the presence or absence of biotin-4-fluorescein (B4F). 
After heat treatment, the samples were loaded onto 12% acrylamide gels, 
prepared as described by Laemmli [34].  
MUTATION PRIMERS (5’– 3’) 
C8A Forward 
 TTCAACCGCCCCGAATGCTCAGAACCCGATC 
 Reverse 
 GTTCTGAGCATTCGGGGCGGTTGAAGTGTC 
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The gels were run at 200 V for 40 minutes and stained in Coomassie Brilliant 
Blue. The BenchMark Protein Ladder (Invitrogen), containing 10 proteins 
ranging in apparent molecular weight from 10 to 220 kDa, was used to 
compare the different oligomeric states of the protein.  
 
4.4.9 Sensitivity to Proteinase Treatment 
The stability of Burkavidin against Proteinase K was assessed in the presence 
and absence of B4F by SDS-PAGE assay. 
The samples were incubated with 386 !M Proteinase K (Promega) for 2 hrs at 
37 °C. Loading buffer (300 mM Tris/HCl pH 6.8; 6% SDS; 30% glycerol; 
0.036% Bromophenol-Blue; optional 50 mM DTT) was added to a final 1/3 
of total volume before charging the gels. 
 
4.4.10 Isothermal Titration Calorimetry (ITC) 
ITC profile for the titration of biotin onto Burkavidin was carried out using a 
VP-ITC titration calorimetry (MicroCal, Northampton, MA, USA) at 25 °C 
in HEPES buffer (50 mM, pH 8).  
Prior to each experiment, all solutions were thoroughly degassed and the ITC 
sample cell washed several times with HEPES buffer solution.  
The titration was carried out injecting biotin (1 mM in HEPES buffer) in the 
reaction cell (VCELL = 1.5 ml) filled with burkavidin (40 !M in HEPES 
buffer). Injections were started after the stability of the baseline had been 
achieved. A typical titration experiment normally consisted of 50 consecutive 
injections of 5 !L and 10 s each, with 10 min interval between each injection 
and stirring at 300 rpm.  
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Heats of dilution of biotin into the buffer alone were used to adjust total 
observed heats of binding. The resulting data were fitted using MicroCal 
ORIGIN software supplied with the instrument.  
 
4.4.11 Titration by HABA 
2-(4’-hydroxyphenylazo)benzoic acid (HABA) forms with Burkavidin a dyed 
complex, which can be detected spectrophotometrically at 506 nm [22]. 
Competitive displacement of HABA by biotin resulted in the decrease of 
absorbance and provided a spectroscopic assay to assess the free biotin-
binding sites in burkavidin.  
The host protein (8 !M, 2.4 mL, 0.0192 !mol) was loaded with a large excess 
of a 9.6 mM HABA solution (584 eq versus burkavidin monomer). Aliquots 
of 0.25 eq (versus Burkavidin monomer) up to 7.0 eq of biotin (0.96 mM) 
were added to HABA ! Burkavidin complex under stirring.  
 
4.4.12 Isoelectric Focusing (IEF) 
Purified proteins at 1mg/ml in water were analysed using a PhastGel IEF – 3-
9 (GE-Healtcare) and compared against a kit of Broad pI Standards (pI 3.5-
9.3) according to supplier’s instructions. 
 
4.4.13 Gel Filtration 
Proteins were dissolved in 50 mM TRIS-HCl, pH 7.4, 100 mM NaCl at 1 
mg/ml. A Superose-20 column (GE-Healthcare) was loaded with 0.5 ml of 
sample and ran at 0.5 ml/ml. 
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4.5 Conclusions 
The natural function of secreted Burkavidin in B. pseudomallei remaines 
speculative. The native host B. pseudomallei was recognized as a causative 
agent of melioidosis [35].  
We hypothesized that Burkavidin’s strong biotin-binding activity might 
contribute to virulence, as secreted proteins were important for Burkholderia 
pathogenicity [36] and biotin deficiency was associated with 
immunodepression [37]. 
However, the presence of closely-related isoforms in the relatively avirulent 
B. thailandensis and B. oklahomensis suggested that Burkavidin was not a 
virulent factor in these organisms [36]. 
On the other hand, the finding that Burkavidin was a secreted avidin 
suggested its potential use in vaccines [38]. Alternatively, its strong biotin-
binding activity could be exploited as diagnostic for Burkholderia [38] and as a 
means of targeting biotinylated antimicrobials.  
In summary, this study represented, to our knowledge, the first demonstration 
of an avidin in a human pathogen with strong biotin-binding activity. This 
avidin may have potential implications in the medical field. 
The low pI of Burkavidin may render this novel protein also useful for 
specific binding of biotinylated DNA, in contrast to avidin that is involved in 
non-specific electrostatic interactions with the negatively charged DNA [39]. 
In combination with a biotinylated metal complex Burkavidin has been 
shown to perform the enantioselective hydrogenation of N-protected 
dehydroamino acids. Further chemogenetic optimization or evolution could 
improve conversion and selectivity [40].  
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In vivo catalysis remains an exciting challenge and Burkavidin represents a 
milestone in this direction as the creation of hybrid enzymes within the cell 
periplasm may allow catalytic reactions to be carried out in vivo.
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Chapter 5 
General Conclusions 
!
This is not the end. It is 
not even the beginning 
of the end. But it is, 
perhaps, the end of the 
beginning 
 
Winston Churchill 
 
The ex nihilo creation of an artificial metalloenzyme, through the construction of 
the entire polypeptide sequence with metal-ions affinity, remains a challenging task 
[1]. For this reason, many efforts have been devoted towards the creation of catalytic 
activity by engineering a novel catalytic site into a native scaffolds, such as protein 
[2] and DNA [3].  
In the aftermath of the pioneering work of Wilson and Whitesides [2a], hybrid 
catalysts have been generated by introducing a new metal-binding site within 
biotin-binding proteins (i.e. streptavidin and burkavidin) [4].   
Biotinylated organometallic fragments are anchored into the proteins within a 
supramolecular approach [5]. A genetic “fine-tuning” of the second coordination 
sphere can improve the “fitness” of hybrid catalysts in term of ee and substrate 
specificity. 
In this study, the influence of the protein scaffold on enantioselectivity and catalytic 
performance of artificial transfer hydrogenases was widely investigated and 
optimized through a “designed” evolution scheme [6]. 
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Inspired by the X-ray crystal structure of a (S)-selective catalyst for the reduction of 
acetophenone derivatives, we selected two close lying residues (K121 and L124) 
for further mutagenesis studies, with the creation of several hybrid variants with 
improved features [5]. We implemented a straightforward protein production and 
purification scheme, amenable to HTS. This high-throughput strategy, described as 
immobilization approach, led to a successful streptavidin purification directly from 
crude cell extract thanks to the high affinity of the protein for biotin, with a 
simplified screening effort towards a larger hybrid-catalyst library investigation [5]. 
In this context, we also scrutinized thermo-denaturation as another strategy to 
simplify streptavidin purification by exploitation of its high thermal stability. 
Preliminary screening for Pd-mediated allylic alkylation using crude cell extract 
was disappointing. However, many efforts can be focused in this direction to 
improve the catalytic activity in cell lysate. 
Artificial metalloenzymes were also generated using burkavidin as novel protein-
scaffold. In combination with a biotinylated metal complex burkavidin has been 
shown to perform the enantioselective hydrogenation of N-protected dehydroamino 
acids [7]. Further chemogenetic optimization or evolution could improve conversion 
and selectivity. 
At this stage, in vivo catalysis remains an exciting challenge and burkavidin 
represents a milestone in this direction as the creation of hybrid enzymes within the 
cell periplasm may allow catalytic reactions to be carried out in vivo [8]. 
The well-defined binding pocket of biotin-binding proteins could be also exploited 
to accommodate small molecule drugs and generate supramolecular assemblies. 
The incorporation of a biotinylated ruthenium piano-stool into streptavidin using a 
supramolecular approach can modulate the macromolecular-target recognition 
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through additional non-covalent interactions. This “surface borrowing” strategy via 
a presenter protein allows to modulate the affinity and the selectivity towards DNA 
telomeres, even in the presence of competing species [9]. 
Accordingly, supramolecular assemblies of drugs within host proteins can be 
proposed as a promising alternative to the current anti-cancer therapeutic agents 
inasmuch as chaperone drug specific delivery to a desired macromolecular target 
[10]. 
In the present form, such hybrid organometallic species cannot be delivered to a 
cell. Nevertheless, a chemo-genetic engineering could improve binding and 
selectivity in vivo. As future perspective, the challenging intracellular delivery of 
supramolecular metallodrugs can be addressed differently, either by appending a 
cell-penetrating peptide sequence to the presenter protein [11] or by exploiting an 
overexpressed protein in cancer cells (i.e. carbonic anhydrase) as presenter scaffold 
[12]. 
Potential important implications in the medical field have been also attributed to 
burkavidin, the first demonstration of an avidin in a human pathogen. Its strong 
biotin-binding activity could be exploited as diagnostic for Burkholderia and as a 
means of targeting biotinylated antimicrobials [13], while its low pI may render this 
novel protein also useful for specific binding of biotinylated DNA, in contrast to 
avidin that is involved in non-specific electrostatic interactions with the negatively 
charged DNA [14]. 
 
 
!
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APPENDIX A 
HPLC Analysis of Allylic Product 
(performed by Mr Cheikh Lo) 
 
OD-H column  
Hexane : iPrOH = 95 : 5; 0.3 mL/min 
207 nm 
 
 
Scaffold Vol reaction Retention Time Area [%] 
13.461 11,4323 
16.878 81,9812 Pure Sav WT 440 !L 
19.958 6,5864 
!
!
!
!
!
!
!
! -II- 
!
Scaffold Vol reaction Retention Time Area [%] 
13.461 2,1648 
16.887 20,7713 Pure Sav WT 2800 !L 
19.951 77,0639 
!
!
!
Scaffold Vol reaction Retention Time Area [%] 
13.479 0,4307 
16.923 0,6585 
Cell Extract 
WT 
2800 !L 
20.039 98,9108 
! -III- 
!
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APPENDIX B 
Molecular Biology Protocol 
(written in collaboration with Mr Narasimha Rao Uda) 
 
 
DAY ONE: 
 
PCR Mutagenesis on ice: (50 µL  total volume) 
• Template (5-25 ng/µL) = 1 µL 
• Primer + (10 µM) = 1.5 µL  (CF 300 nM) 
• Primer – (10 µM) = 1.5 µL (CF 300 nM) 
• dNTP (10 mM total) = 2 µL (CF 0.4 mM) 
• 10X Buffer = 5 µL 
• DMSO (100%) = 2.5 µL (CF 5%) 
• H2O (sterile) = 35 µL 
• Pfu Turbo (2.5 u/ µL) = 1.5 µL (CF 0.075 u/ µL) 
 
Program:  
• 95 °C – 5 ’ 
• START 16X: 
o Start cycle 
o 95 °C – 1’ 
o 60 °C – 1’ (or 50 °C-1’; or 55 °C-1’) 
o 68 °C – 10’ 
o End cycle 
o 68 °C – 60’ 
• 4 °C – overnight  
 
DAY TWO: 
 
Agarose gel 1.2% 
Dpn1 Treatment (for positive sample): 
• 1 µL of Dpn1 in each tube 
• Incubation for 1 h @ 37 °C 
Transformation of cloning cells (DH5! or XL-Blue): 
Prepare LB-AGAR plate: 
• Bactotryptone: 8 g 
• Bactoyeast extract: 4 g 
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• NaCl: 8 g 
• Agar: 12 g 
• H2O: make-up to 800 mL 
• At 50 °C, add antibiotics: AMP (960 µL of 50 mg/mL) 
Transformation of ultra-competent XL-Blue strain: 
• Take the ultra-competent cells out of freezer (- 80 °C) 
• Thaw on ice (always treat cells carefully) 
• Pre-warm LB-agar plate on the bottom shelf of incubator (@ 37 °C) 
• Wait until DTT is completely thawed 
• Add 8 µL of DTT (200 mM frozen stock) into 100 µL of cells 
• Add 5 µL (or 10  µL  if of a weak spot) of PCR product to 100 µL of competent cells and 
mix gently: no up and down! 
• Leave on ice for 15’ 
• Plating into the pre-warmed plates (LB/AMP) and incubation overnight. 
 
DAY THREE: 
Pre-culture for minipreps: 
• In 14 mL Falcon tube: 
o AMP ( 50 mg/mL) = 3.6 µL (CF 60 µg/mL) 
o Glucose (20%) = 15 µL (CF 0.1%) 
o LB = 3 mL (also 5 mL) 
o Inoculation: 1 colony from plate (or glycerol stock) 
o Incubation overnight (37 °C, 250 rpm) 
 
DAY FOUR: 
Minipreps DNA Purification: 
• Centrifuge Falcon tube = 4400 rpm, 4 °C, 5’ 
• Discard supernatant 
• Resuspend pellet with 250 µL “CELL RESUSPENSION SOLUTION” and transfer in 
eppendorf (1.5ml) 
• Add 250 µL “CELL LYSIS SOLUTION” to each sample: invert 8 times to mix (1 
eppendorf for time) 
• Add 10 µL “ALKALINE PROTEASE SOLUTION”: invert 8 times to mix. Incubate 5’ at 
r.t. (to time from the first) 
• Add 350 µL “NEUTRALIZATION SOLUTION”: invert 8 times to mix. 
• Centrifuge at top speed for 10’ at r.t. 
• Insert “SOIN COLUMN” into “COLLECTION TUBE” 
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• Decant cleared lysate into Spin Column 
• Centrifuge at top speed for 1’ at r.t. : discard flow-through and reinsert column into 
collection tube (without cover in centrifuge: no problem) 
• Add 750 µL “WASH SOLUTION” (ethanol added). Centrifuge at top speed for 1’ at r.t. : 
discard flow-through and reinsert column into collection tube 
• Add 250 µL “WASH SOLUTION”. Centrifuge at top speed for 3’ at r.t. : discard flow-
through and reinsert column into collection tube 
• Transfer Spin Column to a sterile 1.5 ml eppendorf. 
• Add 40 µL of “NUCLEASE-FREE WATER” to the spin column: wait 5’. 
• Centrifuge at top speed for 1’ at r.t 
• Discard column and measure concentration in NANODROP (the ratio 260/280 is very 
important: only if it’s >1.8, the DNA is very pure and the concentration in ng/ µL is real) 
• Finally store DNA @ -20°C. 
 
DAY FIVE: 
Transformation of expression strain: BL21(DE3)pLysS 
Prepare LB-AGAR plate: 
• Bactotryptone: 8 g 
• Bactoyeast extract: 4 g 
• NaCl: 8 g 
• Agar: 12 g 
• H2O: make-up to 800 mL 
• At 50 °C, add antibiotics: AMPICILINE (960 µL of 50 mg/mL; Cf: 60 µg/mL), 
CHLORAMPHENICOL (800 µL of 34 mg/mL; Cf: 34 µg/mL), GLUCOSE (80 mL of 
20%; Cf: 2%) 
Transformation of ultra-competent BL21(DE3)pLysS: 
• Take the ultra-competent cells out of freezer (- 80 °C) 
• Thaw on ice (always treat cells carefully) 
• Pre-warm LB-agar plate on the bottom shelf of incubator (@ 37 °C) 
• Wait until DTT is completely thawed 
• Add 8 µL of DTT (200 mM frozen stock) into 100 µL of cells 
• Add 3 µL of plasmid (0.2-0.5 µg of DNA) to 100 µL of competent cells and mix gently: no 
up and down! 
• Leave on ice for 15’ 
• Plating into the pre-warmed plates (LB+AMP+CP+GLU) and incubation overnight. 
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APPENDIX C 
Streptavidin Expression in 20 L of E. coli Cell Culture 
(written in collaboration with Ms Elisa Nogueira) 
 
 
DAY ONE: 
 
In the morning: 
 
Prepare TP MEDIUM 
PRODUCT 20 L Culture 300 mL Preculture 
Bactotryptone 400 g 6 g 
Na2HPO4 26 g 0.39 g 
KH2PO4 20 g 0.3 g 
NaCl 160 g 2.4 g 
Bactoyeast extract 300 g 4.5 g 
d-H2O Make-up to 5 L Make-up to 300 mL 
 
 
Sterilization in Autoclave: 
1. 300 mL TP medium in 3L flask 
2. 100 mL ANTIFOAM in anti-foam bottle + magnet 
3. 900 mL mQ-H2O for antifoam dilution (then keep at 4 °C) 
4. Inoculation bottle 
5. Glucose 20% (100 g in 500 mL) – Final concentration: 0.4% 
6. 400 mL NaOH 1 M 
7. Air filter (from fermentor) 
 
Prepare: 
• Sterile IPTG 0.8 M: 1.9 g in 10 mL H2O (sterile filter under hood) – Final concentration: 0.4 mM 
• Sterile CHLORAMPHENICOL (34 mg/mL): 680 mg in 20 mL Ethanol (sterile filter under hood) – 
Final concentration: 34 µg/mL 
• Sterile AMPICILIN (50 mg/mL): 1.2 g in 24 mL H2O (sterile filter under hood) – Final 
concentration: 50 µg/mL 
• Prepare concentrated 20 L of TP medium (quantities for 20 L but add only 5 L H2O) 
 
In the early afternoon: 
 
IMPORTANT PRECAUTIONS: 
1. High temperature (do not get burned!) 
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2. Lamp vessel (be careful!)  
3. Moving pieces under vessel (do not touch!) 
4. High pressure: !!!  NEVER OPEN VESSEL UNDER HIGH PRESSURE !!!  
5. Read instructions, get help. 
 
 
Sterilisation of 20 L TP medium: 
• Turn on the cryostat – ensure that the level of refrigerant inside the cryostat is OK. If not, add a 
mixture of 10% EtOH/ H2O; 
• Turn on the ventilator in the fermentation room. Close the doors. 
• Empty and clean fermentor (which is kept in 50% ethanol in between fermentations) – rinse it 
twice with water to get rid of ethanol traces; 
• Ensure all septa are intact: if necessary, change the old septa with new ones; 
• pH calibration:  
o Connect pH-meter 
o Cali on MENU 
o Cali meas. 
o 1° ref: pH 4.00 
o When the value is stable: Calibrate 
o 2° ref: pH 7.00 
o When the value is stable: Calibrate 
o Calibration is done 
• Pour the 5 L of concentrated TP medium in the vessel and top-up with 15 L of water, making a 
total volume of 20 L. Before pouring the medium, make sure that the pH-probe is connected on the 
bottom of the vessel and all the entrances/tap are closed! 
• Check the level of antifoam probe (approx. 10 cm above liquid level); 
• Switch on fermentor (main switch); 
• Agitation speed 600 rpm: !" CTRL.M. OFF # $ Controlled: OK (# $ OFF OK to stop) 
• Open air: put 1 beaker at the end of air outlet; 
• Start sterilisation on Temperature panel: !" CTRL.M. OFF # $ Sterilize: OK (# $ OFF OK 
to stop); at start of fermentation, the vessel should be closed and air-outlet open; 
• At 95 °C (more or less after 40 minutes) close the air outlet and press OK to continue; 
• Sterilise at 121 °C for 30 minutes; 
• Then the temperature comes down; 
• At 100 °C, open air outlet and connect air-filter (verify that pressure inside vessel is zero!); 
• At 50 °C add ANTIBIOTICS: 10 mL CP (34 mg/mL) and 12 mL AMP (50 mg/mL), through 
septum; 
• Add 1.5 bar by opening the air inlet (air tap on the wall, and tap on the air tubing), close air outlet 
and air inlet; 
• Switch off the fermentor and cryostat. 
 
Pre-Culture: (under hood) 
• Sterile 300 mL TP medium in 3 L flask 
• Sterile Glucose 20%: 15 mL 
• Sterile CP (34 mg/mL): 300 µL 
• Sterile AMP (50 mg/mL): 360 µL 
• Inoculation with glycerol stock (in -80 °C): keep the glycerol stock in dry-ice 
• Incubation at 37 °C, 250 rpm, overnight. 
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DAY TWO: 
 
In the early morning: 
 
Culture: 
• Switch on the cryostat and the ventilation in the room; 
• Turn on fermentor and programme the temperature to 37 °C; 
• Add ANTIBIOTICS: 10 mL CP (34 mg/mL) and 12 mL AMP (50 mg/mL) (open air outlet to 
bring pressure inside the vessel to zero, check on the manometer): release pressure 
• Take blank (40 mL) 
• Under hood prepare: 
o Mix pre-culture + 400 mL glucose 20% (in the sterile inoculation bottle) 
o Antifoam 10%: add 900 mL of cold water to 100 mL of sterile antifoam and keep on ice 
• Connect acid/base bottles. Leave one free just for the inoculation. Set it up to pH 2.0 if you use the 
Acid pump for inoculation. Afterwards, remember to set it up back to 6.5! 
• At 37 °C, inoculate the medium with pre-culture (open air outlet to bring pressure inside the vessel 
to zero, check on the manometer); use one of the acid/base pumps to inoculate medium or the 
antifoam one. Be sure that the antifoam probe touches the top of the liquid and set up the pump to 
100%. At the end, pull the probe up again (10 cm above the liquid level) and set the pump back to 
20%. 
• Connect Antifoam bottle and set it up on the “Antifoam” panel – 20%, use “controlled” set-up. Put 
the antifoam bottle in a beaker with ice (to keep it cool) and on a stirring plate; 
• Set up agitation to 600 rpm and use “controlled” set-up; 
• Open air inlet to 1.5 bar and leave the air outlet open, so air can circulate through the vessel; 
• Each hour take sample to check OD600 and keep them on ice. 
o Use an UV cuvette (1 mL – BIOLOGIST USE ONLY) 
o SIMPLE READS Program ! Setup ! Read at Wavelength: 600 nm 
o Y-Mode ! Abs x F = 10.0000 OK 
o Blank the Spec ! add 1 mL of the blank sample (medium before inoculation) ! Zero 
o Add 900 µl of Blank + 100 µl of your sample (10x dilution) 
o Mix covering the cuvette with parafilm (be careful with the air bubbles) 
o Read at 600 nm (Abs · 10) 
o Print Report at the end of the fermentation 
• When the OD is between 1.8 and 2, induce – close air inlet, verify that there is no air inside the 
vessel (manometer at 0, air outlet open) and with a syringe add 10ml IPTG 0.8 M (Cf: 0.4 mM) 
(from one of the septum on top of the fermentor) 
• Stop the culture when the OD600 starts to decrease by closing the air (in and out). 
• Set programme temperature to 4 °C and decrease agitation to 250 rpm. 
                      
 Harvest: 
• Cool down the centrifuges to 4 °C 
• Centrifugation programme:  
o 4400 rpm, 4 °C, 10 minutes for the small centrifuge 
o 4400 rpm, 4 °C, 10 minutes for the ultracentrifuge (big one) 
• Discard the supernatant and inactivate the waste (supernatant) with NaClO (bleach) 
• Repeat as much as necessary, i.e. the same centrifuge bottle can be reused over and over again, 
until the 20 L of culture are centrifuged 
• Freeze the pellet at –20 °C. 
• Switch off cryostat 
• Wash the fermentor – rinse it twice with water with the agitation on (maximum speed – 1500 rpm) 
• Add 10L H2O and 10 L ethanol (you can find the container in the yellow cabinet in the basement) 
• Switch off fermentor 
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• Make sure that nothing is left on the way (hallway to the library) / everything is turned off 
(cryostat, main switch of the fermentor, taps (air and water), ventilator...) / biological waste 
disposed in proper containers as well as needles, etc. 
• Rinse the bottles and tubing first with water, second with ethanol, and with water again; finally 
wash them in the dishwasher. DO NOT put them as they are in the dishwasher as the tubes 
burst/caramelise if they’re not previously rinsed. 
• Finally, spin down 1mL of each sample (1 h before induction and all samples after induction), 
discard supernatant and keep labelled pellet at -20 °C to run a SDS-Page gel next day. 
 
DAY THREE: 
 
Resuspension of cell lysate: 
• Thaw the bacterial pellet at room temperature. DO NOT warm them up! 
• Prepare a resuspension buffer: 
o Tris/HCl (pH 7.4, 1 M): 10 mL (Cf : 20 mM) 
o PMSF: 87 mg in 5 mL EtOH (freshly prepared) 
o mQ-H2O: bring volume up to 500 mL 
• Resuspend the pellet in 500 mL of resuspension buffer 
• Add 2-3 mg of DNase1 powder (the tip of a spatula) and incubate at room temperature under 
vigorous stirring (until the nucleic acids are totally degraded – no more slimy strings inside the 
bottles). Add more DNase1 if necessary. 
 
Dialysis in guanidinium hydrochloride 6 M, pH 1.5: 
 
• Prepare a large dialysis bag (Spectra/Por, 6-8.000 MWCO), capable of containing at least 800 mL 
of liquid and let it soak in distilled water (15 min) 
• Prepare 15 L of denaturation buffer: 
o Guanidinium hydrochloride 6 M: 8597.7 g in 15 L of 
distilled water (pH 1.5 with HCl) 
• Pour the bacterial extract into the dialysis bag 
• Place the bag in a tank containing denaturation buffer 
• Dialyse under gentle stirring for 24 h at room temperature 
• The dialysis solution can be reused 2-3 times 
 
 
 
Electrophoresis SDS-PAGE: 
Gel preparation: 
SDS – loading gel 
12% gel – 15 mL for 2 gels 
5 mL of ddH2O 
6 mL of 30% acrylamide 
3.8 mL of 1.5 M Tris pH 8.8 
75 µL of 20% SDS 
100 µL of 15% APS 
6 µL of TEMED 
 
Pour ± 7 mL of gel in each cassette. Add ethanol on top of the gel, until gel is ready (1mL left in the 
falcon tube serves as control). Wash it thoroughly with dH2O before loading the stacking gel. 
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SDS – stacking gel 
5% gel – 6 mL for 2 gels 
3.4 mL of ddH2O 
1 mL of 30% acrylamide 
1.5 mL of 0.5 M Tris pH 6.8 
30 µL of 20% SDS 
40 µL of 15% APS 
6 µL of TEMED 
 
Pour ± 3 mL of gel in each cassette. Carefully place the comb into the cassette (use goggles, as some of 
the gel solution can splash out of the cassette). Use the remaining 1 mL as control. When ready, remove 
the comb carefully (don’t put too much pressure on it as it can break the gel easily). Wash thoroughly 
with dH2O. Place it into the tank, and add 1X SDS buffer immediately to prevent dryness of the gel. 
 
 
Samples preparation: 
• Thaw the bacterial pellet at r.t. 
• Multiply by 40 the OD of each sample you’ve taken during the fermentation. Then add the 
corresponding result in µL of dH2O. 
• Add 1 µL of DNase (10 mg/mL) and incubate for 30 minutes 
• Vortex for 5 minutes 
• Centrifuge the samples: 14000 rpm, 4 °C, 5’ 
• Transfer the supernatant in a new eppendorf: this is the SOLUBLE FRACTION 
• Resuspend the pellet in the same volume of H2O as previously and vortex for 5 minutes: this is the 
INSOLUBLE FRACTION 
• Transfer 20 µL of each sample in a new tube 
• Add 1 µL of B4F (0.6 mM) and incubate for 10’ at r.t. 
• Add 10 µL of LB (3X, without DTT)  
• Mix up and down with the pipette 
• Positive control SAV-WT: 18 µL of H2O; 2 µL of WT (10 mg/mL); 1 µL of B4F; 10 µL 3X LB 
• Load 20 µL on the gel 
• Protein Marker: 8 µL 
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Gel picture: 
                                                   Insoluble fraction       Soluble fraction 
                               M        WT       0     1    2    3          0     1    2    3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAY FOUR: 
 
Dialysis in Tris/HCl 20 mM, pH 7.4: 
• Prepare 15 L of renaturation buffer: 
o Tris/HCl (pH 7.4, 1 M): 300 mL 
o d-H2O: bring volume up to 15 L 
• Transfer the dialysis bag to the renaturation buffer 
• Dialyse under gentle stirring for 16 h at room temperature 
 
 
DAY FIVE: 
 
Dialysis in imino-biotin binding buffer, pH 9.8: 
• Prepare 15 L of imino-biotin binding buffer, to equilibrate the protein in buffer pH  9.8 
o NaHCO3 (1 M, pH 9.8): 750 mL (Final concentration: 50 mM) 
o NaCl (5 M): 1.5 L (Final concentration: 500 mM) 
o dH2O: bring volume up to 15 L 
• Transfer the dialysis bag to the imino-biotin binding buffer 
• Dialyse under gentle stirring for 16 h at 4 °C (in the cold room) 
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DAY SIX: 
 
Centrifugation 
• Cool down the centrifuges to 4 °C; 
• Open membranes and transfer all the content of the membranes to a centrifugation bottle (500 
mL); 
• Centrifugation programme: 10000 rpm, 4 °C, 30 minutes; 
• Keep the supernatant in a new centrifugation bottle and inactivate the waste (pellet) with NaClO 
(bleach); 
• If particles are present, filter the supernatant using Whatman filters, 
• Freeze the supernatant at –20 °C if you don’t purify on the same day. 
 
Purification on an imino-biotin column: 
Defrost your sample. Do not forget that a big volume takes a long time to defrost. Plan your day so you 
won’t start the washing of the FPLC too soon! You will need 2 L of imino-biotin buffer Ph 9.8 and 2 L of 
Acetic Acid 1%. 
Be sure that all tubes are at the bottom of each bottle, so no air bubbles are created inside the system! 
POS 1: Imino-biotin Buffer, pH 9.8 (50 mM NaHCO3, 500 mM NaCl) 
POS 2: Sample 
Buffer B: Acetic Acid 1% 
 
• Software: Prime View 
o UV: 280 nm 
o Cond: conductivity (salt concentration) 
o pH: no probe 
o Pressure: 1MPa (limit) 
o Temperature 
o Conc:  % B 
• Use Esc in order to come back and !" to move in the same level 
• SET PARAMETERS: OK 
o To switch on the UV lamp: 
• Turn ON – Lamp: Lamp Off – OK - !"  - On – OK 
• Esc 
 
• First wash of the system: 
o The whole system has to be washed with water to wash out the ethanol. 
o Plunge the three inlet tubes in a bottle of mQ-H2O and make sure that the three outlet tubes are in 
the waste bottle 
o Perform Programme 5 (Quick-Wash): 
• Run Stored Method % OK % from System % OK – From System No 5 (Data Transfer to PC) % 
Press OK to Start RUN 
• OK 
 
• Initial washing of the system: 
o Three inlet tubes (Red-B, White-A2, Blue-A1) in acetic acid 1% 
o Empty the waste 
o Three outlet tubes in the waste flask 
o Verify that the arm (to collection tubes) is in the correct position   
o Template: OK % Application template: OK % System wash method: OK % B, A, 2…: OK % 
Press OK to Start RUN 
o Method is done: no memory 
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• Washing of A2 Line and equilibration of the column: 
o Place A2 and A1 tubes in the equilibration buffer (imino-biotin buffer) 
o Go to “Manual Run” 
• Set flow rate % 10 mL/min 
• Set buffer valve position ! Pos2 
• Start Run % OK % OK 
o Leave it run for ±50 mins (5 columns volume). 
• Press END % OK % OK 
o Empty the Waste bottle and put a clean one to collect the waste of your protein. 
 
• Streptavidin purification on an imino-biotin column: 
o Add some Tris/HCl 1 M, pH 8.8 to each collection tube on the collector; 
o Measure the volume of your sample in a cylinder and change the programme according to the 
total volume you want to be purified (subtract ±50 mL to the total volume to be sure that air is 
not pumped into the system)  
o Changing the value in the 3rd Breakpoint (in this case, 380 mL – 350 mL total volume) will 
change automatically the values of the other breakpoints. 
• Run Stored Method % OK % from System % OK – From System No 1 (Data Transfer to PC) % 
Press OK to Start RUN 
• OK 
 
o PROGRAMME 1: 
" Breakpoint 30 mL (equilibration of column with imino-biotin buffer pH 9.8): 
! Set method base (mL) 
! Set fraction base (mL) 
! Pressure: 1 MPa 
! Set alarm: no 
! Show: no 
! Edit breakpoint: OK   
o ml (0.0) 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: no 
o Edit time vol: 30.0 mL 
o Save breakpoint: OK 
 
" Breakpoint 30.1 mL (loading of sample): 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
o Set buffer: pos 2 
o Set inject: load 
o Set peak collect: no 
o Autozero: yes 
o Event mark: yes 
o Edit time vol: 30.1 mL 
o Save breakpoint: OK 
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" **Breakpoint 380 mL (end of loading of sample (350 mL total volume) + start column 
washing with imino-biotin buffer pH  9.8): 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 380.0 mL 
o Save breakpoint: OK 
! To change this value: Edit time %  Change %  Save 
 
" Breakpoint 1400 mL (washing with imino-biotin buffer pH 9.8) 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 1400.0 mL 
o Save breakpoint: OK 
 
" Breakpoint 1400.1 mL (start elution with acetic acid 1%). 
o B %: 100 
o Set flow: 10 mL/min 
o Set fraction size: 10.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 1400.1 mL 
o Save breakpoint: OK 
 
" Breakpoint 2000 mL (gradient – elution with acetic acid 1%): 
o B %: 100 
o Set flow: 10 mL/min 
o Set fraction size: 10.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 2000.0 mL 
o Save breakpoint: OK 
 
" Breakpoint 2000.1 mL (washing with imino-biotin buffer pH  9.8): 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
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o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 2000.1 mL 
o Save breakpoint: OK 
 
" Breakpoint 2400 mL (washing with imino-biotin buffer pH 9.8): 
o B %: 0 
o Set flow: 10 mL/min 
o Set fraction size: 0.0 mL 
o Set buffer: pos 1 
o Set inject: load 
o Set peak collect: no 
o Autozero: no 
o Event mark: yes 
o Edit time vol: 0.0 mL 
o Save breakpoint: OK 
o End method 
o Save method 
 
Rinse the system with mQ-H2O, and wash it with 75% EtOH. Leave column and tubing in EtOH to 
prevent the growth of foreign microorganisms. 
 
 
DAY SEVEN: 
 
Dialysis in Tris/HCl 1 0mM, pH 7.4: 
• Prepare 15 L of neutralisation buffer: 
o Tris/HCl (1 M, pH 7.4): 150 mL 
o dH2O: bring volume up to 15 L 
• Dialyse the pure protein under gentle stirring against the neutralisation solution for 16 h at 4 °C. 
 
 
DAY EIGHT: 
 
Dialysis in distilled water (d-H2O): 
• Transfer the dialysis bag in a tank containing distilled water (15 L) and dialyse under gentle 
stirring for 16 h at 4 °C. 
 
DAY NINE: 
 
Dialysis in nanopure water (mQ-H2O): 
• Transfer the dialysis bag in a tank containing mQ-H2O (15 L) and dialyse under gentle stirring for 
16 h at 4 °C. 
 
DAY TEN: 
Protein lyophilisation: 
A lyophiliser creates a very low temperature and low-pressure environment in which aqueous solvents 
will sublime, leaving only solute(s) behind. To have this to work the most efficiently, samples should be 
‘shell’ frozen to maximize surface area. 
Do not use a lyophiliser to remove organic solvents, as they can damage the vacuum pump. 
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• Place your samples in tubes (such as 15 mL or 50 mL Falcon tubes, or even glass test tubes) or 
directly into a thoroughly cleaned lyophiliser vessel 
• Secure a double layer of Kimwipe/Whatman filter over the tube with a rubber band or parafilm; 
pierce it 5-10 times with a needle. 
• Freeze your sample in one of 3 ways: 
a. You can simply put your samples at an angle at -80 °C overnight and lyophilize them the 
next day. While this works, it will take quite a bit of extra time. I recommend this method if 
you have a bunch of samples and you don’t care that it might take the extra time to 
lyophilise. 
b. Or you can simply put your samples at an angle in liquid nitrogen. Take all the precautions 
when handling it. 
c. You can put a small amount of dry ice (about 2 cups) in the bottom of an ice bucket, and then 
slowly pouring methanol onto the dry ice. You will need enough methanol to completely 
immerse your sample. Hold the sample container at an angle and turn it slowly and steadily 
as it freezes, continuing until it is all frozen in layers (or a ‘shell’) up the sides of the 
container. 
• Turn on the lyophiliser (switch on the right side of the equipment), switch on the manual 
refrigeration and wait until the temperature reaches -50 °C. The light on the sigmoidal graph 
should be green. 
• After covering, and being sure that the temperature is OK, place the frozen samples into the 
lyophiliser main vessel, and close the lid. Press the button to turn on the vacuum pump. 
• At this point, note that the vacuum gauge will be close to atmospheric pressure, but should be 
creeping back down. The temperature gauge shouldn’t have moved too much. You can now walk 
away, but I recommend coming back in an hour or so to make sure that your sample is still 
frozen and that the vacuum is still creeping back down. 
• When there is no more ice in your sample (typically 24 h or more depending on the size of your 
sample), turn off the vacuum pump and carefully remove the vessel. 
• Keep your lyophilised samples in the 4°C fridge. 
• Put a bucket under the “cleaning valve” (bottom left) to collect the water. 
• Clean the vessel with paper towel and ethanol. 
 
 
DAY ELEVEN: 
 
Streptavidin quantification by B4F: 
Prepare: 
1. Phosphate buffer Ph 7.0 + BSA (0.1 mg/mL): dissolve 5 mg BSA (at 4 °C) in 50 mL phosphate 
buffer pH 7.0 (Na2HPO4 0.2 M/NaH2PO4 0.2 M, pH 7.0) 
2. SAV stock solution 10 mg/mL (152 µM): 5 mg of pure protein in 500 µL mQ-H2O (this solution 
can be stored at -20 °C for a long time) 
3. Dilution of protein in buffer pH 7/BSA (Final concentration: 0.131 mg/mL = 2 µM): 
" Buffer pH 7.0/BSA: 1973.8µL 
" Protein 10 mg/mL: 26.2 µL 
4. B4F 40 µM in buffer pH 7/BSA: (for one 96-well plate) 
" Buffer pH 7.0/BSA: 2333.4 µL 
" B4F 0.6mM (in DMSO): 166.6 µL 
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METHOD 
 
                                                                                                                                    
                                                                                             1   2   3   4   5   6   7   8   9  10  11  12                                      
                                                           A 
                                                           B 
 
 
 
 
 
 
 
STREPTAVIDIN 
 
A (1-12) Front line: BLANK 
Add 100 µL of phosphate buffer/BSA in each well using a multichannel pipette. 
 
B (1-12) Second line: SAV 
Add 100 µL of 2µM SAV in each well. 
 
B4F 
1st column, n°1 (lines A-B): 40 µM B4F 
Add 8 µL of B4F in each well using a multichannel pipette and mix (up and down) 
 
2nd column, n°2 (lines A-B): 40 µM B4F 
... 10 µL 
 
3rd column, n° 3 (lines A-B): 40 µM B4F 
... 12 µL 
 
4th column, n°4 (lines A-B): 40 µM B4F 
... 14 µL 
 
5th column, n°5 (lines A-B): 40 µM B4F 
 ... 16 µL 
 
6th column, n°6 (lines A-B): 40 µM B4F 
... 18 µL 
 
7th column, n°7 (lines A-B): 40 µM B4F 
... 20 µL 
 
8th column, n°8 (lines A-B): 40 µM B4F 
... 22 µL  
 
9th column, n°9 (lines A-B): 40 µM B4F 
... 24 µL 
 
10th column, n°10 (lines A-B): 40 µM B4F 
... 26 µL 
 
11th column, n°11 (lines A-B): 40 µM B4F 
... 28 µL 
 
12th column, n°12 (lines A-B): 40µM B4F 
... 30 µL 
 
Centrifuge for 1 min at 1000 rpm to remove air bubbles. 
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TECAN READER 
 
Measurement Parameters: 
Measurement mode: Fluorescence Top 
Excitation wavelength: 485 nm 
Emission wavelength: 520 nm 
Excitation bandwidth: 12.0 nm 
Emission bandwidth: 12.0 nm 
Gain: 50 
Number of flash: 10 
Lag time: 0 µs 
Integration time: 40 µs 
Plate definition file: NUN96ft.pdf 
Z-Position: 6900 µm 
Shake duration (Linear Normal): 30 s 
Unit: RFU 
 
Program:  MAGELLAN 6 
• Start Measurement 
• Use Predefined Method 
• Folder Mth 
• Thibaud 
 
 
Calculation: 
Activity %= VB4Fequivalent pointVB4F 
 
 
!
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APPENDIX D 
Streptavidin Expression in 50 mL of E. coli cell culture 
 
 
 
DAY ONE: 
 
Sterilize 250 mL flask with 50 mL TP  
 
Pre-culture in 14 mL Falcon tube for culture: 
• TP Medium: 5 mL 
• Glucose 20%: 500 !L (Cf: 2%) 
• Chloramphenicol (34 mg/mL): 5 !L (Cf: 34!g/mL) 
• Ampicilin (50 mg/mL): 6 !L (Cf: 60!g/mL) 
• Inoculation with glycerol stock 
• Incubation @ 37°C, 250 rpm, overnight 
 
 
 
 
DAY TWO: 
 
Culture in 250 mL flask: 
• TP Medium: 50 mL 
• Chloramphenicol (34 mg/mL): 50 !L (Cf: 34 !g/mL) 
• Ampicilin (50 mg/mL): 60 !L (Cf: 60 !g/mL) 
• Inoculation with 5 mL of pre-culture 
• Incubation @ 34.5 °C, 415 rpm, for 6 hours  
 
! Induction with IPTG (0.8 M): 75 !L 3h after inoculation 
 
• Stop the culture 3 h after induction 
• Centrifugation: 4400 rpm, 10 minutes, @ 4 °C 
• Discard the supernatant and inactive the waste with NaClO 
• Freeze the pellet @ -20 °C 
 
 
 
 
Extraction: 
• Harvested cells are frozen-thawed 
• Cells are resuspended in 1mL of extraction buffer pH 7.4 (Tris/HCl 20 mM; NaCl 100 mM, 
PMSF 1mM) 
• After addition of 10 !L of DNase1 (10 mg/mL), extracts are incubated for 30-90 min @ room 
temperature 
• When DNA is completely destroyed, extracts are microcentrifuged at 14000 rpm for 5 min 
• The pellet is re-extracted with 0.5 mL extraction buffer 
 
For 32 flasks prepare 50 mL of extraction buffer with: 
• Tris/HCl 1M pH 7.4: 1 mL 
• NaCl 5 M: 1 mL 
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• PMSF: 8.6 mg in 0.5 mL of EtOH 
• H2O:  qqb 50 mL 
• DNase1: 5 mg in 0.5 mL of H2O 
• MgCl2 1M: 250 !L 
 
Transfer 1 mL of the extraction buffer in each tube for the first extraction and 0.5 mL for the second 
extraction. 
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APPENDIX E 
Streptavidin Expression in 96-Well Plate Format 
 
 
DAY ONE: 
Pre-Culture in 96-well plate: 
 Mix for 96-wells: 
• Sterile TP medium: 8618.88 !L 
• Sterile Glucose 20%: 960 !L 
• Sterile CP (34 mg/mL): 9.6 µL 
• Sterile AMP (50 mg/mL): 11.52 µL 
Transfer 100 µL in each well with multichannel pipette 
• Inoculation with glycerol stock (in -80°C): keep the glycerol stock in dry-ice 
• Cover with tin foil 
• Incubate at 37 °C, 250 rpm, overnight 
 
 
DAY TWO: 
Culture in 96-deep well plate: 
 
Mix for 96-wells: 
• Sterile TP medium: 48000 !L 
• Sterile CP (34 mg/mL): 48 µL 
• Sterile AMP (50 mg/mL): 57.6 µL 
Transfer 500 µL in each well with multichannel pipette 
• Inoculation with 100 µL of pre-culture (leave tips inside – help aeration and for 
further steps) 
• Cover with tin foil 
• Incubate at 37 °C, 250 rpm, overnight 
Induce with IPTG (14.4 mM in TP medium) 3 hrs after inoculation: 
• Transfer 100 µL of IPTG in a new 96-well plate 
• Add 50 µL of IPTG in each well, by using the same tips you’ve left inside previously 
Stop the culture 3 hrs after induction 
Centrifuge at 4400 rpm, 10 minutes, 4 °C 
Discard the supernatant and inactive the waste with NaClO 
Freeze the pellet @ -20°C. 
 
DAY THREE: 
Resuspension of cell lysate: 
• Thaw the bacterial pellet at room temperature. 
• Prepare a resuspension buffer: 
o HEPES (500 mM, pH 7.5) : 1920 !L 
o DNase (10 mg/mL): 480 !L 
o mQ-H2O: 16800 !L 
• Resuspend the pellet in 200 !L of resuspension buffer 
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• Mix up and down with pipette 
• Shake for " h 
• Centrifuge at 4400 rpm, 10 minutes, 4 °C 
• Load the supernatant in the gel 
 
Electrophoresis SDS-PAGE: 
Gel preparation: SDS – loading gel 
12% gel – 15mL for 2 gels 
5mL of ddH2O 
6mL of 30% acrylamide 
3.8mL of 1.5M Tris pH 8.8 
75µL of 20% SDS 
100µL of 15% APS 
6µL of TEMED 
 
Pour ± 7mL of gel in each cassette. Add ethanol on top of the gel, until gel is ready 
(1mL left in the falcon tube serves as control). Wash it thoroughly with dH2O before 
loading the stacking gel. 
 
SDS – stacking gel 
5% gel – 6mL for 2 gels 
3.4mL of ddH2O 
1mL of 30% acrylamide 
1.5mL of 0.5M Tris pH 6.8 
30µL of 20% SDS 
40µL of 15% APS 
6µL of TEMED 
 
Pour ± 3mL of gel in each cassette. Carefully place the comb into the cassette (use 
goggles, as some of the gel solution can splash out of the cassette). Use the remaining 
1mL as control. When ready, remove the comb carefully (don’t put too much pressure 
on it as it can break the gel easily). Wash thoroughly with dH2O. Place it into the tank, 
and add 1X SDS buffer immediately to prevent dryness of the gel. 
 
 
Samples preparation: 
! Transfer 15 !l of each sample in a new tube 
! Add 1 !l of B4F (0.6 mM) and incubate for 10’ at r.t. 
! Add 7.5 !l of LB (3X, without DTT)  
! Mix up and down with the pipette 
! Load 20 !l on the gel 
 
Gel picture: 
 
 
Low expression                       No expression                  High expression 
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APPENDIX F 
Streptavidin Refolding 
 
 
Culture 
Culture in flasks (500 mL), centrifugation and freezing of the pellet 
 
Stock solutions 
Resuspension Buffer: 
• Tris/HCl (1 M, pH 7.4) = 250 !L 
• PMSF = 2.2 mg in 125 !L of Ethanol 
• H2O = up to 12.5 mL 
 
Inclusion Wash Buffer: 
• Trition X-100 = 5 mL (Cf: 0.5%) 
• Tris/HCl (1 M, pH 7.4) = 20 mL (Cf: 20 mM) 
• NaCl (5 M) = 20 mL (Cf: 100 mM) 
• H2O = up to 1000 mL 
 
PBS 1X: 
• NaCl = 8 g (Cf: 137 mM) 
• KCl = 0.20 g (Cf: 2.7 mM) 
• Na2HPO4 (x 12H2O) = 3.58 g (Cf: 10 mM) 
• KH2PO4 = 0.24 g (Cf: 1.76 mM) 
• mQ-H2O = up to 1 L 
• pH = 7.4 (with NaOH/HCl) 
 
Annotation: the following steps should be stopped at any stage of the wash, by storing the protein in 
the fridge or freezer. 
 
! Thaw the bacterial pellet at room temperature 
! Resuspend the pellet in 12.5 mL of resuspension buffer 
! Add a spatula of DNaseI and incubate under vigorous stirring 
! Centrifuge at 4400 rpm, 30’, 4 °C: keep the supernatant just for negative control 
 
! Resuspend pellet in Tris/HCl (20 mM, pH 7.4) = 3.25 mL 
! Add Tris/HCl (20 mM, pH 7.4) = 3.25 mL 
! Add Lysozyme (10 mg/mL) = 225 !L; shake for 5’ at r.t. 
! Add a spatula of DNaseI, shake for 10’ at r.t. 
! Finally add Inclusion Wash Buffer = 12.5 mL; mix by inverting the tube several times. 
! Centrifuge at 4400 rpm, 30’, 4 °C (keep always the supernatant for control) 
 
First Wash: 
• Resuspend the pellet in 3.25 mL of inclusion wash buffer: crush with spatula and shaking. 
• Add 12.5 mL of inclusion wash buffer: mix by inverting tube 
• Centrifuge at 4400 rpm, 30’, 4 °C (keep supernatant for control) 
 
Second Wash: 
• Resuspend the pellet in 3.25 mL of inclusion wash buffer: crush and shaking. 
• Add 12.5 mL of inclusion wash buffer: mix by inverting tube 
Centrifuge at 4400 rpm, 30’, 4 °C (keep supernatant for control) 
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Third Wash: 
• Resuspend the pellet in 3.25 mL of inclusion wash buffer: crush with spatula and shaking. 
• Add 12.5 mL of inclusion wash buffer: mix by inverting tube 
• Centrifuge at 4400 rpm, 30’, 4 °C (keep supernatant for control) 
 
Fourth Wash: 
• Resuspend the pellet in 3.25 mL of inclusion wash buffer: crush with spatula and shaking. 
• Add 12.5 mL of inclusion wash buffer: mix by inverting tube 
• Centrifuge at 4400 rpm, 30’, 4 °C (keep supernatant for control) 
 
Dissolving in Guanidinium/HCl: 
• Resuspend the pellet in 2 mL of Guanidinium/HCl (6 M, pH 1.5) 
• Centrifuge at 4400 rpm, 30’, 4 °C : keep supernatant with protein 
 
Refolding should be performed in the coldroom at 4 °C 
For 2 mL of Guanidinium/HCl, you need 100 mL of PBS 
 
• Add supernatant into vortexing PBS with a micropipette as slowly as possible. 
 
Dialysis in Imino-biotin buffer (pH 9.8): 
• Pour the PBS solution into the dialysis bag  
• Place the bag in a tank containing Imino-biotin buffer 
 
Imino-biotin affinity column 
 
Dialysis in Tris/HCl (pH 7.4, 10 mM) 
 
Dialyisis in dH2O 
 
Dialysis in mQ-H2O 
 
Lyophilisation 
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APPENDIX G 
Mass Spectrum for the Adduct 
[(!6-p-cymene)Ru(Biot-L)Cl]CF3SO3 (1)/Glutathione (GSH) 
(performed by Mr Malcolm Jeremy Zimbron) 
 
 
 
 
 
 
 
Adduct complex 1/GSH was prepared adding an excess of GSH (83 µM) 
to the Ru (II) complex (12 µM) in H2O. The mass was recorded after only 
5 min at 25 °C. Complex alone (561.9; 597.9; 621.9), GSH (308.0), 
glutathione dimmer (614.9) and adduct (868.8) were identified in the mass 
spectrum.  
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APPENDIX H 
Electrophoretic Mobility Shift Assays (EMSA) 
in 6% Acrylamide Gel 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. D Interaction between telomeric G4A and drug-streptavidin assemblies: a) 1 !  WT-Sav 
and b) 2 !  WT-Sav. The 6% acrylamide gel was run after incubation with of drug-protein 
assembly with 500 ng of telomeric G4A-DNA. Samples were loaded onto the gel in the following 
order: lane 1, G4A; lanes 2, Sav (20 !M); lane 3, a) Ru complex 1 (71.4 !M), b) Ru complex 2 
(71.4 !M); lane 4, 1 or 2 !  WT-Sav; lane 5, G4A and Sav; lane 6, Ru complex and G4A; lane 7, 1 
or 2 !  WT-Sav with G4A (in 20 mM MOPS); lane 8, 1 or 2 !  WT-Sav with G4A (in 75 mM 
MOPS) 
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